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ABSTRACT

Early breast cancer progression involves advancement through specific
morphologic stages including atypical ductal hyperplasia (ADH), ductal carcinoma
in situ (DCIS) and invasive mammary carcinoma (IMC), although not always in a
linear fashion. Histological studies have examined differences in breast tissues
representing these stages of progression, but model systems which allow for
experimental testing of factors influencing transition through these stages are
scarce. The purpose of these studies was to develop a 3D in vitro model of early
breast cancer progression that reflected the in vivo sequence of events, and to
use this system to identify and functionally test genes important in controlling the
processes. The 21T series cell lines, originally derived from the same patient
with metastatic breast cancer, were shown to mimic specific stages of human
breast cancer progression (21PT, ADH; 21NT, DCIS; 21MT-1, IMC) when grown
in the mammary fat pad of nude mice. When grown in 3D Matrigel, the cell lines
showed characteristic morphologies in which aspects of the stage-specific in vivo
behaviours were recapitulated.
Gene expression profiling of the 21T cells revealed characteristic patterns
for each, with differential expression of certain key genes in common with clinical
specimens. Subsequent studies focused on functionally characterizing the roles
of VANGL1, S100A2 and TBX3 in breast cancer progression. Genes were up- or
down-regulated to determine if alterations could affect transitioning between
stages of progression. VANGL1 was differentially expressed in the ADH (21PT)
to DCIS (21NT) transition (higher in DCIS) and was found functionally to promote
iii

the transition from ADH to a malignant phenotype (DCIS and even IMC).
S100A2 and TBX3 were both differentially expressed in the DCIS to IMC (21MT1) transition (S100A2 lower in IMC, TBX3 higher in IMC). S100A2 was found to
functionally inhibit the transition from DCIS to IMC, while TBX3 promoted
progression to invasion.
These studies demonstrate that the 21T series cell lines provide a model
of early breast cancer progression when grown in 3D. In addition, the model
provides a means of testing the functional effects of genes on transitions between
stages of pre-malignant to malignant growth, which may elucidate potential
therapeutic targets.

KEYWORDS: Breast Cancer Progression, Atypical Ductal Hyperplasia, Ductal
Carcinoma in situ, Invasive Mammary Carcinoma, Matrigel, VANGL1, S100A2,
TBX3

iv

CO-AUTHORSHIP

Chapter 2 of the following thesis was previously published as “Human 21T
breast epithelial cell lines mimic breast cancer progression in vivo and in vitro and
show stage-specific gene expression patterns” by L.H. Souter, J.D. Andrews, G.
Zhang, A.C. Cook, C.O. Postenka, W. Al-Katib, H.S. Leong, D.I. Rodenhiser, A.F.
Chambers, A.B. Tuck, in Laboratory Investigation, vol. 90: pp. 1247-1258, 2010.
Copyright permission for thesis reproduction is not required by Laboratory
Investigation, see Appendix A.

The in vivo experiment was conducted prior to the start of this thesis
project by A.B. Tuck, with technical assistance from Charu Hota. The animal
protocol approval can be found in Appendix A. W. Al-Katib was consulted when
analyzing the pathology of the in vivo study. G. Zhang and A.C. Cook performed
preliminary 3D in vitro colony formation assays. I repeated these 3D in vitro
colony formation assays with Matrigel cell plugs of my own and also created the
Matrigel cell plugs for immunohistochemistry. C.O. Postenka performed the H&E
and immunohistochemical staining on the Matrigel plugs, which I then analyzed.
I designed the microarray study and prepared the RNA. J.D. Andrews aided in
the microarray study design and performed preliminary data analysis. In addition,
J.D. Andrews created the clinically relevant database from the literature, which I
then used to choose my genes of interest. H.S. Leong provided image analysis
expertise when analyzing the time lapse invasion assays that I conducted. I

v

wrote the manuscript under the supervision of A.F. Chambers, D.I. Rodenhiser
and A.B. Tuck.

In Chapter 3, I created expression vectors for VANGL1 and TBX3. H.S.
Leong aided in planning the cloning experiments, as well as being available for
consultation during their creation. In addition, H.S. Leong performed the confocal
microscopy experiments using TBX3 overexpressing cells I prepared. Finally,
H.S. Leong conducted the ZsGreen western blot using cell lysates that I
prepared. As with Chapter 2, C.O. Postenka once again performed the H&E and
immunohistochemical staining on Matrigel plugs, which I prepared and then
analyzed. I performed the remainder of the experiments.

vi

DEDICATION

I would like to dedicate this thesis to my wonderful husband, Christopher,
without whom this thesis would never have happened.

vii

ACKNOWLEDGMENTS

I would first like to thank my supervisors, Dr. Ann Chambers and Dr. Alan
Tuck for their support and encouragement throughout my degree. I have learned
so much more under their guidance then just how to design and conduct
experiments. Ann is a wonderful role model for any female scientist and her
dedication is inspiring.

Without Alan’s support and patience, I wouldn’t have

made it this far. I would also like to thank my advisory committee members, Dr.
David Rodenhiser and Dr. Joe Mymryk for their valuable feedback and direction,
which helped shape my work.
Next, I need to acknowledge the many members of the Chambers’ lab. I
have witnessed many members come and go in the 4.5 years that I have been a
part of the laboratory.

All have been helpful at some time or in some way;

however, there are a few that require extra gratitude. First, David Dales is a
wonderful head technician and deserves thanks for answering my many
questions.

Next Carl Postenka needs to be thanked for putting up with my

pestering for slides and for diverting me with BlackBerry discussions.

Joe

Andrews was paramount in my ever making enough high quality RNA for the
microarray study. Thank you Joe for the encouragement during those frustrating
weeks and for teaching me wonderful sayings, like “Fill your boots”. I will never
eat sushi again without remembering David, Carl and Joe. Mike Lizardo has
been a great friend, especially during the writing process, which we experienced
together. The many text messages and phone calls shared between us the past
few months have helped to maintain my sanity. We will make our shirts yet Mike!
viii

Jen Mutrie also needs to be thanked.

Jen is a wonderful person and her

positivity and optimism was a great pick-me-up on difficult days. On the not
difficult days, just having her in the cubicle beside me, made the day more
enjoyable. Finally, I need to express my sincere gratitude to Hon Leong. Hon is
one of the most supportive and encouraging people I have ever met. Thank you
Hon. Your friendship has made a huge difference in my life.
Members of my family also require many thanks.

My parents are

wonderful people that have always supported me. Although not understanding
exactly what I do on a day-to-day basis, their constant encouragement and
motivation was greatly appreciated. Next, Chris Coady, my husband, who is only
a little miffed that I have not taken his name, has been my rock throughout my
degree. He has supported me when I needed someone to lean on, picked me up
when I was down and pushed me to be the person that I had lost. Finally, and
strangely to anyone that does not know me well, I need to acknowledge Chloe.
Chloe is my anti-stress therapy. After a stressful day, Chloe’s blind admiration
and simple desire to remove my socks always erased my bad mood and gave me
the strength to start again.
Lastly, although not directly helping in my thesis project or in thesis writing,
I need to thank the amazing breast cancer survivors I met through Journeys in
Sharing and the generous women I met through SOWCC.

All of these

remarkable women altered how I viewed my research and the motivation for
conducting it.

ix

GRANT SUPPORT

The work described in this thesis has been supported in part by Grant no.
42511 from the Canadian Institutes for Health Research and Grant no. 016506
from the Canadian Breast Cancer Research Alliance with special funding support
from the Canadian Breast Cancer Foundation and the Cancer Research Society.

L.H. Souter was the recipient of a Studentship from the Pamela
Greenaway Kohlmeier Translational Breast Cancer Unit from the London
Regional Cancer Program with funding from the Southwestern Ontario Women’s
Charity Cashspiel Fundraiser for the duration of this thesis project.

x

TABLE OF CONTENTS

CERTIFICATE OF EXAMINATION

ii

ABSTRACT

iii

CO-AUTHORSHIP

v

DEDICATION

vii

ACKNOWLEDGMENTS

viii

GRANT SUPPORT

x

TABLE OF CONTENTS

xi

LIST OF TABLES

xv

LIST OF FIGURES

xvi

LIST OF APPENDICES

xix

LIST OF ABBREVIATIONS

xx

CHAPTER 1. INTRODUCTION
1.1. EARLY BREAST CANCER PROGRESSION
1.1.1. Breast Cancer
1.1.2. Morphology of Early Breast Cancer Progression
1.1.3. Relative Risk of Progression to IMC
1.1.4. Identification of Molecular Targets in Breast Cancer
Progression
1.1.5. Models of Breast Cancer Progression

1
1
2
4
5

1.2. THE 21T SERIES HUMAN BREAST CANCER CELL LINES
1.2.1. Establishment of the 21T Series Cell Lines
1.2.2. Characteristics of the 21T Series Cells

7
7
8

1.3. IN VIVO VS 3D IN VITRO CULTURE
1.3.1. Xenograft Mouse Model Limitations
1.3.2. Matrigel and 3D In Vitro Culture

xi

5

9
9
10

1.4. THESIS BACKGROUND STUDIES AND HYPOTHESES
1.4.1. 21T Series Cell Lines Mimic Stages of Breast Cancer
Progression In Vivo
1.4.2. Thesis Hypotheses

11
11

1.5. EXPERIMENTAL OBJECTIVES

12

1.6. REFERENCES

13

12

CHAPTER 2. 21T SERIES CELL LINES MIMIC SPECIFIC STAGES OF
BREAST CANCER PROGRESSION IN 3D CULTURE AND SHOW
STAGE-SPECIFIC GENE EXPRESSION PATTERNS
2.1. INTRODUCTION

19

2.2. MATERIALS AND METHODS
2.2.1. Cell Lines and Culture
2.2.2. In Vivo Studies
2.2.3. 3D In Vitro Cultures
2.2.4. Morphologic Characterization of 3D In Vitro Cultures
2.2.5. Proliferation and Apoptosis in 3D Culture
2.2.6. Matrigel Invasion Assay
2.2.7. Gene Expression Profiling in 3D Culture
2.2.8. Quantitative Real Time-PCR (qRT-PCR) Validation
2.2.9. Statistical Analysis

22
22
23
24
24
25
25
26
28
29

2.3. RESULTS
2.3.1. In Vivo Cultures of 21T Series Cell Lines Model Stages of
Early Progression
2.3.2. 3D In Vitro Cultures of 21T Series Cells Display Features of
Specific Stages of Early Progression
2.3.3. Differential Proliferation, Apoptosis and Invasiveness of 21T
Series Cells
2.3.4. Profiling Elucidates Differential Gene Expression between the
Three 21T Series Cell Lines Grown in 3D

29
29

2.4. DISCUSSION

46

2.5. REFERENCES

52

xii

33
35
37

CHAPTER 3. THE ROLES OF VANGL1, S100A2 AND TBX3 IN THE
TRANSITIONS BETWEEN STAGES OF EARLY BREAST CANCER
PROGRESSION
3.1. INTRODUCTION
3.1.1. Van Gogh-like 1 (VANGL1)
3.1.2. S100A2
3.1.3. T-box 3 (TBX3)

59
62
65
68

3.2. MATERIALS AND METHODS
3.2.1.
Cell Lines and Culture
3.2.2.
VANGL1 Expression Vector
3.2.3.
TBX3 Expression Vector
3.2.4.
shRNA against S100A2
3.2.5.
Transient and Stable Transfections
3.2.6.
3D In Vitro Cultures
3.2.7.
Collection and Quantification of RNA and Protein from 3D
Cultures
3.2.8.
Quantitative Real Time-PCR (qRT-PCR) Validation
3.2.9.
Western Blotting
3.2.10. Morphologic Characterization of 3D In Vitro Cultures
3.2.11. Proliferation and Apoptosis in 3D Cultures
3.2.12. Transwell Invasion Assay
3.2.13. Matrigel Invasion Assay
3.2.14. Confocal Microscopy
3.2.15. Statistical Analysis

71
71
72
76
80
82
83
83

3.3. RESULTS
3.3.1.
VANGL1
3.3.1.1. VANGL1 mRNA Expression Levels are Altered in
21NT Compared to 21PT Cells
3.3.1.2. VANGL1-Transfected 21PT Cells Show mRNA
and Protein Levels Similar to 21NT Cells
3.3.1.3. 3D In Vitro Cultures of 21PT+VANGL1 Cells
Display Features of More Advanced Progression
than 21PT+EV Cells
3.3.1.4. Altered Proliferation, Apoptosis and Invasive
Ability of 21PT+VANGL1 Cells Indicate
Conversion to a Later Stage of Progression
3.3.2.
S100A2
3.3.2.1. S100A2 mRNA Expression Levels are Altered in
21MT-1 Compared to 21NT Cells
3.3.2.2. 21NT+shS100A2 Cells Show mRNA and Protein
Levels Similar to 21MT-1 Cells
3.3.2.3. 3D In Vitro Cultures of 21NT+shS100A2 Cells
Display Features of a Later Stage of Progression
xiii

84
85
87
88
89
90
91
93
93
93
93
94
97
100
103
103
105
105

3.3.2.4.

3.3.3.

TBX3
3.3.3.1.
3.3.3.2.
3.3.3.3.
3.3.3.4.
3.3.3.5.

21NT+shS100A2 Cells Exhibit Characteristics of
a More Aggressive Phenotype Including
Alterations in Proliferation, Apoptosis and
Invasion
TBX3 mRNA Expression Levels are Altered in
21MT-1 Compared to 21NT Cells
21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 Cells
Show mRNA and Protein Levels Increased Over
21NT+EV Cells
3D In Vitro Cultures of 21NT+TBX3 Cells Display
Features of a More Advanced Stage of
Progression
Altered Proliferation, Apoptosis and Invasive
Ability Indicate 21NT+TBX3 Cells Exhibit
Characteristics of a More Invasive Phenotype
21NT+TBX3 Cells Show Vimentin and ECadherin Alterations Consistent with EMT

3.4. DISCUSSION
3.4.1.
VANGL1 Promotes the Transition from ADH to Invasive
Malignancy
3.4.2.
S100A2 Inhibits the Transition to an Invasive Phenotype
3.4.3.
TBX3 Promotes the Transition to an Invasive Phenotype
3.4.4.
Genes Identified by the 21T Series Model System are
Involved in Controlling the Transitions Between Stages of
Progression

108

113
113
115
121
123
125
127
130
133
135
139

141

3.5. REFERENCES
CHAPTER 4. GENERAL DISCUSSION
4.1. THESIS SUMMARY

148

4.2. DISCUSSION

152

4.3. FUTURE DIRECTIONS

156

4.4. REFERENCES

160

APPENDICES

165

CURRICULUM VITAE

185

xiv

LIST OF TABLES

Table 2.1.

Histopathology of 21T series cell lines in vivo on year after
orthotopic mammary fat pad injection into 6-8 week old nude
mice.

30

Table 2.2.

Genes that are concurrently: (1) significantly different among
the 21T series cell lines, (2) present on clinically relevant
databases from the literature and (3) found within the top 10
functional and canonical pathways represented according to
Ingenuity Pathways Analysis.

40

Table 2.3.

qRT-PCR validated genes of interest showing significant
difference between 21T series cell lines that are of potential
clinical relevance and are of the top 10 functional and
canonical pathways represented (IPA).

44

Table 3.1.

Primer sequences for VANGL1 cloning, TBX3 cloning and
TBX3 qRT-PCR.

74

xv

LIST OF FIGURES

Figure 1.1.

Morphology of early breast cancer progression.

Figure 2.1.

Histopathology of 21T series cells in vivo, 1 year after
injection of 1 x 107 cells into the mammary fat pad of 6-8
week old female nude mice.

32

Figure 2.2.

In vitro characteristics of 21PTci, 21NTci and 21MT-1 cells
after 15 days growth in 3D Matrigel.

34

Figure 2.3.

Proliferative and apoptotic activity of 21PTci, 21NTci and
21MT-1 cells after 9 and 15 days growth in 3D Matrigel.

36

Figure 2.4.

21T series cell invasion through Matrigel matrix.

38

Figure 3.1.

Genes identified as altered between 21T series cell lines
and breast cancer progression stages.

61

Figure 3.2.

VANGL1 cell signalling.

63

Figure 3.3.

Nuclear effects of S100A2.

66

Figure 3.4.

Effects and signalling of TBX3.

69

Figure 3.5.

Plasmid map for VANGL1 expression vector.

75

Figure 3.6.

Cloning primer design and plasmid map for TBX3
expression vector.

78

Figure 3.7.

Plasmid map for S100A2 shRNA vector.

81

Figure 3.8.

mRNA expression levels of VANGL1 in 21PTci and 21NTci
cells grown in 2D and 3D culture.

95

Figure 3.9.

mRNA expression levels of VANGL1 in 21PTci, 21NTci,
21PT and 21PTci cells grown in 3D culture.

96

Figure 3.10.

mRNA and protein levels of VANGL1 after transfection into
21PT cells.

98

Figure 3.11.

Characteristics of 21T and VANGL1 overexpressing cells
after 15 days growth in 3D Matrigel.

99

xvi

3

Figure 3.12.

Proliferative and apoptotic activity of 21T and VANGL1
overexpressing cell lines after 15 days growth in 3D
Matrigel.

101

Figure 3.13.

Invasion of VANGL1 overexpressing cells using a transwell
system.

102

Figure 3.14.

mRNA expression levels of S100A2 in 21NTci and 21MT-1
cells grown in 2D and 3D culture.

104

Figure 3.15.

mRNA expression levels of S100A2 in 21NTci and 21NT
cells compared to 21MT-1 cells.

106

Figure 3.16.

mRNA and protein levels of S100A2 after shRNA
transfection into 21NT cells.

107

Figure 3.17.

Characteristics of 21T and S100A2 knockdown cells after 15
days growth in 3D Matrigel.

109

Figure 3.18.

Proliferative and apoptotic activity of 21T and S100A2
knockdown cell lines after 15 days growth in 3D Matrigel.

110

Figure 3.19.

Cell invasion through Matrigel matrix for 21T and S100A2
knockdown cells.

112

Figure 3.20.

mRNA expression levels of TBX3 in 21NTci and 21MT-1
cells grown in 2D and 3D culture.

114

Figure 3.21.

mRNA expression levels of TBX3 in 21NTci and 21NT cells
compared to 21MT-1 cells.

116

Figure 3.22.

mRNA and protein levels of endogenous TBX3 and TBX3ZsGreen after transfection into 21NT cells.

118

Figure 3.23.

Relationship between TBX3 and ZsGreen using confocal
microscopy.

120

Figure 3.24.

Characteristics of 21T and TBX3 transfected cells after 15
days growth in 3D Matrigel.

122

Figure 3.25.

Proliferative and apoptotic activity of 21T and TBX3
transfected cell lines after 15 days growth in 3D Matrigel.

124

Figure 3.26.

Cell invasion through Matrigel matrix for 21T and TBX3
transfected cells.

126

xvii

Figure 3.27.

Levels of E-cadherin in TBX3-ZsGreen transfected cells
using confocal microscopy.

128

Figure 3.28.

Levels of vimentin in TBX3-ZsGreen transfected cells using
confocal microscopy.

129

Figure 3.29.

The roles of VANGL1, S100A2 and TBX3 in early breast
cancer progression.

140

xviii

LIST OF APPENDICES

Appendix A

Copyright agreement for previously published work and
animal protocol approval

165

Appendix B

Supplementary data for Chapter 2

169

Appendix C

Supplementary data for Chapter 3

177

xix

LIST OF ABBREVIATIONS
2D

Two dimensional

3D

Three dimensional

ADH

Atypical ductal hyperplasia

ALH

Atypical lobular hyperplasia

ANOVA

Analysis of variance

ATP

Adenosine triphosphate

BSA

Bovine serum albumin

cDNA

Complementary DNA

CIP

Calf intestinal phosphatase

Cox-2

Cyclooxygenase-2

DCIS

Ductal carcinoma in situ

DNA

Deoxyribonucleic acid

Dvl

Dishevelled

ECL

Enhanced chemiluminescence

ECM

Extracellular matrix

EGF

Epidermal growth factor

EGFR

Epidermal growth factor receptor

EMT

Epithelial to mesenchymal transition

ER

Estrogen receptor

ERK

Extracellular signal-regulated kinase

ERM

Ezrin, radixin and moesin

EV

Empty vector

FBS

Fetal bovine serum
xx

FGF

Fibroblast growth factor

Fmi

Flamingo

Fzd

Frizzled

GCOS

GeneChip Operating Software

H&E

Hematoxylin and eosin

HEPES

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HER-2

Human epidermal growth factor receptor 2

HDAC

Histone deacetylase

HNSCC

Head and neck squamous cell carcinoma

Ig

Immunoglobulin

IMC

Invasive mammary carcinoma

IPA

Ingenuity Pathways Analysis

iPS

Induced pluripotent stem

KITENIN

KAI1 COOH-terminal interacting tetraspanin

LB

Luria Bertani

LCIS

Lobular carcinoma in situ

MAPK

Mitogen-activated protein kinase

MARCKS

Myristoylated alanine-rich C kinase substrate

MEM

Minimal essential medium

MMP

Matrix metalloproteinase

mRNA

Messenger RNA

NFkB2

Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2

PBS

Phosphate buffered saline

PCP

Planar cell polarity
xxi

PCR

Polymerase chain reaction

PGE2

Prostaglandin E2

PKC

Protein kinase C

PR

Progesterone receptor

PVDF

Polyvinylidene fluoride

qRT-PCR

Quantitative real-time PCR

RNA

Ribonucleic acid

RUNX3

Runt-related transcription factor 3

S100A2

S100 calcium binding protein 2

SDS

Sodium dodecyl sulphate

Shh

Sonic hedgehog

shRNA

Short hairpin RNA

TBS

Tris-buffered saline

TBS-T

TBS with 0.1% Tween

TBX3

T-box 3

TDLU

Terminal duct lobular unit

TGFα

Transforming growth factor alpha

TGFβ

Transforming growth factor beta

µg

Microgram

µL

Microlitre

µm

Micrometer

UMS

Ulnar-mammary syndrome

UTR

Untranslated region

VANGL1

Van Gogh-like 1
xxii

1

CHAPTER 1. INTRODUCTION

1.1. EARLY BREAST CANCER PROGRESSION

1.1.1. Breast Cancer
Every hour of every day, 20 people in Canada are diagnosed with some
form of cancer [1]. Cancer is characterized by uncontrolled growth of cells and
can arise in many different organs within the body. In fact, the Canadian Cancer
Society recognizes over 30 different types of cancer, based on the organ in which
the tumour originates. Cancer may be characterized by uncontrolled growth, but
this oversimplifies the complexity of the disease. Research has determined that
cancer is a highly complex, multistep process that involves numerous alterations
at the molecular level and confers upon cells a growth advantage that facilitates
the conversion of normal cells to malignant cells. Even with this knowledge, our
understanding of the molecular changes and how they drive progression of
cancer is still greatly limited.
Breast cancer is the most common cancer in women [2-4] and is the
leading cause of death in women aged 40 to 59 and the second leading cause,
after lung cancer, for women aged 60-79 [3]. Breast cancers generally arise in
the terminal ductules of the lobular units of the breast [5]. When caught at an
early stage, survivability is very high, as the disease has not spread and local
excision may be curative. However, once the cancer is able to spread to lifesupporting organs, chance of survival is greatly reduced [3].

If the factors

responsible for promoting progression of breast cancer can be discovered, it will

2

be possible to develop new therapeutic interventions directed at inhibiting this
process. In order to find these factors, we need to study the mechanisms of early
breast cancer progression and identify the genes that control the transitions
between the stages of progression.

The gene targets may then be used to

develop therapeutics for treatment.

1.1.2. Morphology of Early Breast Cancer Progression
Invasive ductal carcinoma (of “no specific type”), one of the most common
types of breast cancer, accounts for 20-30% of all newly diagnosed breast
cancers [6].

It has been documented that stem cells from the terminal duct

lobular units (TDLUs) can give rise to atypical ductal hyperplasia (ADH) [5, 7-10].
At the stage of ADH, the breast duct is partially filled with two epithelial cell
populations (Figure 1.1). One population includes atypical cells, which may be
neoplastic, while the second population includes more normal-appearing cells [5,
8, 9]. Ductal carcinoma in situ (DCIS) may arise from ADH and is characterized
by a breast duct filled with neoplastic cells [5, 7, 11-13] (Figure 1.1).

If left

untreated at the DCIS stage, the carcinoma may become invasive (invasive
mammary carcinoma, IMC) and lead to metastases at distant sites [5, 7, 11, 12,
14] (Figure 1.1). These three stages of progression may not always occur in a
linear fashion however, and the histologic patterns are most likely phenotypic
indicators of the underlying molecular events which are driving the stages of
progression [15]. Identification of these molecular events may elucidate both the
timing and likelihood of a lesion’s progression to malignancy. In addition, an

3

fat
lobule

muscle

duct

chest wall /
rib cage

ADH

DCIS

IMC

Normal breast cells
Neoplastic cells

Figure 1.1. Morphology of early breast cancer progression. Stem cells from
the lobular unit give rise to atypical ductal hyperplasia (ADH). During ADH,
two epithelial populations are present within the duct. One population
includes atypical cells, presumed to be neoplastic, while the other population
is more normal-appearing. ADH can progress to ductal carcinoma in situ
(DCIS), which is characterized by a breast duct filled with neoplastic cells.
Finally, DCIS can progress to invasive mammary carcinoma (IMC), in which
cells are able to invade through the basement membrane and move to distant
sites. This image was adapted from http://www.breastcancer.org/symptoms/
types/dcis/diagnosis.jsp.
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understanding of the molecular events may aid us in determining ways to halt
progression at the early stages.

1.1.3. Relative Risk of Progression to IMC
Formation of metastases in vital organs, as a result of IMC is life
threatening. It has already been noted that breast cancer progression may not
always follow a linear pathway from ADH through DCIS to IMC; however,
histological examination of human specimens have demonstrated that ADH and
DCIS are markers for higher risk of IMC occurrence [7, 9, 14, 16].

Atypical

hyperplasias, including ADH and atypical lobular hyperplasia (ALH), are nonobligate precursors of IMC and in fact a diagnosis of ADH or ALH correlates with
an increased risk to develop IMC in either breast [9, 14, 16]. Compared to the
general public, women who have had a biopsy positive for ADH or ALH have a 45 times increased risk of developing IMC [9]. In contrast, DCIS is commonly
regarded as an obligate precursor lesion for IMC and results in an 8-10 times
increased risk for developing invasive disease [9].

DCIS is considered an

obligate precursor due to the common discovery of invasion at the original site of
DCIS diagnosis [16].

Even if progression does not always occur in a linear

fashion, both non-obligate and obligate precursors commonly share histologic
continuity with IMC [14, 15] and analyzing progression from a linear perspective
serves as an appropriate framework for studies into the molecular mechanisms
which drive tumour progression [9, 14, 16].
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1.1.4. Identification of Molecular Targets in Breast Cancer Progression
The molecular events within a cell are driven by the cell’s genotypic
signature.

Both microarray technology, which looks at the gene expression

profile within a cell and proteomics, which looks at the proteins expressed within
a cell, have identified candidate genes and their protein products potentially
involved in breast cancer progression.

These candidates are thought to be

involved in cancer characteristics, such as proliferation, apoptosis, migration,
invasion and adhesion [17-22].

However, although changes have been

associated in the literature with specific stages of progression, there is little
information on what alterations are functionally involved in driving the transitions
between the stages. In essence, we are seeing a static picture of what is actually
a very complex and dynamic process. In order to address which alterations have
significant functional effect, model systems to study progression are needed.

1.1.5. Models of Breast Cancer Progression
Using different approaches, several model systems of early breast cancer
progression have been developed.

Some models have used human breast

epithelial cell lines modified with activated oncogenes to drive production of
premalignant lesions in immune deficient mouse hosts [23, 24, 24-27]). Two of
these models are the HMT-3522 series (reviewed in [23, 27]) and the MCF10AT
series (reviewed in [24, 26, 28]).

The HMT-3522 series was derived from a

woman with fibrocystic change and consists of three cell lines [23, 27]. The
HMT-3522/S1 cell line, produced after in vitro culture of the explant, is
nontumourigenic in nude mice [27]. The HMT-3522/S2 cell line was created by
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EGF-independent growth selection in vitro and is able to form tumours in nude
mice.

However the tumours are slow growing and tumour take is low [27].

Finally, the HMT-3522/T4-2 cell line was created from a HMT-3522/S2 tumour
and these cells are highly tumourigenic [27]. The MCF10AT series was also
derived from a woman with fibrocystic change and represents a wide range of
breast cancer pathologies [24, 26, 28].

The MCF10A cells are normal

immortalized breast epithelial cells [28]. These cells were transfected with T-24
ras and renamed MCF10AneoT [24]. The MCF10AneoT cells are able to form
tumours and in fact the MCF10AT cell line is a derivative of a MCF10AneoT
lesion [24].

The MCF10AT cell line is able to form lesions with various

premalignant histologies, including hyperplasia, ADH and DCIS with a quarter of
the lesions able to progress to invasion [24, 28]. The most advanced cell line in
the series are the MCF10CA cells, which are fully malignant and also form
lesions with histological variation ranging from undifferentiated carcinomas to well
differentiated adenocarcinomas [26, 28].

Both the HMT-3522 and MCF10AT

series systems have proven useful; however, both series suffer from
disadvantages. Both HMT-3522 and MCF10AT series show mixed phenotypes
and lack of stability of the phenotypes after culture. Additionally, the HMT-3522
series lack a pre-DCIS or early stage of progression, while the MCF10AT series
is dependent on a ras transformation, which is an alteration that is uncommon in
spontaneous human breast cancers.

Other breast cancer progression model

systems have made use of murine models that have been genetically engineered
to develop mammary epithelial preneoplasia or neoplasia (reviewed in [29]).
Alternately, other murine models of progression have viral, chemical or hormonal
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agent induced premalignant lesions (reviewed in [30]). It is worth noting however
that in both types of murine models, the pre-malignant lesions being studied are
mouse-derived and these lesions, while being similar to human lesions in some
respects, are still different in other respects due to their mouse origins [29].
Additionally, the morphological progression continuum that has been described in
human breasts cancer has not been described in genetically engineered murine
mammary glands [29]. In order to study the molecular events underlying early
breast cancer progression most efficiently, a human model system that
represents all stages of progression is needed.

1.2.

THE 21T SERIES HUMAN BREAST CANCER CELL LINES

1.2.1. Establishment of the 21T Series Cell Lines
The 21T human cell lines have been proposed to represent a progression
series of early breast cancer. The series consists of three cell lines, which were
derived from a single patient and are representative of different stages of
progression [31]. The 36 year old patient originally presented with estrogen- and
progesterone-receptor negative DCIS plus infiltrating ductal carcinoma (no
special type) [31].

The 21PT and 21NT cell lines were derived from the

mastectomy specimen and have been found to be stably non-tumourigenic and
tumourigenic but non-metastatic, respectively, in nude mice [31]. One year postmastectomy, the patient developed lung metastases with pleural effusion [31].
The third cell line, 21MT-1 cells, was derived from this pleural effusion and has
been found to be both tumourigenic and metastatic [31].
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In order to isolate the 21PT and 21NT cell lines from the mastectomy
specimen, breast tissue was dissociated and cultured [31]. Fibroblasts from this
mixed population were removed from the epithelial population by selective
trypsinization [31]. The resulting pure epithelial population in 2D culture was
composed of both normal-appearing epithelial cells and cells which looked to be
more tumour-like [31]. The tumour-like cells were selectively expanded by both
clonal isolation and serum selection and are what constitutes the 21PT and 21NT
cells [31]. The 21MT-1 cells, which were isolated from the pleural effusion, were
first pelleted down and then cultured in dishes [32]. After cells were attached,
several washes were used to remove red blood cells and debris [32]. Loosely
adhered mesothelial cells were also removed by repeated washing [32]. Percoll
gradient fractionation was finally used to enhance the epithelial population [32].
The few mesothelial cells that remained after fractionation senesced after
prolonged culture [32]. These cells were named 21MT cells. However, after
approximately 100 population doublings two cell populations predominated [31].
One population was easily released from the culture plastic and this population
was dubbed the 21MT-1 cells [31]. All three cell lines (21PT, 21NT, 21MT-1)
were in continuous culture for over 2 years before publication [31].

1.2.2. Characteristics of the 21T Series Cells
As mentioned above, the 21PT cells are non-tumourigenic, while the 21NT
cells are tumourigenic, but not metastatic and the 21MT-1 cells are tumourigenic
and metastatic [31]. Karyotype were originally explored by Band et al. [31] and
further refined by our laboratory [33]. Additional characterization of the cell series

9

has determined that the 21T cells all express cytokeratins 8, 18 and 19 [31, 34],
as well as HMFG-2 [31], identifying them as epithelial cells of mammary origin.
Although all three cell lines were initially thought to be ER and PR negative, as
was the original tumour, subsequent work showed the 21PT cell line to express a
variant ER-receptor, which is not well detected by conventional anti-ER
antibodies [35, 36]. Mutations in the p53 gene were also investigated in the cell
series since mutations in this gene are very common in breast cancer. It was
found that all the 21T series cells have a frame-shift mutation in the p53 gene,
which results in the loss of p53 expression and p53-mediated effects [37].
Finally, the 21T series cell lines all contain lower mRNA levels of epidermal
growth factor receptor (EGFR) than normal breast epithelial cells, while mRNA
levels of transforming growth factor alpha (TGFα), a ligand for EGFR, are
reduced in 21MT-1 cells, but consistent with normal cells in 21PT and 21NT cells
[31]. The HER-2 gene (neu, ERBB2; Human epidermal growth factor receptor 2),
a marker for aggressive breast cancer, is overexpressed at both the mRNA and
protein levels in all 21T series cells, with 21MT-1 cells producing higher levels
than the other 21T series cells [31].

1.3.

IN VIVO VS 3D IN VITRO CULTURE

1.3.1. Xenograft Mouse Model Limitations
Xenograft mouse models are extremely useful when studying human
disease due to the fact that they share organ systems and an immense degree of
genetic similarity to humans [38].

In fact, in the modern era, nearly every
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successful cancer therapy has undergone xenograft testing [39]. Additionally,
murine xenograft models have enabled the identification of early diagnostic
markers and novel therapeutic targets, and an understanding of the in vivo
biology and genetics of human tumour initiation, promotion, progression and
metastasis [38]. However, xenograft mouse models are not perfect. Growth of
human cells in mice requires that the mouse host be immunodeficient.

The

immunodeficiency of the mice means that the mouse host does not possess all
the proper immune response that would be present in a human host [39].
Additionally the fact that human cells are injected into a mouse background can
often result in an inability of the human cells to adapt and can lead to low tumour
take [39]. Other issues arise in the variability that can arise between mice. In
fact, mice purchased from different vendors may reproduce different experimental
results due to genetic differences in the mouse strain between colonies [40].
Finally, mouse models are often slow, making it difficult to produce high
throughput studies and rendering the study of the effects of individual genes on
tumour cells more cumbersome than an in vitro system.

The ease of

manipulation of an in vitro system is also an advantage over an in vivo one. Due
to the shorter time frame and ease of manipulation, there is increasing interest in
the use of 3D in vitro model systems.

1.3.2. Matrigel and 3D In Vitro Culture
In vitro systems are very useful for high throughput studies. However, it
has been shown that when grown in 2-dimensional (2D) in vitro culture, cell lines
have distinctly different morphology and genetic profiles than when grown in vivo
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[41-47].

Moreover, important signals released by the extracellular matrix, which

govern normal homeostasis and tissue phenotypes are lost when cells are
cultured on 2D plastic [41].

Alternatively, if cells are grown in laminin-rich

extracellular matrix 3D cultures, many of these signals remain present [41].
Growing cells in 3D with extracellular matrix signals intact, allows for study of cell
proliferation, apoptosis, cell morphogenesis and invasiveness in a closed system.
In fact, there have been several studies using 3D systems to look at the
molecular control of morphogenesis in breast epithelial cells [43, 48-57].
However, use of a 3D system to directly model aspects of early breast cancer
progression has been limited. Growing the 21T series cell lines in a 3D in vitro
model system, which will mimic the characteristics of their behaviour in vivo,
should produce a more predictive model of the molecular/cellular events
governing early tumour progression compared to a 2D in vitro system.

1.4.

THESIS BACKGROUND STUDIES AND HYPOTHESES

1.4.1. 21T Series Cell Lines Mimic Stages of Breast Cancer Progression In
Vivo
Prior to my own work, experiments in our laboratory were performed in
order to verify the in vivo growth characteristics of the 21T series cell lines. The
three 21T series cell lines were injected into the mammary fat pads of female
nude mice, left for up to a year to develop lesions, and histology was performed
on mammary fat pad and other organs on necropsy. Through the course of this
work, it was discovered that the lesions formed in each case were of
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characteristic morphology on hematoxylin and eosin (H&E) sectioning of the
mammary fat pad (21PTci – ADH; 21NTci – DCIS; 21MT-1 – IMC). The results
of this work have been included in our recent publication [58] and contribute to
the work discussed in Chapter 2 of this thesis. The in vivo data included in
Chapter 2 of this thesis was thus, completed before the beginning of the thesis
work and was the basis for formation of the thesis hypothesis.

1.4.2. Thesis Hypotheses
I hypothesize first that the 21T series cells grown in a 3D culture system
can be used to identify genes involved in the transitions between early stages of
breast cancer. Secondly, I also hypothesize that this 3D system can then be
used to determine the functional role of the identified genes in early breast cancer
progression.

1.5.

EXPERIMENTAL OBJECTIVES

1. To determine the growth characteristics of the 21T series cell lines in 3D in
vitro culture.
2. To identify genes involved in the transition from ADH to DCIS and genes
involved in the transition from DCIS to IMC.
3. To functionally characterize validated genes in the 3D system to determine
their role in induction of tumour progression inhibition.

These experimental objectives are described in detail in Chapters 2 and 3.
Both objectives 1 and 2 are addressed in Chapter 2, which proposes that the 21T
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series cell lines are an appropriate model of early breast cancer progression
when grown in 3D culture. Furthermore, Chapter 2 identified genes that are
specifically altered in the transitions from ADH to DCIS and DCIS to IMC. Three
of these genes, VANGL1, S100A2 and TBX3 were the focus of further study and
are the subject of Chapter 3. It was found that VANGL1 plays a role in the
transition from ADH to DCIS, while both S100A2 and TBX3 are involved in
controlling the transition from DCIS to an invasive phenotype (IMC).
Together these two chapters demonstrate the ability of the 21T series cell
lines to elucidate and test genes involved in controlling the transitions between
stages of early breast cancer progression. Furthermore, genes identified and
validated with this system may prove to be potential therapeutic targets in the
future.
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CHAPTER 2.

21T SERIES CELL LINES MIMIC SPECIFIC STAGES OF

BREAST CANCER PROGRESSION IN 3D CULTURE AND SHOW STAGESPECIFIC GENE EXPRESSION PATTERNS

The contents of this chapter has been adapted from a paper entitled “Human 21T
breast epithelial cell lines mimic breast cancer progression in vivo and in vitro and
show stage specific gene expression patterns”, published in Laboratory
Investigation, vol 90: pp. 1247-1258 (2010), by Lesley H. Souter, Joseph D.
Andrews, Guihua Zhang, Amy C. Cook, Carl O. Postenka, Waleed Al-Katib, Hon
S. Leong, David I. Rodenhiser, Ann F. Chambers and Alan B. Tuck. The in vivo
experiment was conducted prior to this thesis project.

2.1.

INTRODUCTION
Pathologic and epidemiologic evidence has led to a histologic model of

breast cancer evolution in which stem cells from the terminal duct lobular unit
(TDLU) give rise to atypical ductal hyperplasia (ADH) or atypical lobular
hyperplasia (ALH), which can then progress to ductal carcinoma in situ (DCIS) or
lobular carcinoma in situ (LCIS) respectively, and eventually to invasive
mammary carcinomas (IMC) [1-6]. These histologic patterns are, however, most
likely only rough phenotypic indications of underlying cellular and molecular
events determining progression [7], and may not necessarily occur in a linear
fashion. There is currently much interest in identifying the nature of the cellular
and molecular events involved, not only for use in determining at which point a
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lesion is most likely to progress to malignancy, but also in hopes of finding a way
to halt progression at these early stages.
Microarray technology and proteomics have identified candidate genes
with potential involvement in cell proliferation, cell death, cell adhesion, migration,
invasion, etc., at different stages of breast cancer progression [8-13]. Although
providing important information concerning gene expression between samples at
any given stage of progression, this is only a static representation of what is
presumed to be a dynamic process. Model systems are thus needed, in addition
to histological analysis of human breast specimens, to directly evaluate the
effects of expression of specific genes, in order to determine the functional roles
of these genes at different stages of tumour progression.
There have been a number of different approaches to modeling early
breast cancer progression. Some have made use of murine models whereby
premalignant lesions are induced by viral, chemical, or hormonal agents
(reviewed in [14]), or whereby genetically engineered mice are generated which
are susceptible to developing mammary epithelial neoplasia or preneoplasia
(reviewed in [15]). In these instances, it is mouse-derived pre-malignant lesions
that are being generated and studied, which show both similarities and
differences with their human counterparts.

Other models have used human

breast epithelial cell lines that have been spontaneously transformed, transduced
with oncogenic viruses, or transfected with activated oncogenes to derive altered
cells that mimic premalignant lesions when tested in immune deficient rodent
hosts (egs. HMT-3522 and MCF10AT series, reviews in [16, 17, 17-20]). These
systems are useful, but suffer the disadvantages of lack of representation of
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earlier (pre-DCIS) stages of progression (HMT-3522 series), the presence of
mixed phenotypes, lack of stability of the phenotypes after culture (both series),
or the dependence on ras transformation (MCF10AT series).
For ease of experimental manipulation, there has been much interest in
comparing cells of premalignant and malignant status in 3D in vitro cultures [2127]. By allowing cells to grow in 3D conformation in extracellular matrix certain
characteristics of cell morphogenesis, proliferation, apoptosis and invasiveness
may be studied in a controlled system. Using such 3D culture systems, much
information has been generated on the molecular controls of morphogenesis in
breast epithelial cells of different origins [21-23, 28-35]. To this point however,
only limited use has been made of such 3D in vitro systems to directly model
aspects of early breast cancer progression.
The 21T series cell lines, which were derived from a single patient with
metastatic breast cancer, have been proposed to represent a human breast
cancer progression series [36]. The 21PT and 21NT cell lines were established
from the mastectomy specimen and have been found to be stably nontumourigenic, and tumourigenic but non-metastatic, respectively, in nude mice
[36]. The third cell line, 21MT-1, was derived from a malignant pleural effusion
and has been found to be both tumourigenic and metastatic [36]. 21T series cells
all express cytokeratins 8, 18 and 19, as well as HMFG-2 [36], identifying them
as epithelial cells of mammary origin. Although all three cell lines were initially
thought to be ER and PR negative, subsequent work showed the 21PT cell line to
express a variant ER-receptor, which is not well detected by conventional anti-ER
antibodies [37, 38].
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To further explore the potential of the 21T series human breast cell lines
as a functional model of early breast cancer progression, we have investigated
their behaviour both histologically in vivo and in 3D in vitro cultures.
Characterization of these cells at the molecular level, using gene expression
profiling of cells grown in 3D culture, revealed stage-specific differences in genes
involved in certain signalling pathways and functional categories reflective of
progression to a more aggressive phenotype.

Comparison with published

microarray data from clinical human specimens has generated a “genes of
interest” short list, consisting of genes which have potential clinical relevance and
are thus prime candidates for further functional testing and development as
stage-specific targets to block breast cancer progression.

2.2.

MATERIALS AND METHODS

2.2.1. Cell Lines and Culture
The 21T series cell lines (21PT, 21NT, 21MT-1) were obtained as a kind
gift of Dr Vimla Band (Dana Farber Cancer Institute) [36]. These cells were
maintained in culture in α-MEM supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine (both from Gibco Life Technologies, Grand Island, NY),
insulin (1 µg/mL), epidermal growth factor (12.5 ng/mL), hydrocortisone (2.8 mM),
10mM

4-(2-hydroxyethyl)-1-piperazineethanesulfonic

acid

(HEPES),

1mM

sodium pyruvate, 0.1 mM nonessential amino acids and 50 mg/mL gentamycin
reagent (all from Sigma Chemical, St. Louis, MO), as previously described [39].
After addition of all reagents, this growth medium was referred to as αHE. The

23

21PT and 21NT-derived cell lines used in this work, designated 21PTci and
21NTci, are a pooled population of vector-only (pcDNA3) transfected cells and
have been used as control cells for previous work in our laboratory [40]. Culture
medium for these cell lines is the same as for the parental cell lines, with the
addition of 0.2 mg/mL G418 as a selection marker (Gibco Life Technologies).

2.2.2. In Vivo Studies
Female athymic NCr nude mice (nu/nu) were housed and cared for in
accordance with the recommendations of the Canadian Council on Animal Care,
under a protocol approved by the University of Western Ontario Council on
Animal Care. Cell lines were grown in 150 mm tissue culture dishes to ~ 80%
confluency (log phase of growth). The cells were gently trypsinized, washed
twice with sterile PBS, and resuspended in serum-free αHE media at a
concentration of 1x107 cells per 100 µl.

Cells were injected into the second

thoracic mammary fat pad of 8-9 week old female nude mice, as described
elsewhere [41].

Animals were routinely monitored for health and primary

tumours, when palpable, were measured every 7-14 days.

Animals were

euthanized early if the tumour burden became too great, or at the end point of the
experiment (1 year post-injection).

Animals were sacrificed and necropsies

performed, examining the injected mammary fat pad, locoregional lymph nodes,
and all major viscera, whether or not a palpable lesion was present. Tissues
were formalin-fixed, paraffin embedded, sectioned (4 µm thick) and examined
histologically by hematoxylin and eosin (H&E) staining.
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2.2.3. 3D In Vitro Cultures
For all 3D cultures, cells were grown in Matrigel Basement Membrane
Matrix (BD Biosciences, Mississauga, ON) for 9 or 15 days.

Cultures were

created in 48-well plates (Nunc Brand Products, Rochester, NY) with three
distinct layers. The bottom layer consisted of undiluted Matrigel for a solid base.
The middle layer contained a 1:1 mix of Matrigel and 2 x 105 cells in media
supplemented with 0.1% bovine serum albumin (BSA), instead of FBS. These
two layers were topped with growth media supplemented with 0.1% BSA (without
FBS). After growth in Matrigel, 10% neutral buffered formalin was added to the
dishes for 48 hours and the cultures were removed as intact Matrigel plugs. The
formalin-fixed plugs were then processed, paraffin-embedded and sectioned for
H&E staining and immunohistochemistry.

2.2.4. Morphologic Characterization of 3D In Vitro Cultures
Histomorphology was determined by examination of 4 μm, H&E stained
sections of the Matrigel plugs.

Characterization of behaviour included

assessment of extracellular lumen formation, number of groups with polarized
cells, spherical (vs. non-spherical) colony formation and proportion of single cells.
Each of these parameters was assessed in terms of a percentage of total
“events” counted.

Appendix B Figure 1 illustrates each of the cell colony

morphologies. For each cell line, 10 high power (400X) fields of view from three
replicate Matrigel plugs were examined.
events per 10 high power fields.

This yielded between 200 and 275
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2.2.5. Proliferation and Apoptosis in 3D Culture
The 21T series cell lines were grown in Matrigel for 9 or 15 days. Matrigel
plugs were immunostained for the proliferation marker, Ki67, and for the
apoptotic

marker,

caspase

3.

For

caspase

3

immunohistochemistry,

deparaffinized sections were pretreated in a microwave oven for epitope retrieval.
Caspase 3 antibody, which recognized cleaved caspase 3 (Cell Signaling
Technologies, Danvers, MA) was applied (1/300 dilution) for 15 min at room
temperature.

Ki67 staining was performed following a previously published

protocol [42] with Ki67 antibody (Dako, Mississauga, ON) applied (1/150 dilution)
overnight at 4oC. For both caspase 3 and Ki67, detection was performed with the
UltraVision LP Detection System HRP Polymer (Thermo Scientific, Waltham, MA)
kit, following the manufacturer’s protocol.

Slides were counterstained with

Harris’s Hematoxylin. Positive and negative controls were included. For each
cell line, the Ki67 and caspase 3 indices, defined as the number of cells positive
for Ki67 or caspase 3 staining divided by the total cells counted, were calculated
from examination of 10 high power (400X) fields of view from three replicate
Matrigel plugs per cell line, yielding between 200 and 350 cells. In order to
determine the balance of dividing cells vs. apoptosing cells, the ratio of
proliferation over apoptosis was calculated for each cell line.

2.2.6. Matrigel Invasion Assay
21T series cell lines were grown in Matrigel for 9 days in 8-well chamber
slides (Nunc Brand Products). Matrigel cultures were formed as above, with
adjustment made in volumes of the three layers for the smaller 8-well chamber
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slide. 1.5 x 104 cells were used in the middle layer. Slides were then moved to
an incubated stage platform of a Zeiss Axiovert 200M microscope for time lapse
photography. Z-stack microscopy images at 5 positions were taken for each cell
line every 12 hours until day 15 of growth. All cells found within the 5 positions
per cell line (around 100 cells total) were then followed using AxioVision 4.5
software (Carl Zeiss Imaging Solutions) to determine the percentage of cells that
invaded through the Matrigel matrix and the distance the cells traveled. A cell
was defined as moving if any part of the cell was in a different location compared
to the image taken 12 hours previously. The minimum distance a cell could travel
to be designated as moving was 5 µm. The distance a moving cell travelled was
measured using the AxioVision 4.5 software.

2.2.7. Gene Expression Profiling in 3D Culture
For expression profiling in 3D culture, cells were grown in Matrigel for 9
days in 24-well plates (Nunc Brand Products). Matrigel cultures were formed as
above with an adjustment made in volumes of the three layers for the larger 24well plate volume. Three wells per cell line, representing 3 biological replicates,
were grown. Total RNA from each biological replicate was isolated using Cell
Recovery Solution (BD Biosciences) to non-enzymatically dissociate the Matrigel,
followed by TRIzol (Invitrogen International, Mississauga, ON), as per the
manufacturer's instructions. RNA (10 μg) was then sent to the London Regional
Genomics Centre (www.lrgc.ca, London, ON) and was used to produce Biotin
labeled cRNA, which was hybridized to Affymetrix HGU133_Plus_2 arrays
(Affymetrix, Inc., Santa Clara, CA). Washing, scanning and probe quantification
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were carried out according to the manufacturer's instructions, using GeneChip
Operating Software (GCOS, www.affymetrix.com), with target intensity set to 150.
For each array, GCOS output was imported as .txt files into Genespring GX 7.3
software (Agilent Technologies, Santa Clara, CA), and data were normalized as
follows: Values <0.01 were set to 0.01 and the median intensity of each array
was normalized to the 50th percentile of all arrays. Finally, the intensity of each
probe set in each of the three 21NTci or 21MT-1 arrays was divided by the
normalized mean intensity of that probe set in the appropriate control arrays. The
geometric mean of these 3 ratios is reported. In order to control the family-wise
error rate, two separate analyses were performed: 21NTci vs. 21PTci, with 21PTi
as control, and 21MT-1 vs. 21NTci, with 21NTci as control. After normalization,
the data were first prefiltered. Any probe set flagged ‘absent’ by GCOS software
in all 9 arrays was removed from further consideration. The full raw data for all 9
arrays can be found at http://www.ncbi.nlm.nih.gov/geo/, data series GSE18370.
Next, any probe set not changing at least 1.5-fold in 21NTci relative to 21PTci or
21MT-1 relative to 21NTci was removed. Probe sets passing these criteria were
analyzed using the student’s t-test tool in Genespring, with the nominal p-value
set at p<0.05. This resulted in two lists of genes, one with genes significantly
changed in 21NTci vs. 21PTci (Supplemental Table 1) and the other with genes
significantly changed in 21MT-1 vs. 21NTci (Supplemental Table 2). In order to
focus our search to genes relevant in a clinical setting, the “significantly altered”
gene lists were then compared to gene expression profiling information on
clinically relevant databases we established from the literature related to early
progression, invasion/metastasis and prognosis of breast cancer [11-13, 43-51]
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(Supplemental Table 3).

New gene lists created from gene expression

alterations in common with the clinical databases (Appendix B Table 1) were
imported into Ingenuity Pathways Analysis® (IPA) (Ingenuity® Systems,
www.ingenuity.com). Each gene identifier in the data sets was mapped to its
corresponding gene in the Ingenuity Pathways Knowledge Base, and if present,
was considered for analysis. Functional analysis identified biological functions
and/or diseases that were most significant to the data set. Canonical pathway
analysis identified pathways from the IPA library that were most significant to the
data set.

2.2.8. Quantitative Real Time-PCR (qRT-PCR) Validation
Total RNA was extracted from 4 biological replicates of each cell line
following 9 days of growth in 3D Matrigel, using the same methodology employed
for gene expression profiling.

cDNA was synthesized from 1μg total RNA using

Superscript II (Invitrogen International), with random primers (Invitrogen
International), as per the manufacturer's instructions. qRT-PCR was performed
using a Rotor-Gene RG-3000 (Corbett Life Science, San Francisco, CA), in
combination with SYBR-Green.

RT2 qPCR primers for the selected targets

(BAX, CCL20, CCR1, CDH1, CXCR4, DCN, MAX, MCM4, MGA, S100A2,
S100A3, SERPINB5, SNAI2, TBX3, TFF2, TNFAIP3, VANGL1, WISP1, WNT5A)
and RT2 SYBR-Green qPCR Master Mix were purchased from SuperArray
Bioscience Corporation. 18S rRNA was used as an endogeneous control
(SuperArray Biosciences Corporation). Genes were considered to be validated if
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the qRT-PCR results showed statistically significant expression alterations in
agreement with the microarray.

2.2.9. Statistical Analysis
The differences between experimental groups were analyzed using oneway analysis of variance (ANOVA), followed by Tukey’s test for post hoc
analysis.

For the Matrigel invasion assay, a Kruskal-Wallis nonparametric

ANOVA was used when calculating the percent of cells that moved, as the values
were not normally distributed. This was also followed by a Tukey’s post hoc test.
For all statistics, a p-value of less than 0.05 was considered statistically
significant.

2.3.

RESULTS

2.3.1. In Vivo Cultures of 21T Series Cell Lines Model Stages of Early
Progression
Mice injected in the mammary fat pad with each of the three 21T series
cell lines were monitored for tumour growth for up to a year.

This study

confirmed the previously published findings of Band and colleagues [36] that
21PT-derived cells are non-tumourigenic and non-metastatic, 21NT-derived cells
are tumourigenic but non-metastatic, and 21MT-1 cells are tumourigenic and
metastatic in some mice (Table 2.1).

In addition, in our study, systematic

histologic examination of the mammary fat pads of all animals, whether or not
tumours were palpable, was performed at end-point and provided some very
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Table 2.1.

Histopathology of 21T series cell lines in vivo one year after

orthotopic mammary fat pad injection into 6-8 week old female nude mice.

21PTci
21NTci
21MT-1

No. of mice
showing ADH1
only

No. of mice
showing
DCIS2 only

2/32
0/29
0/15

0/32
6/29
0/15

______________________________
1
2

ADH, atypical ductal hyperplasia
DCIS, ductal carcinoma in situ

No. of mice
showing
invasive
carcinoma
0/32
1/29
10/15

No. of mice
showing
metastases
0/32
0/29
5/15
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novel information. Where microscopically discernible lesions formed, each of the
injected cell lines gave rise to a characteristic histomorphology. Mammary fat
pads of 21PTci-injected mice showed scattered ducts with features of ADH
(Table 2.1 and Figure 2.1A).
animals

showed

a

In keeping with ADH [6], involved ducts of these

mixture

of

two

epithelial

cell

populations,

one

atypical/neoplastic appearing (non-high grade), and the other normal/benign
appearing (Figure 2.1A inset).

None of the ducts in 21PTci-injected mice

displayed a morphology that met criteria for DCIS (incomplete duct filling by
atypical cell population, < 2.0 mm in greatest extent). In contrast, mammary fat
pads of 21NTci-injected mice showed a pattern of DCIS (intermediate and high
nuclear grade, solid and cribriform, with zonal necrosis), which in 6/7 of those
mice forming lesions had no associated invasive component (Table 2.1 and
Figure 2.1B). In the one 21NTci-injected animal where associated invasive
carcinoma was present, the degree of invasion was minimal, and no metastases
were seen (Table 2.1). In sharp contrast to both, mammary fat pads of 21MT-1
injected mice showed a pattern of IMC in all instances where a histologically
discernable lesion formed, and half of these were also associated with pulmonary
metastases (Table 2.1 and Figure 2.1C). The in vivo growth characteristics of
these three 21T series cell lines thus reproducibly model distinct histologic stages
of early breast progression, from ADH (21PTci) to DCIS (21NTci) to IMC (21MT1), up to one year after mammary fat pad injection in mice.
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21PTci
A)

21MT-1

21NTci
B)

C)

Figure 2.1. Histopathology of 21T series cells in vivo, 1 year after injection of
1 x 107 cells into the mammary fat pad of 6-8 week old female nude mice.
Histology was analyzed for mammary fat pads of all mice injected. A) 21PTci
cells mimicked aspects of ADH, with both atypical (non-high grade) and
normal-appearing populations visible in a given involved duct/ductule and
with the atypical cell population represented over an area of < 2.0 mm (i.e.
not meeting pathologic criteria for DCIS). B) 21NTci cell morphology
mimicked DCIS, with the neoplastic cells filling an entire mammary fat pad
duct, often with accompanying central zonal necrosis. This pattern was seen
in multiple duct cross-sections (over an area > 2.0mm). C) 21MT-1 cells
displayed a histology of IMC (no special type, SBR Grade III/III), associated
with a background DCIS. All sections are H&E stained. Scale bars represent
200μm, except for the inset of a) and b), which represents 100μm. All
images are 24-bit resolution TIFFs (1.8 MP) captured with an Aperio
Scanscope, scanning with the 400x objective.
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2.3.2. 3D In Vitro Cultures of 21T Series Cells Display Features of Specific
Stages of Early Progression
In order to develop a more rapid, readily manipulatable in vitro system for
assessing the biologic differences between these cells, we made use of a 3D
Matrigel model. Cells were grown in 3D Matrigel plugs for 9 or 15 days, and
characterized using a number of morphologic and functional parameters,
including colony profile (spherical vs. irregular), lumen formation, cell polarization,
proportion of single cells, Ki67 proliferation index, caspase 3 apoptosis index and
cell invasion (by time lapse microscopy). By day 15, 21PTci cells were found to
form many spherical colonies, which had a high proportion of polarized cells and
extracellular lumen formation (Figure 2.2A, D, G).

Interestingly, many of the

21PTci cell colonies had an admixture of cells with nuclei that appeared either
normal or atypical in morphology.

In contrast, 21NTci cells showed fewer

spherical colony profiles, and a lesser degree of cell polarization and lumen
formation than the 21PTci cells (Figure 2.2B, E, G). Most of the 21NTci cell
groups showed significant nuclear atypia. Finally, 21MT-1 cells showed a much
lower proportion of spherical colonies (more were of irregular profile) and a high
proportion of single cells than either of the other lines. Additionally, 21MT-1 cell
groups show even less polarization and extracellular lumen formation than
21NTci cells (Figure 2.2C, F, G).
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21NTci

21PTci

21MT-1

A)

B)

C)

D)

E)

F
)

G)
Percentage of Total Events

80
70
60

NS

50
40
30
20
10
0

Lumen formation

21PTci

Polarized cells

Spherical colonies

21NTci

Single cells

21MT-1

Figure 2.2. In vitro characteristics of 21PTci, 21NTci and 21MT-1 cells after 15
days growth in 3D Matrigel. 21PTci cells (A,D,G) formed more polarized cell groups
than 21NTci (p<0.05) or 21MT-1 (p<0.05) cells, with higher frequency of extracellular lumen formation (~10%, p<0.01 and ~17%, p<0.001 respectively) and more
crisply-defined spherical colonies than 21NTci (p<0.05) or 21MT-1 (p<0.001) cells.
21NTci cells (B,E,G) formed large numbers of cohesive spherical colonies (~38%
compared to 21MT-1 cells, p<0.001), but have less tendency towards cell
polarization. 21MT-1 cells (C,F,G) were present more as single cells (~26% more
than 21PTci cells, p<0.001 and ~13% more than 21NTci cells, p<0.001) and small
groups, which were non-spherical and less polarized (than 21PTci), in an invasive
pattern of distribution. All sections are H&E stained. Images were chosen to
demonstrate structures of 3D cell colonies and not typical cell density within a
Matrigel plug. In (G) for ‘single cells’, an “event” is either a single cell or a cell
group/colony, while for the ‘spherical colonies’, ‘lumen formation’ and ‘polarized
cells’ comparisons, an “event” was defined as a cell group/colony. Also for (G) all
bars within each group are significantly different from each other at a p-value of at
least < 0.05, except when indicated by NS (non significant). Scale bars for (A,B,C)
represent 100μm, while scale bars for (D,E,F) represent 50μm.
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2.3.3. Differential Proliferation, Apoptosis and Invasiveness of 21T Series
Cells
Assessment of proliferative rates by Ki67 immunohistochemistry showed
that at day 9, 21NTci cells showed significantly more proliferative events than
21PTci or 21MT-1 cells (p<0.01) (Figure 2.3A). However, the proliferative rate of
both 21NTci and 21PTci had dropped off by 15 days of growth in Matrigel,
whereas that of 21MT-1 cells was highest at day 15 (3x that of 21PTci, p<0.01)
(Figure 2.3A). Apoptotic rates by caspase 3 immunohistochemistry showed that
there were no significant differences between cell lines at day 9, however by day
15, apoptotic rates drop slightly and not significantly for 21PTci cells and slightly
and significantly (p<0.01) for 21MT-1 cells (Figure 2.3B).

The ratios of

proliferation/apoptosis were calculated for the 21T series cell lines grown in
Matrigel, using Ki67 (proliferation) vs. caspase 3 (apoptosis) index.

Results

indicate that at day 9, 21NTci cells had the highest ratio of proliferation/apoptosis,
compared to 21PTci cells (p<0.05) or 21MT-1 cells (p<0.05) (Figure 2.3C).
However, by day 15, 21MT-1 cells showed an increased proliferation/apoptosis
ratio, which was higher than either of the other 2 cell lines (p<0.01 compared to
21PTci and 21NTci) (Figure 2.3C). The 21NTci cells, which showed a high rate
of growth at day 9, had a significantly decreased (p<0.05) ratio on day 15 (Figure
2.3C).

The

21PTci

cells

showed

a

trend

towards

a

decrease

in

proliferation/apoptosis at day 15 compared to day 9, but this was not significant.
Interestingly, by day 15 (vs. day 9), a higher proportion of 21PTci and 21NTci
cells were present as polarized groups showing extracellular lumen formation,
suggesting that the decrease in ratio of cell proliferation/apoptosis may be related
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Figure 2.3. Proliferative and apoptotic activity of 21PTci, 21NTci and 21MT-1 cells
after 9 and 15 days growth in 3D Matrigel. A) Proliferation was quantified by Ki67
immunohistochemical staining of Matrigel plugs. 21PTci cells showed a modest
proliferative activity at day 9, which trailed off by day 15. 21NTci cells showed an
initial burst of proliferative activity at day 9, which decreased significantly (p<0.01) by
day 15. 21MT-1 cells showed a modest proliferative activity that was higher by day
15. B) Apoptosis was quantified by caspase 3 immunohistochemical staining of
Matrigel plugs. At day 9, there were no significant differences in apoptotic rates
among cell lines. At day 15, apoptotic rates of both 21PTci and 21MT-1 cells
decreased slightly (non significantly and significantly (p<0.05), respectively). C)
When the ratio of proliferation/apoptosis was calculated, 21PTci cells showed a
modest cell division over cell death ratio at day 9, which trended towards a
decreased ratio at day 15, at which time there was evidence of differentiation in
terms of extracellular lumen formation and polarized groups (c.f. Figure 2.2).
21NTci cells showed an initial burst of proliferative activity over apoptosis at day 9,
which decreased significantly (p<0.05) by day 15. 21MT-1 cells showed a modest
proliferation/apoptosis ratio at day 9, which significantly increased (p<0.05) at day
15. * indicates significance at a level of p<0.05.
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to increased differentiation (data not shown), while the 21MT-1 showed very little
polarization/extracellular lumen formation and instead exhibited increased growth
between day 9 and day 15 (cf. Figure 2.2, Figure 2.3).
Finally, to assess invasive ability, cells were grown in Matrigel for 9 days
and then followed with time lapse microscopy until day 15. It was found that
100% of 21MT-1 cells were able to travel through the Matrigel in both horizontal
and vertical directions, compared to only 25% of 21PTci and 30% of 21NTci cells
(Figure 2.4A). In addition 21MT-1 cells traveled 219μm on average over the
seven days, which was significantly (p<0.01) farther than that for 21PTci (22μm)
and 21NTci (18μm) cells (Figure 2.4B). Whereas the majority of 21MT-1 cells
that moved showed individual translational cell movement, 21PTci and 21NTci
cell movement predominantly involved localized arrangement into cell groups
within a confined area.

2.3.4. Profiling Elucidates Differential Gene Expression between the Three
21T Series Cell Lines Grown in 3D
In order to determine differential gene profiles between the 21T series cell
lines, 3D in vitro microarray expression arrays were performed, which identified
stage-specific gene alterations. For the 21PTci to 21NTci comparison, 366 probe
sets were at least 1.5-fold altered (p<0.05) (Supplemental Table 1), whereas for
the 21NTci to 21MT-1 comparison, 3067 probe sets were at least 1.5-fold up- or
down-regulated (p<0.05) (Supplemental Table 2). In order to assess whether
these alterations would potentially apply to breast cancer progression in a clinical
situation (i.e. to establish potential clinical relevance), we compared our list of
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Figure 2.4. 21T series cell invasion through Matrigel matrix. Cells were
grown in Matrigel for 9 days and then transferred to the incubator stage
platform of a time lapse microscope until day 15. Z-stack images were taken
every 12 hours. All individual cells imaged were followed for the full 6 day
interval. A) Percentage of total cells that moved (invaded) through the
Matrigel matrix. A cell was defined as moving if any part of the cell was in a
different location compared to the image taken 12 hours previously. 100% of
21MT-1 cells showed translational movement, compared to only 27% of
21PTci and 33% 21NTci cells. B) Distance (µm) moving cells traveled
through Matrigel matrix. 21MT-1 cells moved significantly further than 21PTci
(p<0.01) or 21NTci (p<0.01) cells, which each showed minimal translational
movement/invasive ability, consistent with the invasive (21MT-1) vs. noninvasive (21PTci, 21NTci) morphologies of these cells when grown in vivo.
*indicates significance at a level of p<0.05.
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differentially expressed genes with a database we generated from established
literature on gene expression profiling of clinical cancer specimens, including
papers related to progression [11-13, 49-51], metastasis [45, 46, 48, 49] and
prognosis [43, 44, 47, 50, 51] of breast cancer (Supplemental Table 3). Overlaps
between our initial gene lists (Supplemental Table 1 and 2) and the clinicallyrelevant databases (Supplemental Table 3) were used to make two more focused
gene lists of statistically altered and potentially clinically-relevant genes (21PTci
to 21NTci: 23 probe IDs; 21NTci to 21MT-1: 208 probe IDs) (Appendix B, Table
1). These gene lists were then uploaded into Ingenuity Pathways Analysis (IPA)
for further analysis, which identified representation of several major functional
and canonical categories. Gene lists were then pared down to all genes found
within the top 10 functional categories and canonical pathways (21PTci to
21NTci: 20 genes; 21NTci to 21MT-1: 66 genes) and the gene function as
described by GeneCards (www.gencards.org) was recorded (Table 2.2). Based
on gene function as described by GeneCards, 19 representative genes between
the two transitions were chosen for 3D qRT-PCR validation, with 2 genes (DCN,
WNT5A) represented in both transitions (Table 2.3). If a gene was significantly
different (p<0.05) between the 2 cell lines of interest and in the same direction as
the microarray, the gene was considered validated. Of the 19 genes, all genes
except BAX and MCM4 were validated by qRT-PCR (Table 2.3). For the 21PTci
to 21NTci comparison, differential expression of BAX, DCN, MAX, MCM4, MGA,
VANGL1, WISP1 and WNT5A were analyzed by real-time PCR. CCL20, CCR1,
CDH1, CXCR4, DCN, S100A2, S100A3, SERPINB5, SNAI2, TBX3, TFF2,
TNFAIP3 and WNT5A were validated in the 21NTci to 21MT-1 comparison. It is
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Table 2.2. Genes that are concurrently: (1) significantly different among the 21T
series cell lines1, (2) present on clinically relevant databases from the literature2
and (3) found within the top 10 functional and canonical pathways represented
according to Ingenuity Pathways Analysis.

Common
Name

Gene Name

21PTci to 21NTci
Alpha thalassemia/mental
ATRX
retardation syndrome Xlinked
BCL-2 associated X
BAX
protein
DCN
Decorin
Endothelial cell growth
ECGF1
factor 1
Jumonji domain containing
JMJD2C
2C
HIST1H4H Histone cluster 1, H4h
MAX
MCM4
MGA
MMP1
NEFL

MYC associated factor X
Minichromosome
maintenance complex 4
MAX gene associated
Matrix metallopeptidase 1
Neurofilament, light
polypeptide

GeneCard Function

Microarray
Fold
Change

Transcription regulator

1.97

Accelerates programmed cell death

-1.75

Affects rate of fibrils formation
Role in maintaining integrity of blood
vessels

7.52

Histone demethylase

1.66

Core component of nucleosome

1.56

Transcription regulator

-1.54

Involved in control of DNA replication

-1.56

Transcription regulator

3.23

Cleaves collagen
involved in maintenance of neuronal
caliber
Required for centrosome assembly and
function

-4.17

1.6

-3.23

PCM1

Pericentriolar material 1

PIK3R1

Phosphoinositide-3kinase, regulatory subunit

Binds to activated protein-Tyr kinase

1.75

PIP

Prolactin-induced protein

Binding factor that plays a role in host
defense against infections

3.95

SFRP4

Secreted frizzled-related
protein 4

Modulator of Wnt signalling

-1.53

SLIT2

Slit homolog 2

Acts as a molecular guidance cue in
cellular migration

-1.92

UPLC1

Development and
differentiation enhancing
factor-like 1

Promotes cell proliferation

9.31

Vang-like 1
WNT1 inducible signal
pathway protein 1

Planar cell polarity signalling molecule
Downstream regulator in the
Wnt/Frizzled signalling pathway

2.19

Wingless-type MMTV
integration site family,
member 5A

Ligand for members of frizzled family

-1.89

VANGL1
WISP1
WNT5A

-1.54

2.18
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21NTci to 21MT-1
AIM2

Absent in melanoma 2
Aldehyde dehydrogenase
3 family, member A1

Tumour suppressor
Involved in detoxification of alcoholderived acetaldehyde

7.16

ANGPTL4

Angiopoietin-like 4

Regulator of angiogenesis

-3.58

BCL3

B-cell CLL/lymphoma 3

Transcriptional activating factor

1.84

BLNK

B-cell linker

Central linker protein that bridges
kinases associated with B-cell receptor
with multiple signalling pathways

26.67

Thiol protease that cleaves IL-1 beta

3.62

Chemotactic factor

19.98

Receptor for C-C type chemokine
Promotes non-amyloidogenic
degradation
Calcium dependent cell adhesion
protein
Involved in the control of cell cycle
Carbohydrate-binding lectin with a
preference for chitin
Plays a major role in tight junctionspecific obliteration of intercellular
space
May play a role in resistance to
chemotherapy

7.85

ALDH3A1

-93.46

CDK2

Caspase 1, apoptosisrelated cysteine peptidase
Chemokine (C-C motif)
ligand 20
Chemokine receptor 1
Cadherin 1, type 1, Ecadherin
Cadherin 11, type 2, OBcadherin
Cyclin-dependent kinase 2

CHI3L1

Chitinase 3-like 1

CLDN4

Claudin 4

CLU

Clusterin

COL4A3

Collagen, type IV, alpha 3

Tumstatin, a cleavage fragment

1.64

CST7

Cystatin F

18.14

CX3CL1

Chemokine (C-X3-C motif)

Inhibits papain and cathepsin L
Soluble form is chemotactic for T-cells
and monocytes,

CXCL2

Chemokine (C-X-C motif)
ligand 2

CASP1
CCL20
CCR1
CDH1
CDH11

CXCR4
CYP1B1
DCN
DGKA
EFEMP1
EMP1
ETV1

Chemokine (C-X-C motif)
receptor 4
Cytochrome P450, family
1, subfamily B,
polypeptide 1
Decorin
Diacylglycerol kinase,
alpha
EGF-containing fibulin-like
extracellular matrix protein
1
Epithelial membrane
protein 1
ETS variant 1

-59.88
-4.13
-3.77
-7.47
-45.87
3.43

2.04

Produced by activated monocytes and
neutrophils and expressed at sites of
inflammation

-23.81

Receptor for the C-X-C chemokine
CXCL12/SDF-1

-3.81

Participates in metabolism of an
unknown biologically active molecule

1.48

Affects rate of fibrils formation
Upon cell stimulation converts the
second messenger diacylglycerol into
phosphatidate
An antagonist of angiogenesis {{146
Sadr-Nabavi,A. 2009; }}
Involved in the drug-resistance
mechanism of tumours
Transcriptional activator

33.94
-4.37
-13.69
-1.81
2.05
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IL13RA2

Interleukin 13 receptor,
alpha 2

Binds as a monomer with high affinity
to interleukin 13
Cytokine that stimulates the
proliferation of T-lymphocytes
Augments natural killer cell activity
Integrin alpha-6/beta-4 is a receptor for
laminin
Blocks interferon-dependent interphase
and stimulates DNA synthesis

IL15

Interleukin 15

IL18

Interleukin 18

-16.5

ITGB4

Integrin, beta 4

KRT7

Keratin 7

LAMB1

Laminin, beta 1

Mediates attachment, migration and
organization of cells into tissues during
embryonic development

1.84

LTBP1

Latent transforming growth
factor beta binding protein
1

May be involved in the assembly,
secretion and targeting of TGFB1

15.51

LY75

Lymphocyte antigen 75

Acts as an endocytic receptor to direct
captures antigens from the
extracellular space to a specialized
antigen-processing compartment

-6.34

MAPRE2

Microtubule-associated
protein, RP/EB family,
member 2

May be involved in microtubule
polymerization and spindle function

-10.73

MCAM

Melanoma cell adhesion
molecule

MMP2

Membrane metalloendopeptidase
Matrix metallopeptidase 2

MMP3

Matrix metallopeptidase 3

MMP7

Matrix metallopeptidase 7

NDP

Norrie disease

NNMT

Nicotinamide Nmethyltransferase

NOX4

NADPH oxidase 4

ORM1

Orosomucoid 1

MME

PCOLCE
PDGFC
PDGFRL
PLAU

Procollagen Cendopeptidase enhancer
Platelet derived growth
factor C
Platelet derived growth
factor receptor-like
Plasminogen activator,
urokinase

Plays a role in cell adhesion and in
cohesion of the endothelial monolayer
at intercellular junctions in vascular
tissue
Biologically important in the destruction
of opioid peptides
Cleaves gelatin, collagens and KiSS1
Can degrade fibronectin, laminin,
gelatins, collagens and cartilage
proteoglycans
Degrades casein, gelatins and
fibronectin
Activates the canonical Wnt signalling
pathway through FZD4 and LRP
coreceptor
Catalyzed the N-methylation of
nicotinamide and other pyridines to
form pyridinium ions
Constitutive NADPH oxidase
Modulates activity of the immune
system during acute-phase reaction
May have metalloproteinase inhibitory
activity
Potent mitogen and chemoattractant
for cells of mesenchymal origin

13.55
6.56

-23.69
-9.44

3.28
2.16
-2.09
7.41
-4.2
-1.61
5.23
1.91
46.41
3.31
-14.29

May function as a tumour suppressor

7.3

Cleaves the zymogen plasminogen to
form active enzyme plasmin

-1.82
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SDC1

Cytohesin 1 interacting
protein
Protein tyrosine
phosphatase, nonreceptor type 12
S100 calcium binding
protein 2
S100 calcium binding
protein 3
Syndecan 1

SERPINB5

Maspin

SLC2A3

Solute carrir family 2

SNAI2

Snail homolog 2, Slug
Suppressor of cytokine
signalling 3

PSCDBP
PTPN12
S100A2
S100A3

SOCS3
TBX3

T-box 3

TFF2

Trefoil factor 2
Tumour necrosis factor,
alpha-induced protein 3
Tumour necrosis factor
(ligand) superfamily,
member 10

TNFAIP3
TNFSF10
TP53
TSLP
TUSC3
TXNIP
WNT5A

ZNF185

Tumour protein p53
Thymic stromal
lymphopoietin
Tumour suppressor
candidate 3
Thioredoxin interacting
protein
Wingless-type MMTV
integration site family,
member 5A
Zinc finger protein 185

____________________________
1

Supplemental Table 1 and 2

2

Supplemental Table 3

Modifies activation of ARFs

18.29

May have a regulatory role in
controlling cell shape and mobility

1.67

Plays a role in suppressing tumour cell
growth
Involved in calcium-dependent cuticle
cell differentiation
Cell surface proteoglycan
Tumour suppressor, blocks growth,
invasion and metastatic properties of
mammary tumours
Facilitative glucose transporter

-1.59
3.67
-4.34
-31.33
4.06

Transcriptional repressor
Involved in negative regulation of
cytokines
Transcription repressor involved in
developmental processes
Inhibits gastrointestinal motility

2.93

Inhibitor of programmed cell death

3.94

Induces apoptosis

-14.93

Acts as a tumour suppressor; induces
growth arrest or apoptosis
Cytokine that induces release of T cellattracting chemokines

7.01
2.84
9.71

1.62
3.88

May be involved in N-glycosylation

-1.99

May act as an oxidative stress
mediator

-3.21

Ligand for members of frizzled family

9.3

May be involved in the regulation of
cellular proliferation and/or
differentiation

-2.7
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Table 2.3.

qRT-PCR validated genes of interest showing significant difference

between 21T series cell lines that are of potential clinical relevance1 and are of
the top 10 functional and canonical pathways represented (IPA).

Common
Name

Gene Name

21PTci to 21Ntci
BCL2-associated X
BAX
protein
DCN

Decorin

MAX

MGA

MYC associated factor X
Minichromosome
maintenance complex 4
MAX gene associated

VANGL1

Vang-like 1

WISP1

WNT1 inducible signal
pathway protein 1

MCM4

Wingless-type MMTV
integration site family,
member 5A
21NTci to 21MT-1
Chemokine (C-C motif)
CCL20
ligand 20
WNT5A

CCR1
CDH1
CXCR4

Chemokine receptor 1
Cadherin 1, type 1, Ecadherin
Chemokine (C-X-C motif)
receptor 4

DCN

Decorin

S100A2

S100 calcium binding
protein 2

S100A3

S100 calcium binding
protein 3

SERPIN
B5

Maspin

SNAI2

Snail homolog 2, Slug

Microarray
Fold
Change

qRT-PCR
Fold
Change2

-1.75

1.03

7.52

6.38

-1.54

-1.38

-1.56

1.14

3.23

2.75

2.19

1.60

2.18

2.15

Ligand for members of
frizzled family

-1.89

-1.61

Chemotactic factor

19.98

10.90

7.85

4.10

-59.88

-2.31

-3.81

-33.33

33.94

72.51

-1.59

-3.02

3.67

6.44

-31.33

-47.20

2.93

33.58

GeneCard Function

Accelerates programmed cell
death
Affects rate of fibrils
formation
Transcription regulator
Involved in control of DNA
replication
Transcription regulator
Planar cell polarity signalling
molecule
Downstream regulator in the
Wnt/Frizzled signalling
pathway

Receptor for C-C type
chemokine
Promotes non-amyloidogenic
degradation
Receptor for the C-X-C
chemokine CXCL12/SDF-1
Affects rate of fibrils
formation
Plays a role in suppressing
tumour cell growth
Involved in calciumdependent cuticle cell
differentiation
Tumour suppressor, blocks
growth, invasion and
metastatic properties of
mammary tumours
Transcriptional repressor
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TBX3

T-box 3

TFF2

Trefoil factor 2

TNFAIP3
WNT5A

Tumour necrosis factor,
alpha-induced protein 3
Wingless-type MMTV
integration site family,
member 5A

Transcription repressor
involved in developmental
processes
Inhibits gastrointestinal
motility
Inhibitor of programmed cell
death
Ligand for members of
frizzled family

2.84

2.70

9.71

6.80

3.94

2.31

9.30

9.34

___________________________
1

Genes found on clinical databases created from the literature [11-13, 43-51]
(Supplemental Table 3)

2

Seventeen genes (not BAX and MCM4) validating the microarray data
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apparent from this analysis that genes associated with the Wnt pathway (e.g.
WNT5A, VANGL1, WISP1), and control of cell proliferation vs cell death (eg.
MAX, MGA), were particularly associated with the 21PTci to 21NTci (ADH vs
DCIS) comparison, whereas in the 21NTci to 21MT-1 (DCIS vs IMC) comparison,
loss

of

tumour

suppressors

(e.g.

SERPINB5,

S100A2),

alterations

in

transcriptional regulators (eg. TBX3, TNFAIP3, SNAI2), chemokines and their
receptors (e.g. CCL20, CCR1), and genes associated with motility/invasiveness
(e.g. TFF2, SERPINB5, S100A2) were identified.

2.4.

DISCUSSION
With the institution of mammographic screening programs and advances

in breast imaging in recent years, breast cancer is being detected at earlier
stages [52]. The liberal use of core biopsies to assess abnormalities detected on
imaging has reduced the number of patients inappropriately going to open biopsy
when these lesions are benign [53], but has also increased the number of
patients for which potential precursor lesions (such as ADH or DCIS) are
detected [54]. When ADH or DCIS are identified on core biopsy, the mainstay of
management is surgical excision (with radiotherapy in most cases of DCIS).
However, there is little information on the natural biology and progression of
these lesions [55].

When there is a chance of residual disease following

treatment, options are limited as to further management when the lesions are
difficult to detect (eg. lack associated calcifications) or are widespread. Further,
in patients who are genetically predisposed to developing these lesions (such as
BRCA1/BRCA2

carriers),

management

options

(short

of

prophylactic
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mastectomies) are limited [56, 57]. Although there are a few molecularly based
systemic options for the management of DCIS either existing or under
investigation, (e.g. tamoxifen for ER positive DCIS, trastuzumab for HER2positive DCIS), a better understanding of the molecular basis of progression is
needed to develop further targeted therapy for these early lesions [58].
Information from clinical studies examining pre-invasive lesions vs.
invasive mammary carcinoma has yielded abundant gene expression profile
differences between stages of progression (ADH vs. DCIS vs. IMC) (eg. [11-13,
49, 50]). What is lacking is the understanding of which of these differentially
expressed genes may be key players regulating transition through the stages of
breast progression, not only to predict which of the lesions are more likely to
progress, but to provide potential novel targets for preventative therapies.
Unfortunately, few in vivo and in vitro model systems exist that would allow
individual candidate genes to be tested for their influence on human breast
cancer progression, or to allow for efficient screening of the many candidate
genes of interest. One such system, the HMT-3522 human breast epithelial cell
series,

has

been

described

and

utilized

to

identify

specific

matrix

metalloproteinases required for the invasive phenotype [59]. A major advantage
of such a system, wherein all of the representative cell lines are derived from the
same patient, is that variability related to the individual’s genetic background is
eliminated (a common problem in comparing across cell lines of differing patient
origin). The system we describe here has all the same advantages, and has the
further advantage of representation of an even earlier stage, pre-DCIS (ADH-like)
phenotype (as we described for the 21PTci cells).
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We found the 21PT-derived cell line 21PTci to be consistently nontumourigenic and non-metastatic after injection into the mammary fat pads of
nude mice, confirming previous work [36]. However, upon histologic examination
of the mammary fat pad of these mice, we found occasional lesions mimicking
that of atypical ductal hyperplasia (ADH). Features consistent with ADH were the
mixture of two epithelial cell populations within a given duct, one normalappearing, the other atypical (and non-high grade), with the atypical cell
population represented over an area of < 2.0 mm [2-4, 6]. Interestingly, when
these cells were grown in 3D Matrigel, they were capable of forming large
numbers of well-defined tubular/acinar structures, with maintenance of cell
polarity in the vast majority of the groups. Furthermore, many of these groups
showed a mixture of cells with normal-appearing and more atypical nuclei.
Proliferative and apoptosis rates were low and cell movement was largely
restricted to collective organization within these groups.
In contrast, we found the 21NT-derived cells to be tumourigenic and nonmetastatic in those mice that did form lesions (tumour take in about 20%), as
described by Band et al. [36]. Although these cells were tumourigenic, we found
that the majority of mice in which lesions formed showed a histology
representative of DCIS, with no associated invasion. The involved ducts showed
a uniform neoplastic cell population, with intermediate and high grade nuclei,
solid and cribriform architectural patterns, with zonal necrosis. Only 1/7 of the
injected animals that formed lesions showed an associated invasive component,
which was localized to the fat pad, with no evidence of locoregional lymph node
involvement or distant metastases. This cell line thus represents a good model of
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DCIS, in that although in most injected animals it maintains morphology of DCIS
only, it does show the potential for a low rate of spontaneous progression to
invasive ability. The phenotype is similar to that described for MCF10DCIS cells
[60], although in contrast to MCF10DCIS, 21NT cells are not ras-transformed (a
rare event in spontaneous human breast cancer), and show a more stable (less
“leaky”) DCIS phenotype than MCF10DCIS cells, which have a higher propensity
for invasion with time in vivo [17]. When 21NTci cells are grown in 3D Matrigel,
features consistent with DCIS-like behaviour, including the tendency of cells to
arrange into groups, but with poor polarization of the constituent cells, nuclear
atypia in all the constituent cells, the spherical, non-infiltrative nature of colonies
that formed, and a lack of translational invasive behaviour when followed by time
lapse microscopy, were observed.
The 21MT-1 cells, as described by Band et al. [36], were found to be
tumourigenic (in the majority of orthopically-injected mice), and metastatic in half
the mice that formed primary tumours. Upon histologic examination, we found
that all of the mice that formed tumours showed invasive mammary carcinoma
(no special type, SBR grade III/III), most with admixed DCIS of intermediate and
high nuclear grade in the background. Consistent with this in vivo phenotype,
when the cells were grown in 3D Matrigel, they formed more disorganized, nonspherical colonies, less polarization or lumen formation of cell groups, more
single cells, and a much greater ability to show translational movement through
Matrigel upon time-lapse microscopy, when compared to the other two cell lines.
We have identified unique differential gene expression profiles for each of
the 21T series cell lines, grown in Matrigel. Interestingly, of those genes with
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evidence for clinical relevance, Wnt pathway alterations (eg. WNT5A, VANGL1,
WISP1) are particularly predominant in the comparison between 21PTci and
21NTci (representing the ADH to DCIS transition). This is consistent with recent
studies implicating both the canonical and noncanonical Wnt signalling pathways
in initiation and maintenance of breast tumourigenesis (reviewed in [61]), as well
as in cancer stem cell self renewal and the initiation of the epithelial to
mesenchymal transition [62]. In particular, the planar cell polarity (PCP) pathway
(a non-canonical Wnt pathway), involving ligand WNT5A, has been said to have
either inhibitory or promoting roles in various cancers, depending on the context
(reviewed in [63]). It has been suggested that early in progression, the PCP
pathway functions mainly in an inhibitory role, by down-regulating canonical Wnt
signalling (through β-catenin), and promoting differentiation, whereas later in
progression, the PCP pathway may promote progression, by stimulating cell
migration and invasion [64].

In the 21T series cell lines, WNT5A is down-

regulated between 21PTci and 21NTci (ADH to DCIS), and is upregulated
between 21NTci and 21MT-1 (DCIS to IMC), in keeping with an early suppressive
role and a later promoting role on progression.
Also prominent amongst genes differentially expressed between 21PTci
and 21NTci were genes associated with signalling processes potentially involved
with control of cell growth vs. apoptosis (eg. MAX, MGA).

Such changes,

resulting in a net increase in cell growth (vs. apoptosis), would be consistent with
the morphologic transition from ADH to DCIS, where the neoplastic cell
population is seen to expand from partially, to completely filling duct crosssections. In the comparison between 21NTci (DCIS-like) and 21MT-1 (IMC-like),

51

which focuses on progression to an invasive and metastatic phenotype,
differentially expressed genes of potential clinical relevance included the loss of
tumour suppressors (eg. SERPINB5, S100A2), alterations in transcriptional
regulators believed to be involved in regulating cell senescence/apoptosis (eg.
TBX3, TNFAIP3) and promoting invasiveness and epithelial to mesenchymal
transition (EMT) (eg. SNAI2), certain chemokines and their receptors (eg. CCL20,
CCR1), and genes more directly associated with motility/invasiveness (eg. TFF2,
SERPINB5, S100A2).

Collectively, these alterations would be expected to

increase the malignancy of breast cancer cells, allowing for invasive and
metastatic phenotypes to emerge in the DCIS to IMC transition.
The advantages of the approach we have taken in these 21T cell
comparisons are two-fold. Firstly, by using a filter for genes showing altered
expression in published clinical literature on early breast cancer progression,
invasion/metastasis and prognosis, we have narrowed our initial search to genes
with potential relevance in a clinical setting. This is not to say that genes showing
altered expression that did not “make” this list are irrelevant, but simply allows us
to focus our search to those with some existing support for clinical import.
Second, the use of the 21T model provides us with a manipulatable in vitro and in
vivo system for future studies to test the relative functional impact of specific
genes on transitions between these early stages of breast cancer progression
(ADH to DCIS to IMC).

We expect that use of this system will provide an

important tool to unlocking some of the intricacies of the molecular influences on
early breast progression. The information gathered will be critical to our ability to
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target and prevent this process and effectively stop breast cancer not just “in its
tracks”, but “before it makes tracks”.

2.5.
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CHAPTER 3.

THE ROLES OF VANGL1, S100A2 AND TBX3 IN THE

TRANSITIONS

BETWEEN

STAGES

OF

EARLY

BREAST

CANCER

PROGRESSION

3.1.

INTRODUCTION

Ductal carcinoma is one of the most prevalent forms of breast cancer [1].
The transition from a premalignant to a malignant, in situ lesion and the transition
from a malignant, in situ lesion to one that can invade and metastasize are both
important transitions in early progression. With reference to ductal neoplasia,
premalignant atypical ductal hyperplasia (ADH) may give rise to ductal carcinoma
in situ (DCIS) [2-6]. This DCIS may then acquire the molecular factors necessary
to penetrate the basement membrane, escape the breast duct and become
invasive (invasive mammary carcinoma, IMC), potentially leading to metastasis at
distant sites [2-4, 6, 7].

The histopathology of these distinct stages is well

described; however, the underlying molecular events controlling progression
remain unclear.

To study the molecular and cellular processes involved in

controlling mammary tumour progression through these stages, predictive model
systems are needed.
Chapter 2 of this thesis described the 21T human breast epithelial cell line
3D model system of early breast cancer progression [8]. The 21T series cell
lines were originally derived from a single patient with metastatic breast cancer
[9] and show characteristics of different stages of breast cancer progression.
Specifically, histologic examination of the lesions arising in nude mice injected
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with these cells, into mammary fat pads, revealed morphologic characteristics of
atypical ductal hyperplasia (ADH) [21PT], ductal carcinoma in situ (DCIS) without
invasion [21NT], and invasive mammary carcinoma (IMC) [21MT-1]. When the
21T series cell lines were grown in a 3D culture system, which mimics the tissue
environment, these growth characteristics were retained.

Additionally, gene

expression profiling of the 21T series cells in 3D culture has revealed stagespecific patterns and has identified many key targets which may be involved in
controlling the transitions between stages of early breast cancer progression [8].
The key targets identified by gene profiling were common to literature
based on clinical specimens of ADH, DCIS and invasive breast cancer (IMC).
The present study sought to functionally characterize the role of three of the
identified targets in controlling the transitions between stages of early breast
cancer progression. For the transition from ADH to DCIS, VANGL1, which was
expressed at higher levels in 21NT (DCIS-like) cells compared to 21PT (ADHlike) cells, was functionally characterized to determine its role in promoting
conversion to malignancy (Figure 3.1). Two genes in the DCIS to IMC transition
were chosen for further analysis. S100A2, which was expressed at a lower level
in 21MT-1 (IMC-like) cells compared to 21NT (DCIS-like) cells, was assessed for
its role in inhibiting progression to invasion (Figure 3.1).

TBX3, which was

expressed at higher levels in 21MT-1 (IMC-like) cells compared to 21NT (DCISlike) cells, was characterized to determine its role in the transition to an invasive
phenotype (Figure 3.1).
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(21NT)

ADH
(21PT)

IMC
(21MT-1)

Normal breast cells
Neoplastic cells

↑ VANGL1

↓ S100A2
↑ TBX3

Figure 3.1. Genes identified as altered between 21T series cell lines and
breast cancer progression stages. VANGL1 is increased in 21NT (DCIS-like)
cells compared to 21PT (ADH-like) cells. S100A2 is decreased in 21MT-1
(IMC-like) cells compared to 21NT (DCIS-like) cells. Finally, TBX3 is
increased in 21MT-1 (IMC-like) cells compared to 21NT (DCIS-like) cells.
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3.1.1. Van Gogh-like 1 (VANGL1)
Van Gogh-like 1 (VANGL1) is a member of the transmembrane 4
superfamily and is the human homolog of the Drosophila polarity gene, van
gogh/strabismus. VANGL1 has been found to promote malignancy and invasion
in several types of cancer, including gastric, squamous cell and laryngeal [10-12].
Additionally, loss of VANGL1 suppresses colon cancer metastasis [13].
Recently, VANGL1 was identified as a binding partner of the metastasis
suppressor KAI1 (CD82) and renamed to KAI1 COOH-terminal interacting
tetraspanin (KITENIN) [10]. It was theorized that VANGL1 promoted metastasis
by interfering with the metastasis-suppressing ability of KAI1 either through its
interaction with KAI1 or by regulating downstream signalling effectors involved in
cell invasion [10] (Figure 3.2). Specifically, KAI1 interacts with integrin α3β1 and
the binding of KAI1 with VANGL1 may interfere with the KAI1-integrin interaction,
leading to a release of α3β1 and an inhibition of integrin-mediated invasion [10].
Additionally, KAI1 is associated with protein kinase C (PKC), which mediates
phosphorylation of MARCKS (myristoylated alanine-rich C kinase substrate) and
ERMs (ezrin, radixin and moesin) resulting in a reorganization of existing actin
structures and allowing for reassembly of new actin structures that promote
migration [14]. It has been theorized that KAI1 suppresses cell motility through a
negative influence on PKC, c-Met and epidermal growth factor receptor (EGFR)
[14].

It is possible that the binding of VANGL1 to KAI1 eliminates the KAI1

suppression effects.
The noncanonical Wnt/planar cell polarity (PCP) pathway plays a role in
cancer progression.

The PCP pathway is activated by the binding of
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Figure 3.2. VANGL1 cell signalling. VANGL1 interacts with the metastasissuppressor KAI1. KAI1 interacts with α3β1 integrin to inhibit invasion. KAI1
also negatively influences protein kinase C (PKC), which mediates
phosphorylation of ERM and MARCKs, leading to actin cytoskeleton
organization and migration. VANGL1 is a core plan cell polarity component
of the Wnt/planar cell polarity (PCP) pathway and acts as a scaffolding
protein for Dishevelled (Dvl) and PKC. This functional complex promotes
motility through signalling with MAPK/ERK to elevate levels of the AP-1
transcription factor. Finally, in mammalian cells, interaction of VANGL1 with
the atypical cadherins Celsr1-3 may be involved in establishment of cell
polarity in a fashion similar to complexes with Flamingo (Fmi) in Drosophila.
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noncanonical Wnt molecules, such as Wnt5a, to the Frizzled (Fzd) receptor.
VANGL1 is a core planar cell polarity component and acts as a scaffolding
protein for Dishevelled (Dvl) and PKC [15] (Figure 3.2). A recent study found that
the functional complex formed by VANGL1, Dvl and PKCδ promotes colorectal
cancer cell migration and invasion [16]. The increased cell motility is dependent
on MAPK/ERK (Mitogen-activated protein kinase/extracellular signal-regulated
kinase) signalling, which leads to elevated levels of the AP-1 transcription factor.
The AP-1 transcription factor is composed of c-Jun, c-Fos and Fra-1 and
regulates expression of matrix metalloproteinases (MMPs), adhesion and
cytoskeleton regulators, which control cell motility and invasion. A separate study
found that AP-1 activation by VANGL1 causes tumour progression in human
gastric cancer [17]. Finally, in Drosophila, Vangl1 has been found to assist in the
establishment of cell polarity through interaction with the atypical cadherin
Flamingo (Fmi) in one cell and a Fmi-Fzd complex in an adjoining cell [14]. In
mammalian cells, atypical cadherin Celsr molecules (1,2,3) have been found to
complex with VANGL1 and may be involved in cell-cell contacts and polarization
similar to Fmi in flies [18-20]. The involvement of VANGL1 in the PCP pathway
further points to the role of VANGL1 in malignancy, as well as invasion.
Although a role for VANGL1 has been established in many types of cancer
(eg. colonic, gastric, head and neck), the role of VANGL1 in breast cancer has
yet to be elucidated. In relation to the 21T human breast epithelial cell line 3D
model system of early breast cancer progression, VANGL1 was elevated in 21NT
(DCIS-like) cells compared to 21PT (ADH-like) cells. The present study made
use of the 21T series cells grown in 3D culture to test the hypothesis that
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overexpressing VANGL1 in 21PT cells would results in the cells acquiring
characteristics of malignancy, making them more like 21NT (or 21MT-1) cells.

3.1.2. S100A2
S100A2 is a member of the S100 EF-hand calcium binding protein family,
several of which have been implicated in cancer progression [21]. S100A2 is an
unusual member in that unlike the majority of the S100 family members, S100A2
expression is downregulated in many cancers and it has been shown to be a
potential tumour suppressor [21].

The exact mechanisms of the tumour

suppressor activity of S100A2 are at present uncertain, although there are
several potential regulatory functions suggested based on its involvement in
different protein-protein interactions, particularly at the nuclear level.

It was

recently discovered that S100A2 binds the p53 tumour suppressor and this may
be involved in the stimulation of p53 activity by S100A2 [22], resulting in cell cycle
arrest and apoptosis (Figure 3.3). A study in lung adenocarcinomas found further
functions of S100A2, including induction of RUNX3 (runt-related transcription
factor 3), and repression of EGFR and NFkB2 (nuclear factor of kappa light
polypeptide gene enhancer in B-cells 2) [23] (Figure 3.3).

Runt domain

transcription factor RUNX3 (runt-related transcription factor 3) is a gastric and
colon tumour suppressor that functions downstream of TGFβ (transforming
growth factor beta) [24].

EGFR signalling is potentially involved in multiple

aspects of malignancy, including tumour growth, inhibition of apoptosis, cell
migration and invasion [25], while NFkB2 has been linked to control over tumour
cell growth, migration and invasion [26].

The tumour suppressing action of
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Figure 3.3. Nuclear effects of S100A2. S100A2 has been shown to reduce
expression of cyclooxygenase-2 (Cox-2), which normally results in the
synthesis and release of prostaglandin E2 (PGE2). PGE2 subsequently
promotes cell migration, proliferation and invasion. S100A2 also inhibits
epidermal growth factor receptor (EGFR) expression, repressing the cell
growth, migration and invasion effects of EGF. Similarly, S100A2 inhibits
NFkB2 (nuclear factor of kappa light polypeptide gene enhancer in B-cells 2)
expression and its associated downstream signalling.
S100A2 also
promotes p53 expression and activity, leading to cell cycle arrest and
apoptosis. Finally, S100A2 has been found to induce RUNX3 (Runt-related
transcription factor 3), which functions downstream of transforming growth
factor β (TGFβ).
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S100A2 has also been theorized to be in part a result of its ability to reduce
cyclooxygenase-2 (Cox-2), the upregulation of which is associated with
tumourigenesis in many cancers [27] (Figure 3.3). In fact, it was found that in
breast cancer cells, Cox-2 overexpression enhanced cell motility and
invasiveness [28].

Cox-2 expression results in the release of the pro-

inflammatory mediator prostaglandin E2 (PGE2), which acts on its cell surface
receptors EP1, EP2, EP3 and EP4 [29].

In head and neck squamous cell

carcinoma (HNSCC), exogenous PGE2 induced cell proliferation and it was
concluded that PGE2 produced in the tumour microenvironment, as a result of
Cox-2 overexpression, promoted the growth of HNSCC cells in both an autocrine
and paracrine fashion by acting on EP receptors, which are widely expressed in
most HNSCC cells [29]. Thus, blocking of Cox-2 by S100A2 should result in
reduced cell motility, proliferation and invasiveness.

Consequently, loss of

S100A2 results in tumour progression.
Although various studies have shown S100A2 to be downregulated in
malignancy of breast cancer [30, 31], very little is known about the exact
functional roles of S100A2 in breast cancer. In relation to the 21T human breast
epithelial cell line 3D model system of early breast cancer progression, S100A2
expression was decreased in 21MT-1 (IMC-like) cells compared to 21NT (DCISlike) cells. The present study used the 21T series cells grown in 3D culture to
test the hypothesis that knocking down S100A2 in 21NT cells would result in the
cells becoming more invasive, with characteristics similar to the 21MT-1 cells.
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3.1.3. T-box 3 (TBX3)
TBX3 is a member of the T-box family of transcription factors that play an
important role in development of many animal species.

Specifically, TBX3

mutant mice have demonstrated that TBX3 is required for expression of Lef-1
and Wnt10b, which induce mammary placodes [32].

In mouse embryo

development, a model has emerged in which TBX3 expression is both induced
and maintained in early mammary gland initiation by Wnt and FGF (fibroblast
growth factor) [33]. Also in mouse development, TBX3 and Sonic hedgehog
(Shh) regulate one another and loss of TBX3 results in loss of Shh [32] (Figure
3.4).

In humans, ulnar-mammary syndrome (UMS), a congenital autosomal-

dominant disorder, is caused by mutations that result in haplo-insufficiency of the
TBX3 protein. UMS is characterized by upper-limb anomalies and mammary
gland hypoplasia, as well as hair, genital and dental defects [34]. Additionally,
TBX3 has been linked to tumourigenesis and is involved in cell cycle control and
inhibition of cell senescence, through both p53-dependent and independent
pathways [35-37]. The p53-dependent pathway signals through p14 (ARF), a
tumour suppressor and cell cycle control protein, which is in turn repressed by
TBX3 [35] (Figure 3.4). More recently, it was discovered that the mechanism of
TBX3 repression of p14 (ARF) involves recruitment of histone deacetylases
(HDACs) [38].

Downregulation or inhibition of p14 (ARF) leads to increased

proliferation and immortalization, as well as failure of apoptosis [32]. Apart from
the p14 (ARF) dependent function of TBX3, in melanoma it was found that TBX3
repressed E-cadherin expression, which leads to enhanced invasiveness [39]
(Figure 3.4). In a similar fashion to that occurring during development, it was
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Figure 3.4. Effects and signalling of TBX3. In development, TBX3 is
induced and maintained by Wnt and fibroblast growth factor (FGF) signalling.
It is also both regulated by Sonic hedgehog (Shh) and regulates Shh. In
cancer, TBX3 has been shown to inhibit senescence and promote
proliferation through repression of P14 (ARF) and consequently p53. TBX3
has also been shown to be inversely related to E-cadherin, resulting in
increased invasiveness and reduced cell-cell adhesion. Finally, in stem cells,
TBX3 promotes pluripotency and reprogramming and dampens
responsiveness to differentiation signals, a function that has not yet been
proven in cancer.
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found in liver cancer that TBX3 transcription is activated by Wnt/β-catenin
signalling [40].

This same study found that TBX3 is a mediator of β-catenin

activity, influencing cell proliferation and survival. TBX2, and TBX3 by relation,
have also been implicated in regulating cell cycle control. TBX2 has been shown
to upregulate Cdc2, which promotes entry into mitosis, and MAD2, which is
involved in spindle checkpoint activation [32].

A recent study of induced

pluripotent stem (iPS) cells found a role for TBX3 in promoting pluripotency [41].
The stem cells are generally generated from mouse embryonic fibroblasts after
treatment with a combination of Oc4, Sox2 and Klf4. However, the addition of
TBX3 improved the pluripotency and reprogramming potential of the cells,
dampening the response to differentiation signals.
Two different isoforms of TBX3 have been identified, TBX3 and TBX3+2a.
The TBX3+2a variant has an extra 22 amino acids, encoded by exon 2a, inserted
into the T-box domain [34]. It was theorized that since the 2a insertion was inside
the highly conserved T-box domain, which is required for deoxyribonucleic acid
(DNA)-binding and protein-protein interactions, this variant would have altered
DNA-binding properties [42]. In fact, Fan and colleagues [42] did find that the
TBX3+2a isoform was unable to bind the consensus T-box DNA-binding site and
this resulted in the isoform not inhibiting senescence, as has been shown for
TBX3, but instead accelerating senescence. A more recent study, however, has
found that TBX3+2a can bind the DNA-binding site and is an anti-senescence
factor in melanoma [43]. The original paper that described TBX3 as an antisenescence factor was published by Brummelkamp and colleagues [35].
Interestingly, the study by Hoogaras et. al. [43] sequenced the cDNA from the
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original Brummelkamp paper and found that it was in fact the TBX3+2a splice
variant that was used in the study, indicating that Brummelkamp et al. [35]
provides further evidence that the TBX3+2a variant does in fact exhibit a
functional effect. The present study also seeks to examine both TBX3 isoforms.
Since most literature refers to TBX3 in general and not in reference to any
isoform, for simplicity in this thesis, when we are referring to both isoforms of
TBX3 (or when an isoform is not identified), we will state TBX3. The two splice
variants will be referred to as TBX3 isoform 1 (TBX3 variant) and TBX3 isoform 2
(TBX3+2a variant).
Very little is known about TBX3 function in breast cancer, although it has
potential as a master regulator and clinical studies have shown it to be elevated
during progression. In relation to the 21T human breast epithelial cell line 3D
model system of early breast cancer progression, TBX3 expression was
increased in 21MT-1 (IMC-like) cells compared to 21NT (DCIS-like) cells. The
present study used the 21T series cells grown in 3D culture to test the hypothesis
that overexpressing both isoforms of TBX3 in 21NT cells would result in the cells
acquiring the characteristics of an invasive phenotype, similar to the 21MT-1
cells.

3.2.

MATERIALS AND METHODS

3.2.1. Cell Lines and Culture
The 21T series cell lines (21PT, 21NT, 21MT-1) were maintained in culture
in αHE media, which consists of α-MEM (minimal essential medium)
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supplemented with 2mM L-glutamine (Gibco Life Technologies, Grand Island,
NY), insulin (1 µg/mL), epidermal growth factor (12.5 ng/mL), hydrocortisone (2.8
mM), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM
sodium pyruvate, 0.1 mM nonessential amino acids and 50mg/mL gentamycin
reagent (all from Sigma Chemical, St. Louis, MO). For regular culture conditions,
the αHE media was further supplemented with 10% fetal bovine serum (FBS;
Gibco Life Technologies) and named αHE10F. Transfected cell lines, created
from the parental 21T series cells were also maintained in αHE10F media. Both
the VANGL1 transfected cells (21PT+EV, 21PT+VANGL1) and the TBX3
transfected cells (21NT+EV, 21NT+ TBX3 Iso1, 21NT+TBX3 Iso2) had 0.2
mg/mL G418 (Gibco Life Technologies) added to the culture medium as a
selection marker, while 0.2 µg/mL Puromycin (Invitrogen Life Technologies,
Mississauga, ON) was added to the medium of S100A2 transfected cells
(21NT+EV, 21NT+shS100A2) as a selection marker.

3.2.2. VANGL1 Expression Vector
An expression vector for VANGL1 was constructed in order to overexpress
VANGL1 protein in 21PT cells and assess its functional role in early breast
cancer progression. To construct the expression vector, VANGL1 cDNA was
PCR-amplified using a pCMV-SPORT expression vector containing VANGL1
(Genbank accession number: BC065272), provided by the Centre for Applied
Genomics at The Hospital for Sick Children (University of Toronto) as the cDNA
template. PCR amplification was performed using Phusion High-Fidelity DNA
Taq Polymerase (New England BioLabs, Pickering, ON) and the following
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conditions: 98oC for 30 sec, followed by 40 cycles of 98oC for 7 sec, 62oC for 15
sec and 72oC for 45 sec and finally a 72oC hold for 8 min. The primers for PCR
amplification can be found in Table 3.1.

Five separate PCR reactions were

completed and run on a 1% agarose gel. Bands at the appropriate size (~1500
kb) were gel extracted, using a QIAquick gel extraction kit (Qiagen, Mississauga,
ON) and pooled.

Next, the VANGL1 PCR product was incubated with T4

polynucleotide kinase (T4 PNK; New England BioLabs) to phosphorylate the
insert. Finally, the VANGL1 PCR product was purified using a QIAquick PCR
purification kit (Qiagen), following the manufacturer’s protocol and the
concentration was determined by spectrophotometry, using a NanoDrop 1000
Spectrophotometer (Thermo Scientific, Mississauga, ON).
VANGL1 was inserted into a pcDNATM3.1/myc-His B plasmid (Invitrogen
Life Technologies), such that the myc tag would be fused to the C-terminus of
VANGL1.

To prepare the plasmid for ligation with the VANGL1 insert, the

plasmid was digested with EcoRV (New England BioLabs) to insert the VANGL1
downstream of the pCMV promoter, into the multiple cloning site (Figure 3.5).
EcoRV digestion results in a blunt end cut.

The plasmid was subsequently

incubated with calf intestinal phosphatases (CIP; New England BioLabs) to dephosphorylate the plasmid.

The plasmid was then electrophoresed on a 1%

agarose gel and extracted using the QIAquick gel extraction kit (Qiagen). The
concentration of the processed plasmid was determined using the NanoDrop
1000 Spectrophotometer (Thermo Scientific).
The plasmid and VANGL1 PCR product were incubated overnight with
ATP (adenosine triphosphate) and T4 DNA ligase (both from New England
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Table 3.1. Primer sequences for VANGL1 cloning, TBX3 cloning and TBX3 qRTPCR.
Primer Name

Sequence

VANGL1 Cloning Primers
Forward
Reverse

5’-GCC ACC ATG GAT ACC GAA TCC ACT-3’
5’-AAC GGA TGT CTC AGA CTG TAA GCG-3’

TBX3 Cloning Primers
Iso2 / Iso1 Frag 1 Forward
Iso1 Frag1 Reverse
Iso1 Frag2 Forward
Iso2 / Iso1 Frag2 Reverse

5’-GCC ACC ATG AGC CTC TCC ATG AGA-3’
5’-CAT GGA GTT CAA TAT AGT AAA TCC ATG TTT GAC-3’
5’-TGG ATT TAC TAT ATT GAA CTC CAT GCA CAA AT-3’
5’-TTC GGG ACC GCC TGC GGG ACC TGT CCG GC-3’

TBX3 qRT-PCR Primers
Endogenous Forward
Endogenous Iso1 Reverse
Endogenous Iso2 Reverse
TBX3-ZsGreen Forward
TBX3-ZsGreen Reverse

5’-GCG GAC TTG TCC CCG GCT GG-3’
5’-CAT GGA GTT CAA TAT AGT AAA TCC ATG TTT GTC TG-3’
5’-CAC TTG GGA AGG CCA AAG TAA ATC CAT G-3’
5’-CAC CGC CAC CCC TTC CTC AAT CTG AAC AC-3’
5’-GTG GCG ACC GGT AGC AAC TAC GGG GAC GCG-3’

Cloning primers for VANGL1 were used to PCR amplify VANGL1, using a pCMVSPORT expression vector containing VANGL1 as template. Cloning primers for
TBX3 were used to PCR amplify isoforms of TBX3 using a pOTB7 expression
vector containing TBX3 as template. A Kozak consensus sequence was added
to the forward primer of the cloning primers, immediately upstream of the
translation start site of the specific gene (VANGL1 or TBX3), to ensure a high
level of translation initiation. Extra amino acids were also added to the reverse
primer of the cloning primers to ensure the specific gene (VANGL1 or TBX3) was
in frame in relation to the plasmid (VANGL1, pcDNATM3.1/myc-His B; TBX3,
pZsGreen-C1). Lastly, the stop codon was removed from the reverse primers so
that myc (VANGL1) or ZsGreen (TBX3), fused to the C-terminus, would be
transcribed.
The two isoforms of TBX3 were PCR-amplified separately.
Amplification of TBX3 Iso1 required production of two TBX3 fragments, which
were annealed to produce TBX3 Iso1, while the forward primer of fragment 1
(Frag1) and the reverse primer of fragment 2 (Frag2) were used to PCR amplify
TBX3 Iso2 (see Figure 3.6). TBX3 qRT-PCR primers were used to amplify
endogenous TBX3 Iso1 and Iso2, as well as the TBX3-ZsGreen fusion product.
For endogenous TBX3, the forward primer was common for both isoforms and
was located within the 5’UTR. The reverse primers for endogenous TBX3 Iso1
spanned the splice junction, while TBX3 Iso2 reverse primer was within the 22 aa
insert, thus ensuring specificity of each isoform during PCR amplification. The
forward primers for TBX3-ZsGreen were downstream of the splice junction, in
order to amplify both isoforms. The reverse primer for TBX3-ZsGreen spanned
the junction between TBX3 and ZsGreen.

75

EcoRV

PCMV

T7

VANGL1

myc

6X
His

TGA

Neomycin

Figure 3.5. Plasmid map for VANGL1 expression vector. Protein expression
was driven by a human cytomegalovirus (CMV) promoter. VANGL1 was
inserted into the multiple cloning site of a pcDNATM3.1/myc-His B plasmid by
restricting enzyme digest with EcoRV, which creates a blunt cut. Insertion
into the multiple cloning site allowed insertion in frame with the myc epitope,
the polyhistide C-terminal tag and the stop codon. The plasmid also
contained a Neomycin resistance gene to enable selection of stable
transfectants.
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BioLabs) at 16 degrees to complete the ligation (Figure 3.5). Competent bacteria
(DH5alpha, made in-house) were then transformed with the ligated plasmid and
streaked on Luria Bertani (LB) agar (Invitrogen Life Technologies) plates with 50
µg/mL ampicillin (Gibco Life Technologies). Thirty bacteria colonies were picked
and expanded in LB+ ampicillin media, and DNA was isolated using a GenElute
mammalian genomic DNA miniprep kit (Sigma Chemical).

The DNA was

digested with KpnI (New England BioLabs) and run on a 1% agarose gel as a
preliminary check to see if the insertion was the correct size and in the correct
orientation. Seven of the 30 clones were sent to the DNA Sequencing Facility at
Robarts Research Institution (London, ON) for sequencing.

Clones with the

proper sequence were used for stable transfections.

3.2.3. TBX3 Expression Vector
Two expression vectors for TBX3 were constructed in order to
overexpress TBX3 protein in 21NT cells and to subsequently assess its functional
role in early breast cancer progression. Since TBX3 has two variants/isoforms,
an expression vector was constructed for both, referred to here as TBX3 Isoform
1 (TBX3 Iso1) and TBX3 Isoform 2 (TBX3 Iso2) (also referred to as TBX3+2a).
To construct the expression vectors, TBX3 Iso1 and TBX3 Iso2 cDNA was PCRamplified using a pOTB7 expression vector containing TBX3 Iso2 (Genbank
accession number: BC025258; Open Biosystems, Thermo Scientific) as the
cDNA template. TBX3 Iso2 has an additional 22 amino acid (66 base pair (bp))
sequence, encoded by exon 2a, inserted into the T-box domain [34]. To obtain
TBX3 Iso2, PCR amplification of the whole transcript was performed using
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Phusion High-Fidelity DNA Taq polymerase (New England BioLabs) and the
following conditions: 98oC for 30 sec, followed by 40 cycles of 98oC for 5 sec,
62oC for 15 sec and 72oC for 1 min and finally a 72oC hold for 8 min. To produce
TBX3 Iso1, two PCR product fragments, representing the transcript before
(fragment 1) and after (fragment 2) the 66 bp TBX3 Iso2 addition, were PCR
amplified (Figure 3.6A), using the same conditions as for TBX3 Iso2. PCR primer
sequences for TBX3 Iso2 and both fragments of TBX3 Iso1 can be found in Table
3.1. Three separate PCR reactions were completed for TBX3 Iso2 and each
fragment of TBX3 Iso1 and then run on a 1% agarose gel. Bands representing
TBX3 Iso2 at approximately 2000 kb were extracted and pooled. For TBX3 Iso1,
a band at ~660 kb for fragment 1 and a band at ~1380 kb for fragment 2 were gel
extracted and pooled. When designing the PCR primers for the two fragments of
TBX3 Iso1, the reverse primer of the upstream amplicon (fragment 1) and the
forward primer for the downstream amplicon (fragment 2) had a 20 bp overlap to
ensure that the ends of these amplicons would anneal in a subsequent PCR
reaction to melt the fragments together. To anneal these two fragments and
generate TBX3 Iso1, 100 ng of each fragment was used as template in a PCR
reaction without primers, using Phusion High-Fidelity DNA Taq polymerase (New
England BioLabs). The cycling conditions were 98oC for 5 min and then 72oC for
15 min. The annealed TBX3 Iso1 PCR product was purified using a QIAquick
PCR purification kit (Qiagen) and then complete TBX3 Iso1 was PCR amplified
using the annealed product as template. The primers for this PCR amplification
were the forward primer for the translational start site for TBX3 (TBX3 Iso2/TBX3
Iso1 fragment 1 forward primer) and the end of the coding sequence immediately
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A)

TBX3 Isoform 2 (TBX3+2a variant)

1

2100

Exon 2a

TBX3 Isoform 1 (TBX3 variant)

658

1
Fragment 1

B)

718

2100
Fragment 2

TBX3 Isoform 1 DNA insert OR
TBX3 Isoform 2 DNA insert

AfeI
PCMV IE

TBX3

ZsGreen

MCS

Neomycin

Figure 3.6. Cloning primer design and plasmid map for TBX3 expression
vector. A) TBX3 isoform 2 contains a 22 amino acid insert encoded by exon
2a. Since isoform 1 was missing the exon 2a insert, primers were designed
to amplify 2 fragments of isoform 1 separately. Fragment 1 encompassed
TBX3 before the 2a insert, while Fragment 2 encompassed TBX3 after the 2a
insert. In addition, an amino acid linker from the Fragment 2 forward primer
was added to the reverse primer for Fragment 1, while an amino acid linker
from the Fragment 1 reverse primer (positive strand) was added to the
forward primer of Fragment 2. Also, the Fragment 1 forward primer
contained a Kozak sequence, while in the Fragment 2 reverse primer, the
stop codon was removed and 2 amino acids were added so that the insert
would be in frame with ZsGreen. The forward primer for Fragment 1 and
reverse primer for Fragment 2 were used to PCR-amplify both isoform 2 and
the complete isoform 1 product once the two fragments were annealed
together. B) Protein expression was driven by a human (CMV) immediate
early (IE) promoter. TBX3 isoforms were inserted into the pZsGreen-C1
plasmid before the ZsGreen coding sequence by restricting enzyme digest
with AfeI, which creates a blunt cut. TBX3 was inserted before ZsGreen,
instead of in the multiple cloning site (MCS) so that ZsGreen would be fused
to the C-terminal of the TBX3 isoforms. The plasmid also contained a
Neomycin resistance gene to enable selection of stable transfectants .
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upstream of the stop codon (TBX3 Iso2/TBX3 Iso1 fragment 2 reverse primer).
The complete TBX3 Iso1 PCR product was then run on a 1% agarose gel and
extracted using a QIAquick gel extraction kit (Qiagen). The extracted TBX3 Iso1
and TBX3 Iso2 PCR products were then incubated with T4 PNK (New England
BioLabs), PCR purified and the concentration of each was determined by
spectrophotometry (NanoDrop 1000 Spectrophotometer, Thermo Scientific).
TBX3 Iso1 and TBX3 Iso2 were inserted separately into pZsGreen-C1
plasmids (Clonetech Laboratories, Mountain View, CA), such that the ZsGreen
was fused to the C-terminus of TBX3 Iso1 or TBX3 Iso2. To prepare the plasmid
for ligation with the TBX3 inserts, the plasmid was digested with AfeI (New
England BioLabs) so TBX3 was inserted upstream of the ZsGreen1 coding
sequence and not in the multiple cloning site (Figure 3.6B). AfeI digestion results
in a blunt end cut. After digestion, the plasmid was incubated with CIP (New
England BioLabs) to de-phosphorylate the plasmid.

The plasmid was then

electrophoresed on a 1% agarose gel and extracted using a QIAquick gel
extraction kit (Qiagen).

The concentration of the processed pZsGreen-C1

plasmid was determined using a NanoDrop 1000 Spectrophotometer (Thermo
Scientific).
The plasmid and TBX3 isoform PCR products were incubated overnight
with ATP and T4 DNA ligase (New England BioLabs) at 16oC to complete the
ligation (Figure 3.6B). Competent bacteria (DH5alpha) were then transformed
with the ligated plasmids and streaked on LB agar (Invitrogen Life Technologies)
plates with 50 µg/mL kanamycin (Gibco Life Sciences). Fifteen bacteria colonies
per TBX3 isoform were picked and expanded in LB+kanamycin media, and the
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DNA was isolated using a GenElute mammalian genomic DNA miniprep kit
(Sigma Chemicals). The DNA was digested with the following restriction enzyme
pairs: AgeI and KpnI, MfeI and XhoI, Nhe1 and HndIII (New England BioLabs).
The resulting fragments were run on a 1% agarose gel as a preliminary check to
see if the insertions were the correct size and in the correct orientation. Five
clones for each isoform were sent to the DNA Sequencing Facility at Robarts
Research Institution (London, ON) for sequencing.

Clones with the proper

sequence were used for stable transfections.

3.2.4. shRNA against S100A2
Short hairpin ribonucleic acid (shRNA) against S100A2 was constructed in
order to determine the role of S100A2 in early breast cancer progression. The
shRNA was a kind gift from Dr Michael Golding (Texas A&M University). Three
separate S100A2 shRNAs in addition to an empty vector shRNA were
constructed (Figure 3.7) [44]. Competent bacteria were transformed with the
plasmids expressing the shRNA’s and streaked on LB agar (Invitrogen Life
Technologies) plates with 50 µg/mL ampicillin (Gibco Life Sciences).

Ten

colonies were chosen for each shRNA plasmid. In order to determine which of
the shRNA’s against S100A2 knocked down S100A2 gene expression most
efficiently, 21NT cells were transiently transfected with all three shRNA’s
separately.

qRT-PCR was used to determine the change in S100A2 mRNA

expression, following the same methodology as above. One shRNA construct
was able to reduce S100A2 mRNA expression by 45% and was subsequently

81

DNA sequence for S100A2 shRNAmir amplification

miR5’

miR3’
Puromycin

5’LTR

IRES

GFP

3’LTR

Packaging
Signal
XhoI EcoR1
Long terminal repeat
Strong Pol II promoter

Figure 3.7. Plasmid map for S100A2 shRNA vector. The plasmid was
obtained as a kind gift from Dr Michael Golding and the map has been
adapted from the one provided by him. This is a miR-based shRNA
expression cassette and is driven by an RNA polymerase II (Pol II) promoter.
The DNA sequence for S100A2 shRNAmir amplification is cloned in between
XhoI and EcoR1 sites. The plasmid contains a Puromycin resistance gene to
enable selection of stable transfectants. The plasmid also contains an
internal ribosome entry site (IRES) for translational initiation in the middle of
the mRNA sequence and a green florescent protein (GFP) tag.
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used for stable transfections. The sequence of the shRNA chosen for S100A2
knockdown can be found in Appendix C Table 1.

3.2.5. Transient and Stable Transfections
Stably transfected cell lines were created to overexpress VANGL1 in 21PT
cells and both isoforms of TBX3 in 21NT cells. In addition, 21NT cells were
stably transfected with shRNA against S100A2, after preliminary transient
transfections with the three S100A2 shRNA constructs mentioned above. For all
stable transfections, empty vector controls were also transfected into the
appropriate cell line.

Lipofectin® Reagent (Invitrogen Life Technologies)

methodology was used for both stable and transient transfections.

The day

before transfection, 21PT or 21NT cells were seeded in 6-well plates at a density
that would result in 80% confluency the next day (350,000 cells per well). The
following day, cells were transfected with 1µg of the appropriate expression
vector or shRNA DNA, following the manufacturer’s protocol.

One day after

transfection, the transfection media was replaced with αHE10F.

Three days

following transfection, total RNA was collected from 21NT cells transiently
transfected with shRNA against S100A2 using TRIzol (Invitrogen Life
Technologies) methodology.

Stable transfections were subcultured into T25

culture flasks (Nunc Brand Products, Rochester, NY) three days following
transfection. Puromycin (S100A2 shRNA vector) or G418 (VANGL1 and TBX3
expression vectors) selection was added to αHE10F growth medium the day
following subculture. Stably transfected cells were expanded and frozen vials
were placed at -80oC.
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3.2.6. 3D In Vitro Cultures
For all 3D cultures, cells were grown in Matrigel Basement Membrane
Matrix (BD Biosciences, Mississauga, ON) for 9 or 15 days.

Cultures were

created in 24-well plates (Nunc Brand Products) for mRNA and protein extraction
and

48-well

plates

(Nunc

Brand

Products)

for

H&E

staining

and

immunohistochemistry. The cultures contained three distinct layers. The bottom
layer consisted of undiluted Matrigel for a solid base. The middle layer contained
a 1:1 mix of Matrigel and cells (4.0 x 105 for 24-well, 2.0 x 105 for 48-well) in αHE
media supplemented with 0.1% bovine serum albumin (BSA; Gibco Life
Sciences). These two layers were topped with growth media supplemented with
0.1% BSA.

3.2.7. Collection and Quantification of RNA and Protein from 3D Cultures
After 9 days in 3D culture, cells were removed from Matrigel using Cell
Recovery Solution (BD Biosciences), which non-enzymatically dissociates the
Matrigel. For each experiment, 3 biological replicates were grown per cell line.
Total RNA and protein were either extracted at the same time or separately.
When total RNA was extracted separately, cell pellets were treated with
TRIzol (Invitrogen Life Technologies) and RNA was extracted as per the
manufacturer’s

instructions.

RNA

concentrations

were

determined

by

spectrophotometry using a NanoDrop 1000 Spectrophotometer (Thermo
Scientific).

Aliquots of total RNA were stored at -20oC until conversion to

complementary DNA (cDNA).
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When only protein was required, cells were washed with RIPA buffer (10
mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5 mM EGTA, 150 mM NaCl, 1% Tx-100,
0.5% DOC, and 0.1% SDS) containing protease inhibitors (1 Complete Mini
Protease Inhibitor cocktail tablet /10 mL, Roche; Mannheim, Germany) and
passed through a 22-gauge needle several times to lyse the cells.

Sterile

microcentrifuge tubes, containing the cell lysates were incubated on ice for 10
minutes and then spun down at 4°C.

Supernatants were transferred to new

microcentrifuge tubes and stored at -20°C.

Protein concentrations were

determined using the BioRad Bradford Assay (Mississauga, ON) and
concentrations were standardized to known BSA concentrations.
When mRNA expression validation was immediately followed by protein
expression validation, RNA and protein were extracted from the same cells. For
these experiments, RNA and protein were extracted using the GE Healthcare
IllustraTM triple prep kit (Baie d’Urfe, QC), following the manufacturer’s protocol.
RNA and protein concentrations were determined in the same method as above.

3.2.8. Quantitative Real Time-PCR (qRT-PCR) Validation
Complementary DNA was synthesized from 1μg total RNA using
Superscript II, with random primers (both from Invitrogen Life Technologies).
qRT-PCR was conducted using a Rotor-Gene RG-3000 temperature cycler
(Corbett Life Science, San Francisco, CA) and RT2 SYBR-Green qPCR Master
Mix (SuperArray Biosciences Corporation, Frederick, MD), following the
manufacturer’s protocol. Since SYBR-Green binds to the minor groove of all
double stranded DNA, RT2 qPCR primers for VANGL1, TBX3, S100A2 and 18S
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rRNA were purchased from SuperArray, which were guaranteed to produce
minimal primer dimers and non-specific product. Primer sets for the different
isoforms of endogenous TBX3 and the TBX3-ZsGreen fusion protein were
designed in house and the sequences can be found in Table 3.1. Expression
levels of all genes were calculated based on a standard curve for that gene.
Standard curves were created with six dilutions from the reverse transcription
product (1, 1:5, 1:25, 1:125, 1:625, 1:3125) and in triplicate. Expression levels of
the housekeeping gene 18S rRNA was also determined for each sample and
quantities were used to normalize values obtained for each gene of interest. All
samples were assayed using three biological replicates and in duplicate.

All

experiments were performed in triplicate with similar results.

3.2.9. Western Blotting
Western blots were conducted using the BioRad Mini Protean II Cell
system. Either 10% (VANGL1 and TBX3) or 12% (S100A2) polyacrylamide gels
containing sodium dodecyl sulphate (SDS) were loaded with denatured whole cell
lysates (25-50 µg) and 5X reducing loading buffer. Gels were run at 60V for
approximately 20 minutes, so the dye front was through the stacking gel and then
the voltage was increased to 120 V for approximately 90 minutes. Polyvinylidene
fluoride (PVDF) membranes (Amersham, GE Healthcare), which had been
activated in methanol, were incubated with gels in cold transfer buffer for at least
10 minutes. Gels and membranes were then transferred at 100 V for 1.5 hours.
Membranes were blocked in 5% milk in TBS-T (tris-buffered saline with 0.1%
Tween) for one hour. To detect VANGL1, a mouse monoclonal antibody (R&D
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Systems, Burlington, ON, catalogue no. MAB5476) was used at 1:1000 in TBS-T.
To detect TBX3 a mouse monoclonal antibody (Sigma Chemicals, catalogue no.
WH0006926M10) was used at 1:1000.

Finally to detect S100A2 a mouse

monoclonal antibody (Abgent, San Diego, CA, catalogue no. AT3754a) was used
at 1:1000 in TBS-T.

Membranes were incubated with primary antibodies

overnight at 4°C, while rocking according to the manufacturers’ instructions. An
antibody against β-tubulin (Invitrogen Life Technologies; catalogue no. 32-2600)
was used as a loading control at 1:2000 in TBS-T and was incubated with
membranes for 1 hour, while rocking. After the primary antibody, the membranes
were washed 3 times for 5 minutes each with TBS-T and then incubated with the
secondary anti-mouse antibody, conjugated to HRP (Amersham, catalogue no.
NXA931; 1:10 000 in TBS-T), for 1 hour at room temperature, while rocking.
After 3 more washes at 5 minutes each with TBS-T, membranes were incubated
with ECL Plus Western Blotting Detection System (Amersham) and then exposed
to film in a dark room.
Alterations to the above Western blot methodology were made in order to
resolve protein bands with the ZsGreen antibody for the TBX3 overexpressing
cells. An 8% SDS polyacrylamide gel was overloaded (329 µg TBX3 Iso1, 203
µg TBX3 Iso2) and run without denaturing/boiling the lysates and without adding
a reducing agent. The gel was run at 65 V for approximately 30 minutes and
then the voltage was increased to 125 V for approximately 90 minutes. A PVDF
membrane, which had been activated in methanol, was incubated with the gel in
cold transfer buffer for at least 10 minutes. The gel and membrane were then
transferred at 35 V for 1.5 hours. The membrane was blocked in 0.1% gelatin
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(Sigma Chemical) in TBS-T for 1.5 hours. To detect ZsGreen, a rabbit polyclonal
antibody (Clonetech Laboratories, catalogue no. 632474) was used at 1:1000 in
0.1% gelatin in TBS-T and incubated with the membrane overnight at 4°C, while
rocking. After incubation, the membrane was washed 5 times for 5 minutes each
with TBS-T and then incubated with the secondary anti-rabbit antibody
conjugated with HRP (Millipore, Billerica, MA, catalogue no. AP132P; 1:10 000 in
0.1% gelatin in TBS-T) for 1.5 hours at room temperature, while rocking. After 3
more washes at 5 minutes each with TBS-T, the membrane was incubated with
ECL Plus Western Blotting Detection System and then exposed to film in a dark
room as above.

3.2.10. Morphologic Characterization of 3D In Vitro Cultures
After 9 and 15 days growth in Matrigel, 10% neutral buffered formalin was
added to the 48-well dishes for 48 hours.

Once cultures were stiffened, the

cultures were removed as intact Matrigel plugs. The formalin-fixed plugs were
then processed, paraffin-embedded and sectioned into 4µm slices for H&E
staining and immunohistochemistry.
Histomorphology of the cell lines in 3D culture was determined by
examination of H&E stained sections of the Matrigel plugs.

Morphologic

characterization was based on assessment of extracellular lumen formation,
number of groups with polarized cells, spherical (vs. non-spherical) colony
formation and proportion of single cells (Appendix B Figure 1). Each of these
parameters was assessed in terms of a percentage of total “events” counted. In
relation to extracellular lumen formation, number of groups with polarized cells
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and spherical colonies, an event was defined as a cell group. In relation to the
proportion of single cells seen in the plug, an event was defined as either a single
cell or a cell group. For each cell line being studied, 10 high power (400X) fields
of view from three replicate Matrigel plugs were examined. This yielded between
200 and 275 events per 10 high power fields.

3.2.11. Proliferation and Apoptosis in 3D Cultures
Matrigel plugs from 9 and 15 days cultures were immunostained for the
proliferation marker Ki67, and for the apoptotic marker caspase 3.

Ki67

immunohistochemistry was performed as described previously [45] with the Ki67
antibody (Dako, Mississauga, ON, catalogue no. M7240) applied (1/150 dilution)
overnight at 4oC. For caspase 3 immunostaining, a microwave oven was used to
pretreat deparaffinized sections for epitope retrieval. Caspase 3 antibody, which
recognized cleaved caspase 3 (Cell Signaling Technologies, Danvers, MA,
catalogue no. 9662) was applied (1/300 dilution) for 15min at room temperature.
For both Ki67 and caspase 3, positive staining was detected with an UltraVision
LP Detection System HRP Polymer (Thermo Scientific, Waltham, MA) kit,
following the manufacturer’s protocol.
included for both assays.

Positive and negative controls were

All slides were counterstained with Harris’s

Hematoxylin.
Both Ki67 and caspase 3 indices were calculated for each cell line. The
indices were defined as the number of cells positive for Ki67 or caspase 3
staining divided by the total cells counted. For each cell line being studied, 10
high power (400X) fields of view from three replicate Matrigel plugs were
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examined, yielding between 200 and 350 cells.

A ratio of proliferation over

apoptosis was also calculated for each cell line, in order to determine the balance
of dividing cells vs. apoptosing cells.

3.2.12. Transwell Invasion Assay
A transwell system was used to look at the invasion potential of VANGL1
overexpressing cells.

The systems consisted of 2 chambers separated by a

porous membrane coated with Matrigel. Cells were seeded in the upper chamber
of the transwell system and allowed to invade towards a chemoattractant (FBS)
in the lower chamber. The day before the assay, transwell inserts with 8 µm
pores (Corning Life Sciences, Lowell, MA) were coated with 20 µg Matrigel,
diluted in sterile water. Plates were left to dry overnight in the tissue culture
hood. The following day, Matrigel coated transwells were reconstituted by adding
100µL αHE media supplemented with 0.1% BSA. The plates were incubated on
a shaker at room temperature for 90 minutes. During this incubation, cells were
collected and diluted to 4 x 105 cells/mL in αHE plus 0.1% BSA. In order to
determine the invasive ability of the cells, 800µL of αHE plus 10% FBS was
added to the lower chamber of the transwell system. To the upper chamber, 100
µL of the cell suspension was added (final cell concentration of 4 x 104 cells/well).
Plates were then incubated for 72 hours at 37oC and 5% CO2. After the assay
was complete, the upper chambers of the transwells were removed, inverted and
fixed for 20 minutes with 1% gluteraldehyde in 1X PBS. The membranes of the
upper transwells were then rinsed with sterile water. Cells were stained with
Harris’ haematoxylin for 15 minutes and then the membranes were rinsed again.
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Addition of 1% NH4OH (in sterile water) for 1 minute was used to intensify the cell
staining. The transwell membranes were rinsed one final time with sterile water.
Non-invasive cells which were attached to the upper surface of the transwell
membranes were removed using a cotton Q-tip.
allowed to dry overnight.

The transwells were then

Once dry, five high powered fields (200X) were

photographed per transwell membrane. Cells that invaded to the underside of
the membrane were counted from these pictures using the cell counter plug-in on
ImageJ (Open source software, National Institute of Health, USA).

Three

biological replicates were used for this assay and the experiment was completed
twice with similar results.

3.2.13. Matrigel Invasion Assay
Time lapse microscopy was used to quantify the invasive ability of S1002
knockdown and TBX3 overexpressing 21NT cells through 6 days of culture in
Matrigel. An invasion assay using time lapse microscopy was chosen for genes
involved in the 21NT (DCIS) to 21MT-1 (IMC) transition because 21MT-1 cells
are unable to pass through the 8 µm pores of a transwell system. On average,
21MT-1 cells are 30 µm in diameter, are often polygonally-shaped and when
grown in a transwell system, many cell aggregates form on the upper surface of
the transwell membrane. In contrast, 21NT cells are 19 µm in diameter, more
spindle-shaped in a transwell system and pass freely through 8 µm pores. Thus,
a transwell system would not provide a fair assessment of the invasive ability of
the S100A2 knockdown and TBX3 overexpressing 21NT cells compared to the
21MT-1 cells. For the time lapse Matrigel invasion assay, cells were grown 3D
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Matrigel in 8-well chamber slides (Nunc Brand Products) for 9 days. Matrigel
cultures were made as described previously, with scaled down volumes of the
three layers for the 8-well chamber slide. In addition, the number of cells in the
middle layer was reduced to 1.5 x 104. After 9 days, the slides were then moved
to an incubated stage platform of a Zeiss Axiovert 200M microscope for time
lapse photography. Z-stack microscopy images at 5 positions were taken for
each cell line every 12 hours until day 15 of growth. All cells found within the 5
positions per cell line (about 100 cells total) were then followed using AxioVision
4.5 software (Carl Zeiss Imaging Solutions), to determine the percentage of cells
that invaded through the Matrigel matrix and the distance the moving cells were
able to travel. A cell was defined as moving if any part of the cell was in a
different location compared to the image taken 12 hours previously.

The

minimum distance a cell could travel to be termed as moving was 5 µm. The
distance a moving cell travelled was measured using the AxioVision 4.5 software.

3.2.14. Confocal Microscopy
Confocal microscopy was used to detect protein levels of the TBX3ZsGreen fusion product transfected cells. 21NT, 21NT+TBX3 Iso1, 21NT+TBX3
Iso2 and 21NT+EV cells were grown on 22 mm round tissue culture grade
coverslips (VWR, Mississauga, ON) inside 6-well plates (Nunc Brand Products)
for 24 hours. Cell medium was removed and cells were fixed with 2% formalin for
10 minutes. Wells were rinsed with 1X PBS and then permeabilization buffer
(0.05% saponin, 0.10% BSA, 0.075% glycine) was added for 10 minutes. After
rinsing with PBS, the cells were blocked with 10% normal goat serum (Invitrogen
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Life Technologies) for 30 minutes. Without removing the goat serum, primary
antibodies were added in more goat serum. To detect TBX3, the same mouse
monoclonal antibody (Sigma Chemicals) used for Western blotting was used at a
concentration of 1:400. To detect vimentin, a mouse monoclonal antibody (Dako,
Burlington, ON; clone 3B4, catalogue no. 632474) was used at a concentration of
1:250. To detect E-cadherin, a mouse monoclonal antibody (BD Biosciences,
catalogue no. 610181) was used at 1:650. Finally, an IgG1 k isotype control
mouse monoclonal antibody (BD Pharmigen, catalogue no. BD554121) was used
at 1:300. Primary antibodies were incubated with cells overnight at 4oC. After
primary antibody was removed and wells were rinsed with 1X PBS, AlexaFluor
594 goat anti-mouse IgG (Invitrogen Life Technologies, catalogue no A-11005;
1:1000 in goat serum) was incubated with cells for 1.5 hours. Wells were rinsed
again and Hoecsht 33342 (Invitrogen Life Technologies, catalogue no. H1399;
1:5000 in PBS) was added for 45 minutes in the dark. After rinsing the wells one
final time with PBS, coverslips were mounted onto glass slides for confocal
microscopy.
Confocal laser scanning microscopy was performed using an Olympus
FluoViewTM FV1000 coupled to the IX81 Motorized Inverted System Microscope
at The Victoria Research Laboratory Confocal Microscope Core Facility.
Sequential channel scans of each stained section were optimized for maximum
signal to noise ratio and minimal laser power output.
processing were performed with ImageJ software (NIH).

Image analysis and
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3.2.15. Statistical Analysis
The differences between experimental groups were analyzed using oneway analysis of variance (ANOVA), followed by Tukey’s test for post hoc
analysis. Statistical analysis was performed using GraphPad Instat 3 (La Jolla,
CA). For all statistics, a p-value of less than 0.05 was considered statistically
significant. In all bar graphs, bars labeled with letters that are not the same
indicate this significant difference. Alternately, bars labeled with the same letters
are not significantly different from each other.

3.3.

RESULTS

3.3.1. VANGL1
In work described in Chapter 2, VANGL1 was found to be elevated in
21NT (DCIS-like) cells compared to 21PT (ADH-like) cells [8]. To determine the
functional role of VANGL1 in this transition (ADH to DCIS), VANGL1 was
transfected into 21PT cells and the cells were analyzed using several functional
assays, including colony profile (spherical vs. irregular), lumen formation, cell
polarization, proportion of single cells, proliferation index, apoptosis index and
cell invasion.

3.3.1.1. VANGL1 mRNA Expression Levels are Altered in 21NT Compared
to 21PT Cells
Since the 21T series model of early breast progression was created in a
3D system, before generating transfectants, we first wanted to determine whether
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the differential expression of VANGL1 mRNA (between 21PT and 21NT) could
also be seen in 2D culture. Using qRT-PCR, we determined that when grown in
2D culture, VANGL1 is in fact elevated 1.8-fold in 21NTci compared to 21PTci
cells (Figure 3.8). However, this was less of an increase than that seen for 3D
culture (2.2-fold; Figure 3.8). Thus, the progression stage-specific expression of
VANGL1 is more pronounced when cells are grown in 3D than in 2D.
Additionally, the 21PT and 21NT cells used for the microarray analysis
contained an empty neo-selection vector (21PTci, 21NTci). Since we planned to
transfect VANGL1 into the 21PT cells, we decided to use the parental 21PT and
21NT cells, to eliminate any issues that may arise with two transfected vectors.
To ensure that VANGL1 mRNA was similarly altered in the parental cell lines,
qRT-PCR was used to determine the difference in VANGL1 mRNA expression
between the parental lines. It was found that VANGL1 mRNA is increased 2.6fold in 21NT parental cells compared to 21PT parental cells (Figure 3.9). From
these data, it was determined that VANGL1 mRNA is elevated in parental 21NT
(DCIS-like) cells compared to parental 21PT (ADH-like) cells.

3.3.1.2. VANGL1-Transfected 21PT Cells Show mRNA and Protein Levels
Similar to 21NT Cells
A

myc-tagged

VANGL1

expression

vector

was

constructed

and

transfected into 21PT cells (21PT+VANGL1). In addition, a control empty vector
was also transfected into 21PT cells (21PT+EV). Both qRT-PCR and Western
blotting were used to determine if levels of VANGL1 were increased in
21PT+VANGL1 cells and how these levels compared to 21PT and 21NT
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Figure 3.8. mRNA expression levels of VANGL1 in 21PTci and 21NTci cells
grown in 2D and 3D culture. For ease of comparison, the mRNA expression
level for 21PTci was set to 1 for both 2D and 3D. In 2D culture, VANGL1
mRNA is 1.8-fold higher in 21NTci compared to 21PTci cells, while in 3D
culture, the difference in mRNA expression is 2.1-fold. For 2D culture, cells
were grown in 6-well plates for 72 hours, while for 3D culture, cells were
grown in Matrigel for 9 days. mRNA expression levels were calculated as a
ratio with 18S rRNA, a housekeeping gene. In this figure and all subsequent
figures, bars labeled with letters that are not the same indicate significant
difference between the bars at a p-value of at least <0.05 (i.e. ‘a’ vs ‘b’, ‘a’ vs
‘c’ and ‘b’ vs ‘c’). Statistics were performed before levels were modified to set
21PTci levels as 1.
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Figure 3.9. mRNA expression levels of VANGL1 in 21PTci, 21NTci, 21PT
and 21NT cells grown in 3D culture. For ease of comparison, the mRNA
expression level for 21PTci was set to 1. VANGL1 mRNA was expressed at
the same level in both 21PTci and the parental 21PT cell lines. The mRNA
expression is 2.2-fold higher in 21NTci cells compared to 21PTci cells. For
the parental cell lines, VANGL1 mRNA is 2.6-fold higher in 21NT cells vs.
21PT cells. Cells were all grown in 3D Matrigel for 9 days before RNA was
extracted. mRNA expression levels were calculated as a ratio with 18S
rRNA, a housekeeping gene. Bars labeled with letters that are not the same
indicate significant difference between the bars at a p-value of at least <0.05.
Statistics were performed before levels were modified to set 21PTci levels as
1.
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(parental) cells. It was found that VANGL1 mRNA and protein levels were indeed
increased in transfected cells to the same levels as 21NT cells (Figure 3.10).

3.3.1.3. 3D In Vitro Cultures of 21PT+VANGL1 Cells Display Features of
More Advanced Progression than 21PT+EV Cells
In order to assess the ability of VANGL1 to alter morphologic
characteristics of 21PT cells in 3D, VANGL1 transfected cells, as well as control,
21PT, 21NT and 21MT-1 cells, were grown in Matrigel matrix for 9 and 15 days.
By day 15, it was apparent that 21PT+VANGL1 cells had a reduced ability to form
extracellular lumena and polarized cells compared to 21PT+EV (and 21PT
parental) cells (Figure 3.11).

In fact, 21PT+VANGL1 cells did not form any

lumena. Additionally, the reduced ability to form polarized cells was even more
pronounced than for the 21MT-1 (IMC-like) cells (29% compared to 43%). These
findings suggest that the 21PT+VANGL1 cells were less organized than the
21PT+EV cells, or even 21NT and 21MT-1 cells. In addition, 21PT+VANGL1
cells had a reduced ability to form spherical colonies over that of the 21PT+EV
control and parental 21PT cells, as well as both the 21NT and 21MT-1 cells
(Figure 3.11). A higher proportion of single cells compared to 21PT+EV cells
were also noted in the 21PT+VANGL1 Matrigel plugs (Figure 3.11). Reduced
ability to form spherical colonies and a greater proportion of single cells are
characteristics consistent with more invasive phenotype, a feature that was
directly tested as described in section 3.3.14. Similar 3D morphologic trends
were seen in day 9 cultures (Appendix C, Figure 1).
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Figure 3.10. mRNA and protein levels of VANGL1 after transfection into
21PT cells. VANGL1 was fused to a myc-tag and stably transfected into
21PT cells using Lipofectin Reagent. mRNA and protein were extracted from
cells grown in Matrigel for 9 days. A) VANGL1 mRNA levels are highest in
21PT+VANGL1 cells and 21NT cells. Control 21PT+empty vector (EV) cells
had the same mRNA level of VANGL1 as 21PT cells. mRNA levels were
obtained using real-time quantitative PCR. Bars labeled with letters that are
not the same indicate significant difference between the bars at a p-value of
at least <0.05. Western blotting (B) shows a similar increase in VANGL1
(70kDa) protein expression in 21NT+VANGL1 cells. Proteins were detected
with a monoclonal anti-VANGL1 antibody.
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Figure 3.11. Characteristics of 21T and VANGL1 overexpressing cells after
15 days growth in 3D Matrigel. 21PT+VANGL1 cells show no lumen
formation and fewer polarized cells than 21PT+EV cells, indicating that the
VANGL1 cells are more disorganized. In addition, VANGL1 transfected cells
also formed far fewer spherical colonies, with the percentage being lower than
even 21MT-1 cells. The percentage of single cells seen in Matrigel plugs for
21PT+VANGL1 cells was at the same level as 21NT cells. 21PT+EV cells
show no differences from 21PT cells. For (A), all sections were H&E stained
and the scale bar represents 50 µm. In (B) for ‘single cells’, an event is either
a single cell or a cell group, whereas for the ‘lumen formation’ , ‘polarized
cells’ and ‘spherical colonies’ comparisons, an ‘event’ was defined as a cell
group only. Bars labeled with letters that are not the same indicate significant
difference between the bars at a p-value of at least <0.05. Statistics for each
comparison were calculated separately from the other comparisons.
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3.3.1.4.

Altered

Proliferation,

Apoptosis

and

Invasive

Ability

of

21PT+VANGL1 Cells Indicate Conversion to a Later Stage of Progression
Proliferation and apoptosis indices were calculated for the VANGL1
overexpressing cells. Ki67 immunohistochemistry for proliferation was conducted
for cells grown in Matrigel for 9 and 15 days. By day 15, proliferation rates for
21PT+VANGL1 were 17.5%, compared to only 2% for 21PT+EV cells and 3.5%
for 21NT cells (Figure 3.12A). Assessment of apoptosis by caspase 3 was done
on cells grown in Matrigel for 9 and 15 days, and showed that by day 15,
21PT+VANGL1 cells had an increased apoptosis index compared to 21PT+EV
cells (Figure 3.12B). However, this increase in apoptosis mirrored that of 21NT
cells. The ratios of proliferation/apoptosis were calculated for 21PT, 21PT+EV,
21PT+VANGL1 and 21NT cell lines grown in Matrigel, using the Ki67
(proliferation) divided by the caspase 3 (apoptosis) index. Results indicate that at
day 15, 21PT+VANGL1 cells have a much higher ratio of proliferation/apoptosis,
compared to 21PT, 21PT+EV or 21NT cells (p<0.001) (Figure 3.12C). Similar
results were seen at day 9 (Appendix C, Figure 2).
To assess the invasive ability of the VANGL1 overexpression cells,
invasion assays were conducted using a transwell system. 21PT, 21PT+EV,
21PT+VANGL1 and 21NT cells were all seeded in the upper chamber of the
transwell system and allowed to invade through Matrigel to reach the FBS
chemoattractant in the lower chamber of the transwell system. It was found that
significantly more 21PT+VANGL1 cells were able to invade through the Matrigel
than either the 21PT (or 21PT+EV) or 21NT cells (Figure 3.13). These results
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Figure 3.12. Proliferative and apoptotic activity of 21T and VANGL1
overexpressing cell lines after 15 days growth in 3D Matrigel. Proliferation
(A) was quantified by Ki67 immunohistochemical staining of Matrigel plugs,
while apoptosis (B) was quantified by caspase 3 immunohistochemistry.
21PT+VANGL1 cells showed a large increase in proliferation (A) over
21PT+EV cells, while apoptosis levels (B) increased to 21NT cell levels.
When the ratio of proliferation/apoptosis was calculated (C), VANGL1
overexpressing cells showed a much higher ratio than the 21PT+EV and
even the 21NT cells. 21PT+EV cells showed no differences from the 21PT
cells. Bars labeled with letters that are not the same indicate significant
difference between the bars at a p-value of at least <0.05.
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Figure 3.13. Invasion of VANGL1 overexpressing cells using a transwell
system. VANGL1 overexpressing cells, as well as 21PT, 21PT+EV and 21NT
cells were seeded in the upper chamber of the transwell system and allowed
to invade through 20 µg of Matrigel, towards FBS. After 72 hours, more
21PT+VANGL1 cells were able to invade than any of the other 21T cell lines.
For each cell line, 5 high power fields (HPF) were counted per three
replicated. Bars labeled with letters that are not the same indicate significant
difference between the bars at a p-value of at least <0.05.
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indicate that the VANGL1 overexpressing cells are more invasive than 21PT or
21NT cells.

3.3.2. S100A2
As described in Chapter 2, S100A2 was found to be reduced in 21MT-1
(IMC-like) cells compared to 21NT (DCIS-like) cells [8].

To determine the

functional role of S100A2 in the transition to an invasive phenotype, shRNA
against S100A2 was transfected into 21NT cells and the cells were analyzed
using several functional parameters, including colony profile (spherical vs.
irregular), lumen formation, cell polarization, proportion of single cells,
proliferation index, apoptosis index and cell invasion by time lapse microscopy.

3.3.2.1. S100A2 mRNA Expression Levels are Altered in 21MT-1 Compared
to 21NT Cells
Since the 21T series breast cell line model of early breast cancer
progression was created in a 3D system, prior to generating transfectants we
wanted to determine whether this differential expression of S100A2 mRNA
between 21NTci and 21MT-1 would also be seen when the 21T series cells were
grown in 2D culture. Using qRT-PCR, we determined that when cells are grown
in 2D, S100A2 is in fact decreased 3.4-fold in 21MT-1 compared to 21NTci cells
(Figure 3.14). This reduction in S100A2 mRNA is comparable to the 3.2-fold
reduction seen in 21MT-1 cells grown in 3D (Figure 3.14). From these data, it
was determined that the stage-specific gene expression pattern of S100A2 can
be found in cells grown in both 2D and 3D culture.
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Figure 3.14. mRNA expression levels of S100A2 in 21NTci and 21MT-1 cells
grown in 2D and 3D culture. For ease of comparison, the mRNA expression
level for 21NTci was set to 1 for both 2D and 3D. In 2D culture, S100A2
mRNA is 3.4-fold lower in 21MT-1 compared to 21NTci cells, which is not
significantly different from the 3.2-fold difference seen in 3D culture. For 2D
culture, cells were grown in 6-well plates for 72 hours, while for 3D culture,
cells were grown in Matrigel for 9 days. mRNA expression levels were
calculated as a ratio of 18S rRNA, a housekeeping gene. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05. Statistics were performed before levels were
modified to set 21NTci levels as 1.
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The previous microarray analysis used 21NT cells containing an empty
neo-selection vector (21NTci). Since we planned to knockdown S100A2 in the
21NT cells, we decided to use the parental 21NT cells, to eliminate any issues
that may arise with two transfection vectors in the same cell line. qRT-PCR was
used to determine the differential expression of S100A2 in 21MT-1 cells vs. the
parental 21NT cell line. It was found that S100A2 mRNA is decreased 3.5-fold in
21MT-1 cells compared to 21NT parental cells (Figure 3.15).

Thus, S100A2

mRNA is indeed reduced in 21MT-1 (IMC-like) cells compared to parental 21NT
(DCIS-like) cells.

3.3.2.2. 21NT+shS100A2 Cells Show mRNA and Protein Levels Similar to
21MT-1 Cells
Short hairpin (sh) RNA against S100A2 was obtained and transfected into
21NT cells (21NT+shS100A2). In addition, a control empty shRNA vector was
also transfected into 21NT cells (21NT+EV).

Both qRT-PCR and Western

blotting were used to determine if levels of S100A2 were decreased in
21NT+shRNA cells and how these levels compared to 21NT and 21MT-1 cells. It
was found that S100A2 mRNA and protein levels were indeed decreased in
transfected cells to the same levels as 21MT-1 cells (Figure 3.16).

3.3.2.3. 3D In Vitro Cultures of 21NT+shS100A2 Cells Display Features of a
Later Stage of Progression
3D in vitro cultures were used to assess the ability of S100A2 to alter
morphologic characteristics of 21NT cells. S100A2 knockdown cells, as well as
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Figure 3.15. mRNA expression levels of S100A2 in 21NTci and 21NT cells
compared to 21MT-1 cells. For ease of comparison, the mRNA expression
level for 21NTci was set to 1. S100A2 mRNA was expressed at the same
level in both 21NTci and the parental 21NT cell lines. The mRNA expression
is decreased 3.2-fold in 21MT-1 cells compared to 21NTci cells and 3.5-fold
compared to 21NT parental cells. Cells were all grown in 3D Matrigel for 9
days before RNA was extracted. mRNA expression levels were calculated as
a ratio with 18S rRNA, a housekeeping gene. Bars labeled with letters that
are not the same indicate significant difference between the bars at a p-value
of at least <0.05. Statistics were performed before levels were modified to
set 21NTci levels as 1.
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Figure 3.16. mRNA and protein levels of S100A2 after shRNA transfection
into 21NT cells. An shRNA vector against S100A2 was stably transfected
into 21NT cells using Lipofectin Reagent. mRNA and protein were extracted
from cells grown in Matrigel for 9 days. A) S100A2 mRNA is knocked down
in 21NT+shS100A2 cells to 21MT-1 levels. Control 21NT+empty vector (EV)
cells had the same mRNA level of S100A2 as 21NT cells. mRNA levels were
obtained using real-time quantitative PCR. Bars labeled with letters that are
not the same indicate significant difference between the bars at a p-value of
at least <0.05. B) Western blotting shows a similar decreased in S100A2
(12kDa) expression in 21NT+shS100A2 cells. Proteins were detected with a
monoclonal anti-S100A2 antibody.
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control vector transfected 21NT, 21NT parental and 21MT-1 cells, were grown in
Matrigel matrix for 9 and 15 days.

By day 15, it was obvious that

21NT+shS100A2 cells had completely lost the ability to form extracellular lumena
(Figure 3.17). In addition, S100A2 knockdown cells had a reduced ability to form
polarized cells compared to 21NT+EV, 21NT and 21MT-1 cells (Figure 3.17).
These findings suggest that the 21NT+shS100A2 cells were less organized than
21NT cells, or even 21MT-1 cells. The ability to form spherical colonies was also
reduced in 21NT+shS100A2 cells, to the same level as the invasive 21MT-1 cell
line (Figure 3.17).

Additionally, the proportion of single cells seen in

21NT+shS100A2 Matrigel plugs was the same as those seen for 21MT-1 cells
(Figure 3.17).

Thus, the S100A2 knockdown cells possessed several

characteristics consistent with increased invasiveness, similar to 21MT-1 cells.
Similar trends were seen in day 9 cultures (Appendix C, Figure 3). Alteration in
invasiveness of 21NT+shS100A2 cells was then directly assessed as described
in 3.3.2.4.

3.3.2.4. 21NT+shS100A2 Cells Exhibit Characteristics of a More Aggressive
Phenotype Including Alterations in Proliferation, Apoptosis and Invasion
Assessment of proliferative rates by Ki67 immunohistochemistry and
apoptosis rates by caspase 3 were performed for the S100A2 knockdown cells.
Immunohistochemistry for proliferation and apoptosis was conducted on Matrigel
plugs from cells grown in Matrigel for 9 and 15 days. By day 15, proliferation
rates for 21NT+shS100A2 were 11.5%, compared to 3.5% for 21NT+EV cells
and 6% for 21MT-1 cells (Figure 3.18A). The apoptosis index showed that at day
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Figure 3.17. Characteristics of 21T and S100A2 knockdown cells after 15
days growth in 3D Matrigel. 21NT+shS100A2 cells show complete loss of
lumen forming ability and fewer polarized cells than 21NT+EV or 21MT-1
cells, indicating that the S100A2 knockdown cells are less organized. In
addition, S100A2 shRNA cells also formed fewer spherical colonies than
21NT+EV cells and in line with 21MT-1 cells. The percentage of single cells
seen in Matrigel plugs for 21NT+shS100A2 cells was at the same level as
21MT-1 cells. 21NT+EV cells show no differences from 21NT cells. For (A),
all sections were H&E stained and the scale bar represents 50 µm. In (B) for
‘single cells’, an event is either a single cell or a cell group, whereas for the
‘lumen formation’ , ‘polarized cells’ and ‘spherical colonies’ comparisons, an
‘event’ was defined as a cell group only. Bars labeled with letters that are not
the same indicate significant difference between the bars at a p-value of at
least <0.05. Statistics for each comparison were calculated separately from
the other comparisons.
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Figure 3.18. Proliferative and apoptotic activity of 21T and S100A2 knockdown
cell lines after 15 days growth in 3D Matrigel. Proliferation (A) was quantified by
Ki67 immunohistochemical staining of Matrigel plugs, while apoptosis (B) was
quantified by caspase 3 immunohistochemistry. 21NT+shS100A2 cells showed
an increase in proliferation (A) over 21NT+EV and 21MT-1 cells, while apoptosis
levels (B) of S100A2 shRNA cells were not different from 21NT+EV cells. When
the ratio of proliferation/apoptosis was calculated (C), S100A2 knockdown 21NT
cells showed a ratio in line with 21MT-1 cells. 21NT+EV cells showed no
differences from the 21NT cells. Bars labeled with letters that are not the same
indicate significant difference between the bars at a p-value of at least <0.05.
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15, there was no difference in apoptosis rates between 21NT+EV and
21NT+shS100A2 cells (Figure 3.18B).

However, 21MT-1 cells have a lower

apoptosis rate at day 15 compared to 21NT, 21NT+EV and S100A2 21NT
knockdowns.

Ratios of proliferation/ apoptosis were calculated for 21NT,

21NT+EV, 21NT+shS100A2 and 21MT-1 cell lines grown in Matrigel, using the
Ki67 (proliferation) vs. the caspase 3 (apoptosis) index. The ratios indicate that
at day 15, 21NT+shS100A2 cells have a proliferation/apoptosis ratio that is the
same as 21MT-1 cells and higher than 21NT+EV and 21NT cells (Figure 3.18C).
Similar results were seen at day 9 (Appendix C, Figure 4). These results indicate
that S100A2 knockdown cells have a similar growth profile to the invasive 21MT1 (IMC-like) cells.
To assess the invasive ability of the S100A2 knockdown cells, 21NT,
21NT+EV, 21NT+shS100A2 and 21MT-1 cells were grown in Matrigel for 9 days
and then followed with time lapse microscopy until day 15. It was found that
similarly to 21MT-1 cells, 100% of 21NT+shS100A2 cells were able to travel
through the Matrigel in both horizontal and vertical directions, compared to only
~30%% of 21NT+EV cells (Figure 3.19). In addition, S100A2 knockdown cells
traveled 212 μm on average over the six days, which was significantly (p<0.01)
farther than 21NT+EV cells (15 μm) cells, but similar to 21MT-1 cells (205 μm).
These results indicate that the S100A2 knockdown cells invade in a manner
similar to 21MT-1 cells.
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Figure 3.19. Cell invasion through Matrigel matrix for 21T and S100A2
knockdown cells. Cells were grown in Matrigel for 9 days and then
transferred to the incubator stage platform of a time lapse microscope until
day 15. Z-stack images were taken every 12 h and all cells were followed for
the entire 6-day incubation. (A) Percentage of total cells that invaded
(moved) through the Matrigel matrix. A higher percentage of 21NT+
shS100A2 cells were able to move than 21NT or 21NT+EV cells. The
percentage of S100A2 knockdown cells that were able to invade through
Matrigel was 100%, similar to 21MT-1 cells. Similarly, when looking at the
distance (µm) moving cells are able to travel through the matrix (B), S100A2
knockdown cells were able to travel as far as 21MT-1 cells. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05.
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3.3.3. TBX3
In work described in Chapter 2, TBX3 was found to be increased in 21MT1 (IMC-like) cells compared to 21NT (DCIS-like) cells [8]. There are two isoforms
of TBX3, created by alternative splicing.

TBX3 isoform 2 (TBX3 Iso2), also

known as TBX3+2a is the full transcript, while TBX3 Isoform 1 (TBX3 Iso1), also
known as TBX3 (common form), has 22 amino acids spliced out of exon 2. To
determine the functional role of both isoforms of TBX3 in the transition to an
invasive phenotype, the isoforms were transfected separately into 21NT cells.
Functional assays including colony profile (spherical vs. irregular), lumen
formation, cell polarization, proportion of single cells, proliferation index,
apoptosis index, cell invasion and presence of epithelial to mesenchymal
transition (EMT) markers were then used to analyze the cells.

3.3.3.1. TBX3 mRNA Expression Levels are Altered in 21MT-1 Compared to
21NT Cells
Since the 21T series model of early breast cancer progression was
created in a 3D system, prior to generating transfectants, we first wanted to
determine whether the differential expression of TBX3 between 21NTci and
21MT-1 cells was specific to 3D culture. Using qRT-PCR, we determined that
when 21NTci and 21MT-1 cells are grown in 2D culture, TBX3 is elevated 1.7fold in 21MT-1 compared to 21NTci cells (Figure 3.20). This was less of an
increase than that seen for 3D culture (2.8-fold; Figure 3.20). Thus, the stagespecific gene expression pattern of TBX3 is more pronounced when cells are
grown in 3D than in 2D.
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Figure 3.20. mRNA expression levels of TBX3 in 21NTci and 21MT-1 cells
grown in 2D and 3D culture. For ease of comparison, the mRNA expression
level for 21NTci was set to 1 for both 2D and 3D. In 2D culture, TBX3 mRNA
is 1.7-fold higher in 21MT-1 compared to 21NTci cells, while TBX3 mRNA
expression is increased 2.7-fold in 21MT-1 cells compared to 21NTci cells
when grown in 3D culture. For 2D culture, cells were grown in 6-well plates
for 72 hours, while for 3D culture, cells were grown in Matrigel for 9 days.
mRNA expression levels were calculated as a ratio with 18S rRNA, a
housekeeping gene. Bars labeled with letters that are not the same indicate
significant difference between the bars at a p-value of at least <0.05.
Statistics were performed before levels were modified to set 21NTci levels as
1.
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When microarray analysis was completed with the 21T series cells, the
21NT cells contained an empty neo-selection vector (21NTci). Since we planned
to transfect TBX3 into the 21NT cells, we decided to use the parental 21NT cells,
to eliminate any issues that may arise with two transfected vectors. To ensure
that TBX3 mRNA levels were similarly altered in the parental cell lines, qRT-PCR
was used to determine the increase in TBX3 mRNA expression in 21MT-1 cells
compared to both the 21NTci and parental 21NT cell lines. It was found that
TBX3 mRNA was increased 2.9-fold in 21MT-1 cells compared to 21NT parental
cells (Figure 3.21). From these data, it was determined that TBX3 mRNA was
elevated in 21MT-1 (IMC-like) cells compared to parental 21NT (DCIS-like) cells.

3.3.3.2.

21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 Cells Show mRNA and

Protein Levels Increased Over 21NT+EV Cells
Expression vectors containing TBX3 isoform 1 fused to ZsGreen and
TBX3 isoform 2 fused to ZsGreen were constructed and transfected into 21NT
cells (21NT+TBX3 Iso1, 21NT+TBX3 Iso2).

In addition, a control expression

vector containing only ZsGreen was also transfected into 21NT cells (21NT+EV).
Quantitative RT-PCR was used to determine the endogenous mRNA levels of the
two TBX3 isoforms in transfected cells, as well as empty vector control, 21NT
(parental) and 21MT-1 cells. In addition, the mRNA level of the TBX3-ZsGreen
fusion product was determined.

To quantify and distinguish the endogenous

transcript from the transgene, a forward primer for the endogenous forms
targeting 5’UTR (untranslated region) was designed, while reverse primers which
either spanned (TBX3 Iso1) or were within the splice junction (TBX3 Iso2) were
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Figure 3.21. mRNA expression levels of TBX3 in 21NTci and 21NT cells
compared to 21MT-1 cells. For ease of comparison, the mRNA expression
level for 21NTci was set to 1. TBX3 mRNA was expressed at the same level
in both 21NTci and the parental 21NT cell lines. The mRNA expression is
2.8-fold higher in 21MT-1 cells compared to 21NTci cells and 2.9-fold higher
compared to 21NT parental cells. Cells were all grown in 3D Matrigel for 9
days before RNA was extracted. mRNA expression levels were calculated as
a ratio with 18S rRNA, a housekeeping gene. Bars labeled with letters that
are not the same indicate significant difference between the bars at a p-value
of at least <0.05. Statistics were performed before levels were modified to
set 21NTci levels as 1.
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designed, to ensure the isoforms were amplified separately (Table 3.1).

For

quantitation of only the TBX3-ZsGreen transgene, forward primers were designed
to anneal to a sequence downstream of the splice junction, while the reverse
primer was designed to anneal to a sequence specific to the TBX3-ZsGreen
junction (Table 3.1). Results indicate that 21NT+TBX3 Iso1 and 21NT+TBX3
Iso2 cells both have increased TBX3-ZsGreen mRNA expression for their
respective isoform over that of 21NT+EV cells (Figure 3.22A), although the levels
in 21NT+TBX3 Iso2 transfectants are higher than 21NT+TBX3 Iso1 (6.6-fold over
21NT+EV, compared to 3.5-fold). Also, mRNA of endogenous TBX3 isoform 1 is
increased 2.0-fold in 21NT+TBX3 Iso1 cells and 1.6-fold in 21NT+TBX3 Iso2
cells (Figure 3.22A).

Similarly, mRNA of endogenous TBX3 isoform 2 is

increased 1.8-fold in 21NT+TBX3 Iso1 cells and 2.9-fold in 21NT+TBX3 Iso2
cells (Figure 3.22A). Endogenous TBX3 isoform 1 mRNA is increased in 21MT-1
cells 3.7-fold compared to 21NT+EV cells, while isoform 2 mRNA is increased
2.6-fold in 21MT-1 cells compared to 21NT+EV cells (Figure 3.22A). Thus, via
mRNA it appears that both isoforms of TBX3 are increased in transfected cells
over 21NT cells.
Western blots using a monoclonal antibody against TBX3 were also
performed to determine the protein level of TBX3 in the transfected cell lines, as
well as 21NT, 21NT+EV and 21MT-1 cells. A band at 80kDa was resolved,
which corresponds to endogenous TBX3 (Figure 3.22B). Since the two isoforms
are only 22 amino acids different in size, separate bands for each isoforms could
not be resolved. TBX3 protein at this size was increased in 21NT+TBX3 Iso1
and 21NT+TBX3 Iso2 compared to 21NT (and 21NT+EV) cells (Figure 3.22B).
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Figure 3.22. mRNA and protein levels of endogenous TBX3 and TBX3-ZsGreen after
transfection into 21NT cells. The two isoforms of TBX3 (TBX3 Iso1, TBX3 Iso2) were
separately fused to ZsGreen protein and stably transfected into 21NT cells. mRNA and
protein were extracted from cells grown in Matrigel for 9 days. In cells transfected with only
TBX3 Iso1, (A) endogenous TBX3 Iso1 mRNA is increased as well as the TBX3-ZsGreen
fusion product. Similarly, cells transfected with TBX3 Iso2 alone (A) show increased
endogenous TBX3 Iso2 as well as TBX3-ZsGreen mRNA. Control 21NT+empty vector (EV)
cells had the same mRNA level of both TBX3 isoforms and TBX3-ZsGreen, compared to
21NT cells. mRNA levels were obtained using real-time quantitative PCR. For ease of
comparison, the mRNA expression level for 21NT was set to 1 for endogenous TBX3, while
21NT+EV was set to 1 for the fusion product. Bars labeled with letters that are not the same
indicate significant difference between the bars at a p-value of at least <0.05. Western
blotting (B) shows similar increases in endogenous TBX3 (80kDa) protein for both
transfected cell lines and presence (C) of a TBX3-ZsGreen fusion protein (100 kDa) in
21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 transfected cells. The 21NT+EV cell lines also
show a ZsGreen product. A β-tubulin loading control was used in (B), however different
amounts of protein were loaded in (C) to resolve bands. Thus, (C) is not used to compare
amounts of TBX3-ZsGreen protein but to show expression only. Proteins were detected
with a monoclonal anti-TBX3 antibody (B) or a polyclonal anti-ZsGreen antibody (C).
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However, since the transfected TBX3 was fused to ZsGreen, which is
approximately 20kDa, the fusion protein should have been resolved at
approximately 100kDa. No band was resolved at this location (Figure 3.22b)
when using the TBX3 antibody, even after altering many blot conditions, including
amount of protein loaded, concentration of primary and secondary antibody,
incubation time with primary and secondary antibody, transfer time and exposure
time. Instead, immunoblotting with a polyclonal antibody against ZsGreen was
used in order to resolve the protein band corresponding to the TBX3-ZsGreen
fusion protein. 21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 cells both showed protein
banding at approximately 100kDa (Figure 3.22C), corresponding to the size
expected for TBX3 (80 kDa) plus ZsGreen (20 kDa). The empty vector control
cells (21NT+EV) showed a protein band resolved at approximately 60kDa (Figure
3.22C). Although the predicted protein size of ZsGreen is ~20kDa, this 60kDa
band could represent a trimeric form of ZsGreen because this blot was performed
under non-denaturing and non-reducing conditions.
Confocal microscopy was also employed to determine the relationship
between TBX3 and ZsGreen. Both 21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 cell
lines showed increased TBX3 and ZsGreen compared to 21NT cells (Figure
3.23). Much of the TBX3 and ZsGreen signal also colocalized, indicating that the
increased TBX3 was a result of the transfected ZsGreen fusion protein. Thus,
TBX3 is increased in the transfected cell line compared to 21NT cells. It is also
worth noting that a proportion of the ZsGreen signal was confined to the nuclear
volume (34% of total signal for TBX3 Iso1, 23% of total signal for TBX3 Iso2),
consistent with TBX3’s action as a transcription factor.
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Figure 3.23. Relationship between TBX3 and ZsGreen using confocal
microscopy. 21NT (A), 21NT+TBX3 Iso1 (B) and 21NT+TBX3 Iso2 (C) cells
were grown on coverslips for 24 hrs. Cells were fixed and stained with an
anti-TBX3 antibody. In order to incorporate florescence, the secondary was
conjugated to Alexa488 (red). Cells were also stained with Hoechst (blue) for
nuclear detection. The 21NT cell line (A) lacked ZsGreen expression. The
transfected cell lines (B, C) show more TBX3 than the 21NT (A) cells. In the
TBX3-ZsGreen transfected cell lines (B, C), the majority of the TBX3 and
ZsGreen signal colocalized, indicating that most of the increased TBX3 is a
result of the transfected ZsGreen fusion protein. Scale bar represents 10
µm.
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3.3.3.3. 3D In Vitro Cultures of 21NT+TBX3 Cells Display Features of a More
Advanced Stage of Progression
To assess the ability of TBX3 to alter morphologic characteristics of 21NT
cells, TBX3-transfected cells (both isoforms), as well as control, 21NT and 21MT1 cells, were grown in Matrigel matrix for 9 and 15 days. At day 15, it was
apparent that both 21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 cells had a reduced
ability to form extracellular lumena and polarized cells compared to 21NT+EV
cells (Figure 3.24).

For TBX3 isoform 1 overexpressing cells, ability to form

extracellular lumena were reduced to the same levels as 21MT-1 cells; however,
for TBX3 isoform 2 overexpressing cells, the ability to form extracellular lumena
was reduced past 21MT-1 levels (Figure 3.24). Overexpression of both isoforms
resulted in reduced ability to form polarized cells past levels seen for 21MT-1
cells (Figure 3.24).

These findings suggest that both 21NT+TBX3 Iso1 and

21NT+TBX3 Iso2 cells were less differentiated than 21NT+EV cells and perhaps
even less differentiated than 21MT-1 cells. Both TBX3 variant overexpressing
cells also had a reduced ability to form spherical colonies compared to 21NT+EV
cells, although not lower than 21MT-1 cells (Figure 3.24). Similarly to 21MT-1
cells, 21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 cell Matrigel plugs showed a higher
proportion of single cells compared to 21NT+EV control cells (Figure 3.24).
Matrigel plugs of TBX3 overexpressing cells also showed a small percent of very
large, irregularly shaped, loosely packed aggregates, unlike any seen with 21T
series cells in 3D culture before (Figure 3.24). These results are consistent with
the conclusion that the TBX3 overexpressing cells acquired characteristics of
invasive behaviour, similar to those seen with 21MT-1 cells. Similar trends were
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Figure 3.24. Characteristics of 21T and TBX3 transfected cells after 15 days
growth in 3D Matrigel. 21NT +TBX3 Iso1 and Iso2 cells form fewer lumens
and polarized cells than 21NT+EV cells, indicating that the TBX3 cells are
less organized. In addition, TBX3 transfected cells also formed less spherical
colonies, in line with the invasive 21MT-1 cell line and more single cells, also
similarly to 21MT-1 cells. 21NT+EV cells show no differences from 21NT
cells. For (A), all sections were H&E stained and the scale bar represents 50
µm. In (B) for ‘single cells’, an event is either a single cell or a cell group,
whereas for the ‘lumen formation’ , ‘polarized cells’ and ‘spherical colonies’
comparisons, an ‘event’ was defined as a cell group only. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05. Statistics for each comparison were calculated
separately from the other comparisons.
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seen in day 9 cultures (Appendix C, Figure 5).

Invasive ability of the TBX3

transfectants was then directly tested as described in section 3.3.3.4.

3.3.3.4.

Altered Proliferation, Apoptosis and Invasive Ability Indicate

21NT+TBX3 Cells Exhibit Characteristics of a More Invasive Phenotype
Proliferation and apoptosis rates were calculated for the TBX3
overexpressing cells after growth in 3D Matrigel for 9 and 15 days.
Immunohistochemistry using Ki67 was used to calculate proliferation indices,
while caspase 3 immunohistochemistry was used to calculate apoptosis indices.
By day 15, proliferation rates for 21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 were
greatly increased over 21NT, 21NT+EV or 21MT-1 levels (Figure 3.25A). In fact
21NT+TBX3 Iso1 cells had 61.0% proliferating cells, while 21NT+TBX3 Iso2 had
58.8% proliferating cells, compared to 3.5% seen for 21NT+EV cells and 6% for
21MT-1 cells.

The apoptosis index showed that at day 15, there was no

difference in apoptosis rates between 21NT+EV (and 21NT) and 21NT+TBX3
Iso1 or 21NT+TBX3 Iso2 cells (Figure 3.25B). However, 21MT-1 cells have a
lower apoptosis rate at day 15 compared to 21NT+EV and TBX3 overexpressing
cells. Ratios of proliferation/apoptosis were then calculated for 21NT, 21NT+EV,
21NT+TBX3 Iso1, 21NT+TBX3 Iso2 and 21MT-1 cell lines grown in Matrigel,
using the Ki67 vs. the caspase 3 index. The ratios indicate that at day 15, both
TBX3 overexpressing cell lines have proliferation/apoptosis ratios that are greatly
increased compared to 21NT+EV (p<0.001) and 21MT-1 (p<0.001) cells (Figure
3.25C). Similar results were seen at day 9 (Appendix C, Figure 6).
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Figure 3.25. Proliferative and apoptotic activity of 21T and TBX3 transfected
cell lines after 15 days growth in 3D Matrigel. Proliferation (A) was quantified
by Ki67 immunohistochemical staining of Matrigel plugs, while proliferation
(B) was quantified by caspase 3 immunohistochemistry. 21NT+TBX3 Iso1
and Iso2 cells showed a large increase in proliferation (A) over 21NT+EV
cells, while apoptosis levels (B) remained similar to the 21T cells. When the
ratio of proliferation/apoptosis was calculated (C), TBX3 transfected cells
showed a much higher ratio than the 21NT+EV and even the 21MT-1 cells.
21NT+EV cells showed no differences from the 21NT cells. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05.

125

In order to assess the invasive ability of the TBX3 overexpressing cells,
21NT, 21NT+EV, 21NT+TBX3 Iso1, 21NT+TBX3 Iso2 and 21MT-1 cells were
grown in Matrigel for 9 days and followed with time lapse microscopy until day 15.
It was found that 83.7% of TBX3 isoform 1 overexpressing cells were able to
travel through the Matrigel, while 92.7% of TBX3 isoform 2 overexpressing cells
were able to invade (Figure 3.26). This is significantly more than 21NT+EV cells
(p<0.001) and not significantly different from the 100% of 21MT-1 cells that are
able to invade through Matrigel. In addition, 21NT+TBX3 Iso1 cells traveled 154
μm on average over the seven days, while 21NT+TBX3 Iso2 cells traveled 182
μm, both of which were significantly (p<0.01) farther than the 15 μm traveled by
21NT+EV cells, but similar to 21MT-1 cells (212 μm). These results indicate that
the TBX3 overexpressing cells (both isoform 1 and 2) are as invasive as 21MT-1
cells.

3.3.3.5.

21NT+TBX3 Cells Show Vimentin and E-Cadherin Alterations

Consistent with EMT
While maintaining the TBX3 cells (21NT+TBX3 Iso1, 21NT+TBX3 Iso2) in
2D culture, it was noted that the cells had a more mesenchymal-like or spindled
appearance than the 21NT or 21NT+EV control cells. To determine if the cells
had undergone an EMT conversion, confocal microscopy was used to analyze
expression of two EMT markers, vimentin and E-cadherin. Since we had already
established that TBX3 colocalized with ZsGreen, ZsGreen presence was used to
determine cells with increased TBX3 expression.

The confocal microscopy

demonstrated that E-cadherin is greatly reduced in both 21NT+TBX3 Iso1 and
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Figure 3.26. Cell invasion through Matrigel matrix for 21T and TBX3 transfected
cells. Cells were grown in Matrigel for 9 days and then transferred to the
incubator stage platform of a time lapse microscope until day 15. Z-stack
images were taken every 12 h and all cells were followed for the entire 6-day
incubation. (A) Percentage of total cells that invaded (moved) through the
Matrigel matrix. A higher percentage of 21NT+TBX3 Iso1 and Iso2 cells were
able to invade than 21NT or 21NT+EV cells. In fact, the percentage of TBX3
cells that were able to invade through Matrigel was not significantly different
from the invasive 21MT-1 cells. Similarly, when looking at the distance (µm)
moving cells are able to travel through the matrix (B), TBX3 transfected cells
were able to travel as far as 21MT-1 cells and significantly further than
21NT+EV or parental 21NT cells. Bars labeled with letters that are not the same
indicate significant difference between the bars at a p-value of at least <0.05.
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21NT+TBX3 Iso2 cells compared to 21NT+EV cells (Figure 3.27). Isoform 1
overexpressing cells appear to have an even greater E-cadherin reduction than
the isoform 2 overexpressing cells. In contrast, vimentin is greatly increased in
the TBX3 overexpressing cells compared to 21NT+EV controls (Figure 3.28).
These results indicate that TBX3 may have indeed induced an EMT conversion in
the overexpressing cells.

3.4. DISCUSSION
Gene expression profiling of clinical breast cancer specimens has yielded
abundant differences between stages of progression (eg. [46-50]). However, this
gene profiling has not elucidated which of these differently expressed genes are
key players in functionally regulating the transitions through stages of breast
cancer. Moreover, there are few model systems, in vitro or in vivo, that can be
used to test the influence of candidate genes on human breast cancer
progression. The 21T human breast epithelial cell line 3D model system of early
breast cancer progression which we have previously described (Chapter 2 and
[8]) has been used in the present study to functionally characterize gene targets
identified as stage-specifically altered between ADH, DCIS and IMC. A major
advantage of this system lies in the isogenic background of these cells,
eliminating individual genetic background variability, which can cloud results
when comparing across cell lines of different patient origin.

A second major

advantage hinges on the ability of the cells to represent specific stages of
progression when grown in 3D in vitro culture [8]. Use of a 3D system allows us
to rapidly (9-15 days) test multiple functional characteristics of candidate genes to
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Figure 3.27. Levels of E-cadherin in TBX3-ZsGreen transfected cells using
confocal microscopy. 21NT+EV (A), 21NT+TBX3 Iso1 (B) and 21NT+TBX3
Iso2 (C) cells were grown on coverslips for 24hrs. Cells were fixed and
stained with an anti-E-cadherin antibody. In order to incorporate florescence,
the secondary was conjugated to Alexa488 (red). Cells were also stained
with Hoechst (blue) for nuclear detection. Both cells transfected with TBX3
Iso1 (B) and TBX3 Iso2 (C) show reduced levels of E-cadherin compared to
empty vector control cells (21NT+EV; A). Scale bar represents (A) 20 µm,
(B) 10 µm and (C) 8 µm.
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Figure 3.28. Levels of vimentin in TBX3-ZsGreen transfected cells using
confocal microscopy. 21NT+EV (A), 21NT+TBX3 Iso1 (B) and 21NT+TBX3
Iso2 (C) cells were grown on coverslips for 24 hrs. Cells were fixed and
stained with an anti-vimentin antibody. In order to incorporate florescence,
the secondary was conjugated to Alexa488 (red). Cells were also stained
with Hoechst (blue) for nuclear detection. Both cells transfected with TBX3
Iso1 (B) and TBX3 Iso2 (C) show increased levels of vimentin compared to
empty vector control cells (21NT+EV; A). Scale bar represents (A) 20 µm
and (B,C) 9 µm.
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determine their role in regulating the transitions through the stages of breast
cancer.

3.4.1. VANGL1 Promotes the Transition from ADH to Invasive Malignancy
VANGL1 was overexpressed in 21PT (ADH-like) cells to learn if the
transfected cells would acquire attributes of a malignant (DCIS and or invasive)
phenotype. We compared the 21PT+VANGL1 cells to parental 21PT (and control
21PT+EV) cells, as well 21NT cells, which represent DCIS, to determine the role
of VANGL1 in this early transition. When grown in 3D Matrigel, the VANGL1
overexpressing cells appeared less organized.

This was based on the cells’

complete loss of the ability to form extracellular lumena and the decreased ability
to form polarized cells. In fact the reduction in ability to form polarized cells was
decreased beyond even that of the 21MT-1 cells, which are invasive and actually
represent IMC when grown in 3D culture and in vivo.

The VANGL1

overexpressing cells also had a greatly reduced ability to form spherical colonies
compared to the parental 21PT cells (even more reduced than for the 21MT-1
cells) and showed an increased percentage of single cells. These features would
suggest that VANGL1 overexpressing cells did acquire characteristics of
malignancy, that were at least progressed to the point of a DCIS-like (21NT-like)
phenotype, and for some features suggestive of an invasive (21MT-1-like)
phenotype. This increased invasive ability was substantiated by the invasion
assay, which showed that the VANGL1 overexpressing cells were indeed more
invasive

than

21NT

immunohistochemical

cells.
staining

Proliferation
with

Ki67,

rate,
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demonstrated

visualized
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overexpressing 21PT cells had a greatly increased rate of cell growth compared
to the 21PT parental line, the 21PT+EV control cells and the 21NT line. In fact
this increase in proliferation was past the levels observed for 21MT-1 cells in
other experiments (see Figure 3.17 and 3.24 for documented rates). However,
the apoptosis rate for VANGL1 transfected 21PT cells was also increased, but
only to levels usual for 21NT cells. When we calculated a ratio of proliferating
over apoptosing cells, we saw that the ratio for VANGL1 overexpressing cells
was much higher than for 21PT, 21PT+EV or 21NT cells, indicating that the
VANGL1 overexpressing cells have a growth advantage.
The

characteristics

of

invasive

ability

seen

with

the

VANGL1

overexpressing cells may be a result of the ability of VANGL1 to negatively
interact with the metastasis suppressing actions of its binding partner, KAI1.
Previous studies have shown that VANGL1 increases metastatic ability through
its interaction with KAI1 [10, 11]. Additionally, the role of VANGL1 in the PCP
(planar cell polarity) pathway may elucidate the reason we see progression past
DCIS (21NT cells) with VANGL1 overexpressing cells.

The role of the PCP

pathway in cancer development is controversial. Previously it has been shown
that the canonical Wnt/β-catenin pathway is upregulated in tumourigenesis and
that there is antagonism between canonical Wnt signalling and noncanonical Wnt
signalling, leading to a belief that PCP signalling should suppress tumourigenesis
[51]. Moreover, Wnt5a, a noncanonical Wnt, is downregulated in many types of
cancer [52-56] and a tumour suppressing role for Wnt5a, as an antagonist of
Wnt/β-catenin signalling has evolved [15]. However, in other studies, especially
in cancer of advanced stage, Wnt5a is upregulated and associated with invasion,
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metastasis and angiogenesis [15, 57-59]. From this, a new theory involving a
biphasic role for the PCP pathway has emerged [15]. It was theorized that at
early stages activated Wnt/β-catenin signalling is involved in the transformation
from normal cells to neoplastic ones, while PCP signalling, which is often
mediated by Wnt5a, inhibits progression by antagonizing Wnt/β-catenin
signalling. However, tumours are still able to develop by escaping the inhibition
of PCP signalling, either by downregulation of PCP signalling or upregulation of
downstream effectors of canonical Wnt signalling. As the tumour progresses, the
role of PCP signalling becomes altered to promote migration and invasion and
support angiogenesis, which all contribute to metastasis in advanced stage
cancers [15]. As was mentioned previously, the binding of non-canonical Wnt
molecules, such as Wnt5a, to the Fzd receptor, activates the PCP pathway [15].
Interestingly, we previously found that Wnt5a mRNA is moderately high in 21PT,
low in 21NT and very high in 21MT-1 (see real-time validation in Chapter 2 (Table
2.3) and [8]). Hence the theory of a dual role for the PCP pathway fits with the
21T model system. At early stages of progression VANGL1 is low even though
Wnt5a is slightly elevated, potentially resulting in low PCP signalling and reduced
antagonism of Wnt/β-catenin signalling.

By the stage of DCIS, VANGL1 is

increased, potentially resulting in increased PCP signalling (which may require
VANGL1). Finally, in IMC, Wnt5a levels increase (with further activation of the
PCP pathway), while VANGL1 remains elevated. Thus, the effects of a noncanonical pathway signal (such as that from Wnt5a) may differ depending on
whether or not the cells are expressing VANGL1 (tumour suppressing in the
absence of VANGL1, promoting of malignancy in the presence of VANGL1).
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These results also suggest that the increased expression of VANGL1 promotes
progression to both in situ and invasive mammary carcinoma.

3.4.2. S100A2 Inhibits the Transition to an Invasive Phenotype
S100A2 was knocked-down in 21NT (DCIS-like) cells to determine if the
transfected cells would undergo a transition to a more invasive phenotype. We
compared the 21NT+shS100A2 cells to 21NT, 21NT+EV and 21MT-1 (IMC-like)
cells, to evaluate the role of S100A2 in this later transition. When cultured in 3D
Matrigel, the S100A2 knockdown cells showed a more disorganized pattern of
growth than both 21NT (and 21NT+EV) and 21MT-1 cells, with complete loss of
the ability to form extracellular lumena and a lack of cell polarization. In terms of
spherical colonies formed and presence of single cells, the S100A2 knockdown
21NT cells showed levels altered from that of the parental DCIS-like 21NT (or
21NT+EV) cells and similar to the levels of IMC-like, 21MT-1 cells.

The 3D

invasive characteristics of S100A2 knockdown cells were directly assessed by
invasion assay using time lapse microscopy. Not only were 100% of S100A2
knockdown 21NT cells able to invade through Matrigel, but these cells were also
able to travel as far through Matrigel as 21MT-1 cells. Immunohistochemical
staining for Ki67 (proliferation) and caspase 3 (apoptosis), performed on Matrigel
plugs, showed that the proliferation rate of S100A2 knockdown cells was
increased over both 21NT (and 21NT+EV) and 21MT-1 cells, while the apoptosis
rate for the transfected cells did not differ from the 21NT parental cells or
21NT+EV control cells. When we calculated a ratio of proliferation to apoptosis
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we found that the growth profile of the S100A2 knockdown cells matched that of
21MT-1 cells.
Previous studies have theorized that the tumour suppressing ability of
S100A2 is a direct consequence of its ability to block Cox-2 [27]. Since in the
present study, we are knocking down S100A2, the enhanced cell motility,
invasiveness, and proliferation effects associated with Cox-2 activity [28, 29]
should be present and we do see these characteristics in the S100A2 knockdown
cells.

However, the mRNA expression of Cox-2 is not significantly higher in

21MT-1 cells compared to 21NT cells [8].

Thus, at least for the 21T model

system of early breast cancer progression, S100A2 may be enhancing the
invasiveness characteristics via a Cox-2-independent pathway.
A possible alternative mechanism of S100A2 effects is via regulation of
RUNX3. The 21T microarray analysis (Chapter 2 and [8]) has shown that there is
decreased RUNX3 in 21MT-1 cells. RUNX3 signals downstream in the TGFβ
pathway, which has been shown to play a complex role in breast cancer. It has
been demonstrated that during early breast tumour outgrowth, elevated TGFβ is
tumour suppressive, while at later stages there is a switch towards induction of
malignancy and progression [60-62]. Since previous literature has indicated that
S100A2 can induce RUNX3 [23] and as there are reduced levels of S100A2 in
21MT-1 cells, it is possible that the tumour suppressing abilities of RUNX3 [24],
and consequently TGFβ signalling are inhibited due to loss of S100A2.
Similarly, previous literature has shown that S100A2 represses NFkB2
[23], and we have previously shown that 21MT-1 cells have increased NFkB2
(Chapter 2 and [8]). It may be then that low levels of S100A2 in 21MT-1 cells
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result in a lack of repression and overactivity of NFkB2, perhaps resulting in
NFkB2 being able to exert its oncogenic control over apoptosis, cell cycle,
migration and differentiation [26]. The lack of apoptosis alteration in S100A2
knockdown cells was surprising, considering S100A2 is thought to stimulate p53
activity [22]. However, the 21T series cells do all have a p53 mutation [63], which
may have altered the sensitivity of the p53 pathway to S100A2 effects.

3.4.3. TBX3 Promotes the Transition to an Invasive Phenotype
We transfected constitutive expression vectors of both isoforms of TBX3
into 21NT (DCIS-like) cells to determine if the transfected cells would acquire
attributes of an invasive phenotype. We compared the 21NT+TBX3 Iso1 and
21NT+TBX3 Iso2 cells to both 21NT+EV (and 21NT) cells and invasive 21MT-1
cells, to determine the role of TBX3 in this stage of progression (from in situ to
invasive disease). Western blotting with a combination of a monoclonal mouse
antibody against TBX3 and a polyclonal rabbit antibody against ZsGreen was
able to resolve protein banding indicating that 21NT transfectants did indeed
express the TBX3-ZsGreen fusion protein.

Due to the design of the TBX3

expression vector, the empty vector control cells (21NT+EV) were able to
produce ZsGreen.

Western blotting of the control cells with the ZsGreen

antibody resolved a protein band at 60 kDa, which is three times larger than the
expected 20 kDa size of ZsGreen. It is believed that since this Western blot was
performed under non-denaturing and non-reducing conditions that the 60 kDa
product was a ZsGreen trimeric complex.

As further evidence that 21NT

transfectants expressed the TBX3-ZsGreen fusion protein, PCR primers, which
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distinguished between endogenous TBX3 and the fusion protein were designed
and the PCR results indicated that transfected cells of both TBX3 variantZsGreen fusion constructs had increased mRNA expression of the fusion TBX3ZsGreen protein.

Further analysis using confocal microscopy and the TBX3

antibody, as well as ZsGreen signal, showed that the transfected cells had
increased TBX3 and that much of the TBX3 signal colocalized with ZsGreen
signal.

These three experiments determined that the transfected TBX3

overexpressing cells did have increased TBX3. Although TBX3 overexpressing
cells were transfected with isoform specific TBX3 fused to ZsGreen, an increase
in endogenous TBX3 observed by qPCR and Western blotting reveals that TBX3
transgene expression can induce increased endogenous TBX3 expression in
21NT cells. We theorize that TBX3 works in a feed forward manner such that
increased TBX3 leads to induction of TBX3 transcription. This induction appears
to not be specific for either isoform, as overexpression of one isoform leads to
transcriptional induction of both isoforms, with the specific overexpressed isoform
being induced at a higher level than the alternate isoform.
When grown in 3D Matrigel, 21NT cells overexpressing both TBX3
isoforms appeared more disorganized, based on the cells’ reduced ability to form
extracellular lumena and polarized groups, compared to either the empty vector
21NT control cells, or 21MT-1 cells. In addition, in 21NT cells transfected with
both TBX3 isoforms, several very large, highly disorganized and irregular shaped
cell aggregates were seen in 3D Matrigel colonies. Both TBX3 overexpressing
cell lines had reduced ability to form spherical colonies, similar to 21MT-1 cells.
Also similar to 21MT-1 levels, TBX3 Iso1 and TBX3 Iso2 overexpressing cells

137

had a higher percentage of single cells present in the Matrigel plugs than 21NT
cells. Since the TBX3 overexpressing cells acquired 3D colony morphologies
more closely related to 21MT-1 cells than 21NT cells, it appeared that both
isoforms of TBX3 were able to drive transfected 21NT cells to an invasive
phenotype. This was directly confirmed by invasion assay in 3D Matrigel using
time lapse microscopy.

A large proportion of TBX3 Iso1 and TBX3 Iso2

overexpressing cells were able to invade through Matrigel. In addition, these
invading cells were able to travel as far through Matrigel as 21MT-1 cells. When
we examined proliferation and apoptosis rates of the TBX3 overexpressing cells,
we found that the proliferation rate of both TBX3 isoform transfectants was
greatly increased over 21NT+EV and 21MT-1 cells. Interestingly, in the large
irregular cell aggregates, that were previously mentioned, more than 90% of the
cells stained positive for Ki67. The apoptosis rates for the TBX3 overexpressing
cells were not significantly different from the parental 21NT cells or 21NT+EV
control cells. Not surprisingly, when we calculated a ratio of proliferation over
apoptosis, the ratio for both isoforms of TBX3 overexpressing cells was much
higher than for 21NT+EV and 21MT-1 cells, indicating that the TBX3
overexpressing cells have a growth advantage.
In apparent agreement with the study by Hoogaars and colleagues [43],
we have found that transfection of both isoforms of TBX3 show similar functional
effects, inducing an invasive phenotype. However, in our work, transfection of
one TBX3 isoform did result in low level increase in expression of the alternate
isoform, such that functional effects seen could have been the result of some
combination of the two. Previous studies have determined that TBX3 achieves
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senescence bypass through both p53-dependent and independent pathways [35,
37]. The p53-dependent pathway signals through p14 (ARF), which is repressed
by TBX3 [35]. Interestingly, regarding the 21T microarray data from Chapter 2,
that we have previously published [8], we did not see a decrease in p14 (ARF) in
21MT-1 cells (compared to 21NT cells) represented on our list of genes with
significantly altered expression (Supplemental Table 2).

However, upon

examination of the raw microarray data, we have found that p14 (ARF) mRNA
was reduced 1.4-fold in the 21MT-1 cells, compared to 21NT cells, just missing
our 1.5-fold changed cut off, such that whether or not TBX3 may be acting
functionally through repression of p14 (ARF) in these cells requires further
investigation. TBX3-induced invasiveness may also be a result of its ability to
repress E-cadherin, which has been shown in the past [39] and in the present
study.
The present study builds on the limited evidence that there is a potential
role of TBX3 in EMT [39]. EMT is a process by which epithelial cells alter their
phenotype and acquire mesenchymal-like properties, through disruption of
intercellular adhesion, leading to enhancement of cell motility [64]. Mesenchymal
cells, in contrast to epithelial cells, have the ability to migrate as individual cells,
thus the aim of this phenotype modulation is to grant the otherwise stationary
epithelial cells the ability to break away from the primary site, penetrate into
surrounding tissues and move to distant sites [65, 66]. In vitro functional markers
for EMT include increased migration, invasion, scattering and elongation of cell
shape [64], all of which we see for the TBX3 overexpressing cells. In addition, it
has been well documented that cells that have undergone EMT have decreased
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E-cadherin, as well as increased vimentin [64], both of which we also see in the
TBX3 overexpressing cells (both isoforms). These findings indicate that TBX3
may induce EMT. A more thorough analysis looking at other markers of EMT,
including increased fibronectin, snail1, snail2 (slug) and accumulation of βcatenin in the nucleus, would further this theory.

3.4.4. Genes Identified by the 21T Series Model System are Involved in
Controlling the Transitions Between Stages of Progression
The present study has made use of the 21T human breast epithelial cell
line 3D model system to functional characterize genes previously identified as
altered between stages of early breast cancer progression [8]. We determined
that VANGL1 drives cells towards a more malignant and a more invasive
phenotype and promotes the transition from ADH through DCIS to IMC (Figure
3.29).

Loss of S100A2, as well as elevated TBX3 promotes invasive

characteristics and promotes the transition from DCIS to IMC (Figure 3.29). The
21T 3D model system is thus a powerful tool that not only is able to identify
targets with potential significance in breast cancer progression, but also provides
a rapid and manipulatable system to test the functional characteristics of the
targets.
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DCIS
(21NT)

ADH
(21PT)

IMC
(21MT-1)

Normal breast cells
Neoplastic cells

↑ VANGL1
↓ Cell organization
↑ Cell invasion
↑ Cell proliferation/apoptosis

↓ S100A2
↓ Cell organization
↑ Cell invasion
↑ Cell proliferation/apoptosis

↑ TBX3
↓ Cell organization
↑ Cell invasion
↑ Cell proliferation/apoptosis
↑ EMT markers

Figure 3.29. The roles of VANGL1, S100A2 and TBX3 in early breast cancer
progression. VANGL1 drives cells towards a more malignant and a more
invasive phenotype and promotes the transition from ADH through DCIS and
in some respects to IMC. Loss of S100A2 promotes invasive characteristics
and the transition from DCIS to IMC. Similarly, TBX3 (both isoforms)
promotes characteristics of invasiveness and the transition from DCIS to
IMC.
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CHAPTER 4. GENERAL DISCUSSION

4.1. THESIS SUMMARY
The work described in this thesis has addressed the need to identify
molecular factors that drive cells to transition through the stages of early breast
cancer progression.

Early breast cancer progression involves advancement

through specific morphologic stages including atypical ductal hyperplasia (ADH),
ductal carcinoma in situ (DCIS) and invasive mammary carcinoma (IMC),
although not necessarily always in a linear fashion [1-5]. Although the pathology
of these distinct stages is well described, the underlying molecular events
controlling progression remain unclear. Model systems are required to study the
molecular events and determine the molecular changes that are driving
progression. This thesis made use of the 21T series human breast epithelial cell
lines grown in a 3D Matrigel system. I hypothesized that when grown in 3D
culture, the 21T series cells could be used to identify genes involved in the
transition from ADH to DCIS and the transition from DCIS to IMC. Additionally, it
was hypothesized that the 3D model system could be further used to determine
the role of the identified genes in early breast cancer progression. In order to
address these hypotheses, three objectives were defined. First, it was necessary
to determine the growth characteristics of the 21T series cell lines in 3D in vitro
culture. Next, the 3D system was used to identify genes potentially involved in
the transition from ADH to DCIS and in the transition from DCIS to IMC. Finally,
the validated genes were functionally characterized in the 3D system to
determine their role in induction of tumor progression.
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The 21T series cell lines, all originally derived from a single patient with
metastatic breast cancer, have been previously proposed to represent a
mammary tumour progression series [6]. In Chapter 2 (and [7]), we reported that
the 21T cell lines indeed mimicked specific stages of

human breast cancer

progression when grown in the mammary fat pad of nude mice, albeit after a
year.

More specifically, the 21PT-derived cells developed lesions with

morphologic features of ADH, while the 21NT-derived cells formed lesions of
DCIS and the 21MT-1 cells lesions of IMC. In order to develop a more rapid,
readily manipulatable in vitro assay for examining the biologic differences
between these cell lines, we have used a 3D Matrigel system. When the three
cell lines were grown in 3D Matrigel, they showed characteristic morphologies in
which quantifiable aspects of stage-specific in vivo behaviours (i.e. differences in
acinar structure formation, cell polarization, colony morphology, cell proliferation,
cell invasion) were recapitulated in a reproducible fashion. Additionally, in order
to determine differential gene expression profiles between the 21T series cell
lines, in vitro expression arrays were performed on cells grown in 3D culture.
Genes that were significantly altered (p<0.05) at least 1.5-fold in either the
transition from ADH to DCIS, or DCIS to IMC, were further considered. In order
to assess whether these alterations were clinically relevant, we compared our list
of differentially expressed genes with a database we generated from established
literature on gene expression profiling of breast cancer clinical cancer specimens
[8-19]. Ingenuity Pathways Analysis was then used to choose genes involved in
the most highly altered canonical pathway and functional categories. Finally,
GeneCards (www.genecards.org) was used to further explore the potential role of
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the genes in breast cancer. Nineteen genes (Table 2.3) were then chosen for
real-time qRT-PCR validation, with seventeen genes showing the same
expression trend as the microarray. These genes were specifically altered in
either the transition from pre-malignant (ADH: 21PT cells) to malignant growth
(DCIS: 21NT cells), or the transition from growth within a duct (DCIS: 21NT cells)
to invasion at the primary site (IMC: 21MT-1 cells).
From the PCR validated list, three genes were chosen for functional
testing in the 21T series 3D model system. For the transition from ADH to DCIS,
VANGL1 was functionally characterized to determine its role in promoting
conversion to malignancy (in situ and/or invasive disease).

Two genes

differentially expressed in the DCIS to IMC transition were chosen for functional
characterization, S100A2 and TBX3, to determine their role in progression to an
invasive phenotype. Experimental studies focusing on these three genes were
the basis for the work in Chapter 3.
VANGL1 was found to be elevated in 21NT (DCIS-like) cells compared to
21PT (ADH-like) cells.

To determine the functional role of VANGL1 in the

malignant transition, a myc-tagged VANGL1 expression vector was constructed
and transfected into 21PT cells.

The resulting VANGL1 overexpressing cells

were functionally characterized according to colony profile (spherical vs.
irregular), lumen formation, cell polarization, proportion of single cells,
proliferation index, apoptosis index and cell invasion. The cells were found to
have lost characteristics of the parental 21PT cells and gained some of those
typically seen for 21NT or 21MT-1 cells. The VANGL1 overexpressing 21PT
cultures were found to be more disorganized (less polarized cell groups, less
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extracellular lumen formation) than 21NT or even 21MT-1 cells. Additionally,
when a ratio of proliferation over apoptosis was calculated for the VANGL1
overexpressing cells, these cells had a higher ratio than 21NT cells.
Furthermore, direct examination of invasiveness using transwell assay showed
that the VANGL1 transfected 21PT cells had gained a significant level of
invasiveness. Thus, the introduction of VANGL1 into 21PT cells induced change
from a more ADH-like phenotype, beyond the stage of a DCIS, to a clearly
invasive phenotype, without the need for any further experimental intervention.
S100A2 was found to be reduced in 21MT-1 (IMC-like) cells compared to
21NT (DCIS-like) cells.

To determine the functional role of S100A2 in the

transition to an invasive phenotype, shRNA against S100A2 was transfected into
21NT cells and the cells were analyzed using several functional parameters,
including colony profile (spherical vs. irregular), lumen formation, cell polarization,
proportion of single cells, proliferation index, apoptosis index and cell invasion by
time lapse microscopy. The S100A2 knockdown 21NT cells were found to have
lost characteristics of parental 21NT cells and gained those of 21MT-1 cells. The
cells formed more disorganized groups (less polarized, less extracellular lumen
formation) than either 21NT or 21MT-1 cells and showed a growth profile (ratio of
proliferation to apoptosis) similar to 21MT-1 cells.

In addition, knockdown

S100A2 in 21NT cells resulted in cells that were invasive in 3D Matrigel to a
degree comparable to 21MT-1 cells.

Thus, loss of S100A2 in these cells

originally mimicking DCIS, promotes their progression to the invasive phenotype.
TBX3 was found to be increased in 21MT-1 (IMC-like) cells compared to
21NT (DCIS-like) cells. To determine the functional role of both isoforms of TBX3
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in the transition to an invasive phenotype, expression vectors of the isoforms
fused to ZsGreen were transfected separately into 21NT cells. Functional assays
including colony profile (spherical vs. irregular), lumen formation, cell polarization,
proportion of single cells, proliferation index, apoptosis index, cell invasion and
presence of EMT markers were then used to analyze the cells.

The TBX3

overexpressing 21NT cells obtained characteristics more similar to 21MT-1 cells
than to the parental 21NT cells. Both TBX3 overexpressing isoform variant cells
formed more disorganized colonies (less polarization, less extracellular lumen
formation) and had a much higher proliferation vs. apoptosis ratio than any of the
parental 21T cell lines (including 21MT-1). In addition, assays in 3D Matrigel
showed the TBX3 overexpressing cells (both isoforms) to be more invasive than
the 21MT-1 cells. Thus, overexpression of either isoform of TBX3 is capable of
inducing a transition of the DCIS-like 21NT cells to a clearly invasive phenotype.
Together, these studies have revealed that the 21T cell series 3D model
system is a powerful tool that not only is able to identify targets with potential
significance in breast cancer progression, but also provides a rapid and
manipulatable system to test the functional characteristics of the targets.

4.2. DISCUSSION
Much interest surrounds the need to determine new molecular targets for
breast cancer therapy. To this end, information from clinical studies examining
pre-invasive lesions vs. invasive mammary carcinoma has yielded abundant
gene expression profile differences between stages of progression (eg. [8-12]).
The limitation we are facing is appropriate processing and synthesis of this data.

153

Several of these studies looked at specimens from different patients, leading to
genetic differences that can mask the importance of specific gene targets. Also
testing the involvement of individual genes in progression takes time, especially
when using in vivo culture.
The 21T series 3D model system is of great advantage in this regard. As
was discussed in Chapter 2, the parental cell lines stably represent three distinct
stages of breast cancer.

This is advantageous over the HMT-3522 and

MCF10AT breast epithelial cell line systems, since both show mixed phenotypes
and lack stability after culture [20-24]. Additionally, the 21T series cell lines are
all derived from one patient, thus having an isogenic background. As a result,
targets identified by the system are more likely to be those associated with
cancer progression, as opposed to variation between individuals. Finally, the
ability of the 21T series cell lines to represent the stages of progression in a 3D in
vitro system allows us to rapidly test multiple functional characteristics of
candidate genes to determine their role in regulating the transitions through the
stages of breast cancer.

The three targets examined in this thesis were

VANGL1, S100A2 and TBX3, all of which have been identified as genes altered
during progression in expression array profiling of clinical specimens, but for
which very little functional information in relation to a role in breast cancer
progression is currently available.
VANGL1 is a transmembrane protein that has been implicated in
promoting malignancy and invasion of gastric, squamous, colon and laryngeal
cancer [25-30]; however, no functional information is available in relation to
breast cancer progression. The tumour enhancing ability of VANGL1 is believed
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to be a result of both the negative interaction of VANGL1 with KAI1, a metastasis
suppressor, and through the PCP signalling pathway, which is influenced by
VANGL1. The microarray data from Chapter 2 identified VANGL1 as increased
in 21NT (DCIS-like) compared to 21PT (ADH-like) cells.

Consequently, in

Chapter 3, we investigated the role of VANGL1 in the transition from ADH to
DCIS. The 3D functional assays indicate that cells overexpressing VANGL1 did
acquire characteristics of malignancy; however, several of the criteria examined
indicated that the cells had progressed even further and had acquired
characteristics of invasion. The present data implicates a role for VANGL1 in
early breast cancer progression.

This role may be achieved through the

interaction of VANGL1 with KAI1, which blocks inhibitor effects of KAI1 on
signalling and/or through the interaction of VANGL1 with the Wnt5a/Fzd/Dvl
complex to alter signalling via the noncanonical Wnt/PCP pathway.

Future

studies that focus on these interactions would more fully elucidate the role of
VANGL1 in early breast cancer (see section 5.3).
S100A2 is a member of the S100 calcium binding family and has been
implicated in tumour suppression [31]. The tumour suppressing abilities have
been noted in several forms of cancer and are theorized to be partly obtained
through the interaction of S100A2 with the Cox-2 pathway [32], p53 signalling
[33], RUNX3, EGFR and NFkB2 signalling [34]. In Chapter 3, we characterized
the role of S100A2 in the transition from DCIS to IMC. S100A2 was knockeddown in 21NT (DCIS-like) cells to mimic the decreased S100A2 mRNA levels in
21MT-1 compared to 21NT cells that were discovered in Chapter 2. The 3D
functional

assays

indicate

that

S100A2

knockdown

cells

did

acquire
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characteristics of invasion. These results give evidence for the first time that
S100A2 may indeed be a gatekeeper of the invasive phenotype in breast cancer
progression, such that downregulation of S100A2 allows the transition from the in
situ to the invasive phenotype. The potential mechanisms of this phenomenon
warrant further study (as described in section 5.3).
TBX3 is a member of the T-box family of transcription factors, previously
linked to tumourigenesis and senescence bypass [35-37]; however, very little is
known about the function of TBX3 in breast cancer. There are two isoforms of
TBX3, which are created by alternative splicing [38]. Although TBX3 Iso1 (TBX3
splice variant) has been consistently implicated in senescence inhibition, there is
controversy over whether TBX3 Iso2 (TBX3+2a variant) is also tumour promoting
in action [39, 40]. Our interest in TBX3 in the transition from DCIS to IMC arose
as a result of the microarray data in Chapter 2 that demonstrated that TBX3 was
increased in 21MT-1 (IMC-like) cells compared to 21NT (DCIS-like) cells.

In

Chapter 3, we overexpressed both isoforms of TBX3 in 21NT (DCIS-like) cells to
see if the transfected cells would acquire attributes of an invasive phenotype.
When grown in 3D Matrigel, cells overexpressing both TBX3 isoforms did acquire
attributes of the invasive phenotype, indicating for the first time that TBX3 (both
isoforms) may influence the progression of breast cancer from the in situ to
invasive phenotype. This data also provides evidence in the controversy over
function of the two TBX3 isoforms, indicating that both isoforms show function in
this system (consistent with Hoogaars and colleagues [40]). Other mechanisms
of TBX3 effect include repression of p14 (ARF) [36] and induction of EMT through
repression of E-cadherin [41]. These mechanisms could be explored in future
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work (as discussed in section 5.3) to determine a more exact mechanism for the
functional effect seen here.
The 21 human epithelial cell line 3D model system is a powerful tool. The
system represents distinct stages of early breast cancer progression and has
been shown to correctly predict molecular targets capable of affecting the
transitions through these stages. In addition to identifying the targets, this model
also provides a rapid and manipulatable system to test the functional
characteristics of the targets. In this way, we are identifying genes as potential
key regulators in the transitions of early breast progression, ideal for development
as targets for preventative therapies directed at attacking cancer at its roots
(before the development of invasive disease). At the same time, further use of
this system will continue to provide insight into the molecular processes that drive
early progression.

5.3. FUTURE DIRECTIONS
This thesis demonstrated that the 21T series 3D model system, which
represents distinct stages in early breast cancer progression, can be used not
only to identify genes which are involved in controlling the transitions between
stages of progression, but also provides a means to functionally characterize the
gene targets. The results from these studies raise a number of experimental
questions that may form the basis of interesting continuation projects designed to
further our understanding of early breast cancer progression.
First, choosing potential genes to further study from microarray data is
challenging.

We originally chose nineteen genes to validate with PCR and
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determined that seventeen of the genes showed the same expression alteration
trend by PCR as by microarray (Table 2.3). Only three of these seventeen genes
were characterized, leaving fourteen genes ready for functional characterization.
Also, several rules and guidelines were used in Chapter 2. These rules were
used to ensure that genes chosen for further study were clinically relevant and
involved in highly altered canonical pathways and functional categories; however,
this does not mean that all genes important in progression were caught. Thus,
the array data still holds much potential for further mining to identify genes
involved in progression.
Second, the characterization of VANGL1, S100A2 and TBX3 has provided
very exciting information about the roles of these genes in early breast cancer
progression.

However, there are still areas for each gene that need further

development.

Additionally, now that the functional effects of these candidate

genes have been carefully characterized in vitro, the more time consuming and
expensive confirmatory nude mouse assays can be done in a more selective
fashion. Since 21T series cells require one year to develop lesions in mammary
fat pads of nude mice, selective injection of cells that are up- or down-regulated
for the well characterized gene targets will save much time and money. Injection
of VANGL1 overexpressing 21PT cells into nude mice can be compared to
21PT+EV, 21NT and 21MT-1 cells to determine if VANGL1 results in progression
to DCIS or even IMC. S100A2 knockdown 21NT cells can be injected into nude
mice and compared to 21NT+EV and 21MT-1 cells to determine if loss of S100A2
drives 21NT cells to an IMC phenotype.

Finally, injection of TBX3

overexpressing 21NT cells (both isoforms) into nude mice can be compared to
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21NT+EV and 21MT-1 cells to determine if TBX3 promotes development of IMC.
It will also be interesting to see if manipulation of any of these genes will result in
a reduced latency in lesion development in nude mice.
Given the interplay between VANGL1 and Wnt5A in the planar cell polarity
(PCP) pathway, it would be of interest to further explore the relationship between
these two genes in PCP signalling. To examine the interplay between VANGL1
and Wnt5a, Wnt5a could be upregulated in 21NT cells, which have low Wnt5a
(compared to 21PT cells), but elevated VANGL1 (compared to 21PT cells).
Functional assays could then be used to analyze the effects on the transitions
through early breast cancer progression. This manipulation would also aid in our
understanding of the biphasic role of the PCP pathway in breast cancer.
Additionally, it would be interesting to determine whether VANGL1 affects the
Wnt/Fzd/Dvl interaction and this could be easily viewed by comparing the
downstream PCP signals after up- and down-regulating VANGL1. Finally, since
VANGL1 can potentially complex with and regulate KAI1, further study into the
levels of KAI1 in the 21T series cells, as well as examination for direct interaction
of VANGL1 with KAI1 and potential effects on activation of downstream targets of
KAI1 (growth factor receptors and integrins) may elucidate if the promotion of
malignancy and invasion observed here is due in part to VANGL1 regulation of
KAI1.
Much of the literature points to the down-regulation of Cox-2 gene
expression by S100A2 as a means by which S100A2 exerts its tumour
suppressing ability. We did not see an alteration in Cox-2 expression with the
microarray data, with the level of change that we had set for our initial screen.

159

However given that S100A2 has been shown to repress Cox-2, resulting in
reduced tumourigenesis, it would be of interest to perform a qRT-PCR
experiment to more accurately determine if Cox-2 is altered in the 21T series
cells as well as the S100A2 knockdown cells. Also, it would be worth examining
the regulation of S100A2 on both NFkB2 and RUNX3 and their respective
signalling pathways, given that both the literature and our microarray data have
elucidated a possible role for S100A2 signalling through these genes. qRT-PCR
experiments could be conducted to determine if the levels of NFkB2 and/or
RUNX3 are altered in the S100A2 knockdown cells compared to the 21NT+EV
control cells.

Additionally, levels of downstream effectors in the respective

pathways of each of these genes can be viewed to determine if loss of S100A2
affects signalling.
Since TBX3 is a transcription factor, its effects on cells are numerous.
Two pathways identified by the literature and partly corroborated by this thesis
involve a role with p14 (ARF) and in EMT. Given that levels of p14 (ARF) are
marginally decreased in 21MT-1 cells compared to 21NT cells, it would be of
interest to determine if there is an alteration in expression of p14 (ARF) in the
TBX3 (both isoforms) overexpressing 21NT cells.

This thesis also used

decreased E-cadherin and increased vimentin as indicators that TBX3 may play a
role in promoting EMT. To further analyze this theory, other markers of EMT,
including increased fibronectin, snail1, snail2 (slug) and accumulation of βcatenin in the nucleus, could be investigated.
Collectively these studies indicate that the 21T 3D model system is an
influential tool that not only is able to identify targets with potential significance in
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breast cancer progression, but also provides a rapid and manipulatable system to
test the functional characteristics of the targets. Continued research in the areas
described above should elucidate more targets in early breast cancer progression
and further our understanding of the targets already identified, which will aid in
the development of novel detection, treatment and preventative strategies for
progression.
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A)

B)

C)

D)

Figure 1. Examples of each type of cell colony examined in the 3D colony
morphology assay. A) represents a cell group/colony, while B) represents a
single cell. C) is representative of a spherical colony, while A) would not be
considered spherical. The cell colony in D) is able to form an extracellular
lumen, while a lumen is not present in the cell colony displayed in C). Finally,
the cells within the colony in D) are polarized, as the nuclei are basally
oriented, while the cells found within the cell colony in C) are not polarized.
Scale bar represents 10 µm.
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Table 1. Genes that are significantly different among the 21T series cell lines
(Supplemental Table 1 and 2) and also present on clinically relevant databases
from the literature (Supplemental Table 3).
A) 21PTci to 21NTci
Probe Set ID

Gene Symbol

21NTci
(ratio to 21PTci)

216620_s_at

ARHGEF10

0.59

211022_s_at

ATRX

1.97

208478_s_at

BAX

0.57

211813_x_at

DCN

0.60

242605_at

DCN

7.52

220668_s_at

DNMT3B

1.39

217497_at

ECGF1

1.60

208180_s_at

HIST1H4H

1.56

209984_at

JMJD2C

1.66

210662_at

KYNU

4.98

208403_x_at

MAX

0.65

242479_s_at

MCM4

0.62

230848_s_at

MGA

3.23

204475_at

MMP1

0.24

221805_at

NEFL

0.31

209997_x_at

PCM1

0.65

212240_s_at

PIK3R1

1.75

206509_at

PIP

3.95

204051_s_at

SFRP4

0.65

219103_at

UPLC1

9.31

229997_at

VANGL1

2.19

229802_at

WISP1

2.18

213425_at

WNT5A

0.53

B) 21NTci to 21MT-1
Probe ID

Gene Symbol

21MT-1
(ratio to 21NTci)

208161_s_at

ABCC3

0.05

202850_at

ABCD3

0.61

206513_at

AIM2

7.16

224655_at

AK3L1

0.47

224151_s_at

AK3L1

0.30

205623_at

ALDH3A1

0.01

223333_s_at

ANGPTL4

0.28
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222608_s_at

ANLN

0.38

1552619_a_at

ANLN

0.37

208702_x_at

APLP2

0.58

204205_at

APOBEC3G

3.37

201288_at

ARHGDIB

0.03

209394_at

ASMTL

1.96

218782_s_at

ATAD2

0.43

222740_at

ATAD2

0.40

213106_at

ATP8A1

0.10

202391_at

BASP1

4.23

204908_s_at

BCL3

1.84

209373_at

BENE

0.06

210538_s_at

BIRC3

2.49

230499_at

BIRC3

2.23

207655_s_at

BLNK

0.04

203571_s_at

C10orf116

0.01

211368_s_at

CASP1

3.62

205476_at

CCL20

19.98

205099_s_at

CCR1

7.85

201131_s_at

CDH1

0.02

207173_x_at

CDH11

0.24

204252_at

CDK2

0.26

213618_at

CENTD1

0.07

209395_at

CHI3L1

0.13

209396_s_at

CHI3L1

0.09

201428_at

CLDN4

0.02

208792_s_at

CLU

3.43

225438_at

CML66

0.50

204740_at

CNKSR1

0.29

222073_at

COL4A3

1.64

212489_at

COL5A1

0.15

203325_s_at

COL5A1

0.11

207442_at

CSF3

11.23

210140_at

CST7

18.14

823_at

CX3CL1

2.04

204470_at

CXCL2

0.04

211919_s_at

CXCR4

0.20

209201_x_at

CXCR4

0.07

217028_at

CXCR4

0.04

202435_s_at

CYP1B1

0.18

202436_s_at

CYP1B1

0.15
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202437_s_at

CYP1B1

0.10

211896_s_at

DCN

33.95

209335_at

DCN

21.17

211813_x_at

DCN

20.03

201893_x_at

DCN

15.35

242605_at

DCN

1.77

210749_x_at

DDR1

0.18

1007_s_at

DDR1

0.13

208779_x_at

DDR1

0.06

207169_x_at

DDR1

0.04

211272_s_at

DGKA

0.23

222621_at

DNAJC1

1.93

201843_s_at

EFEMP1

0.07

201842_s_at

EFEMP1

0.04

201325_s_at

EMP1

0.28

214782_at

EMS1

1.85

201313_at

ENO2

10.08

217061_s_at

ETV1

2.05

211742_s_at

EVI2B

3.64

221565_s_at

FAM26B

0.21

202995_s_at

FBLN1

0.46

202994_s_at

FBLN1

0.13

201540_at

FHL1

7.54

218035_s_at

FLJ20273

0.07

214915_at

FLJ25476

0.62

214211_at

FTH1

2.84

206002_at

GPR64

0.30

219327_s_at

GPRC5C

0.08

212873_at

HA-1

2.63

216693_x_at

HDGFRP3

0.40

213537_at

HLA-DPA1

11.27

212143_s_at

IGFBP3

0.02

210095_s_at

IGFBP3

0.01

206172_at

IL13RA2

13.55

205992_s_at

IL15

6.56

206295_at

IL18

0.06

226218_at

IL7R

14.04

205798_at

IL7R

3.87

208436_s_at

IRF7

3.73

228462_at

IRX2

0.25

204990_s_at

ITGB4

0.04
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1566465_at

KCNK1

0.11

204678_s_at

KCNK1

0.02

204679_at

KCNK1

0.02

212314_at

KIAA0746

0.16

206785_s_at

KLRC1

3.77

212236_x_at

KRT17

2.16

213680_at

KRT6B

0.26

209016_s_at

KRT7

0.11

213711_at

KRTHB1

0.09

241305_at

KYNU

2.98

210663_s_at

KYNU

2.32

204385_at

KYNU

2.04

211651_s_at

LAMB1

1.84

202728_s_at

LTBP1

15.51

205668_at

LY75

0.16

213489_at

MAPRE2

0.09

202350_s_at

MATN2

0.19

211340_s_at

MCAM

3.28

242479_s_at

MCM4

1.69

203417_at

MFAP2

0.54

203434_s_at

MME

2.16

204475_at

MMP1

20.75

201069_at

MMP2

0.48

205828_at

MMP3

7.41

204259_at

MMP7

0.24

219959_at

MOCOS

2.35

37408_at

MRC2

0.16

201521_s_at

NCBP2

1.64

209949_at

NCF2

0.16

206022_at

NDP

0.62

202237_at

NNMT

5.23

202238_s_at

NNMT

5.05

219773_at

NOX4

1.91

205552_s_at

OAS1

0.36

213075_at

OLFML2A

0.09

205041_s_at

ORM1

46.41

210448_s_at

P2RX5

2.15

202465_at

PCOLCE

3.31

214582_at

PDE3B

0.27

222719_s_at

PDGFC

0.07

218718_at

PDGFC

0.02
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205226_at

PDGFRL

7.30

205960_at

PDK4

0.04

225207_at

PDK4

0.02

221816_s_at

PHF11

0.08

225136_at

PLEKHA2

0.48

205479_s_at

PLAU

0.59

236297_at

PLXDC2

1.62

201578_at

PODXL

0.10

210910_s_at

POMZP3

0.52

203407_at

PPL

0.05

201602_s_at

PPP1R12A

1.66

201858_s_at

PRG1

5.89

209606_at

PSCDBP

18.29

202006_at

PTPN12

1.67

203029_s_at

PTPRN2

20.15

210127_at

RAB6B

0.48

218723_s_at

RGC32

0.02

200962_at

RPL31

0.50

204268_at

S100A2

0.25

206027_at

S100A3

3.67

203453_at

SCNN1A

0.19

201286_at

SDC1

0.19

204855_at

SERPINB5

0.03

209044_x_at

SF3B4

1.81

209980_s_at

SHMT1

0.04

213355_at

SIAT10

0.44

206510_at

SIX2

0.23

202800_at

SLC1A3

6.78

1569054_at

SLC1A3

5.98

206097_at

SLC22A1LS

2.03

202498_s_at

SLC2A14

3.60

202499_s_at

SLC2A3

4.06

206628_at

SLC5A1

0.56

209830_s_at

SLC9A3R2

0.06

213139_at

SNAI2

2.93

220987_s_at

SNARK

0.67

227697_at

SOCS3

7.01

212560_at

SORL1

0.12

220922_s_at

SPANXB1

18.34

220217_x_at

SPANXC

5.36

218638_s_at

SPON2

0.21
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233555_s_at

SULF2

0.05

224724_at

SULF2

0.02

202168_at

TAF9

2.00

225973_at

TAP2

2.07

225544_at

TBX3

2.84

203919_at

TCEA2

0.65

214476_at

TFF2

9.71

201506_at

TGFBI

3.65

201147_s_at

TIMP3

15.63

219580_s_at

TMC5

0.03

222450_at

TMEPAI

0.02

202644_s_at

TNFAIP3

3.94

206025_s_at

TNFAIP6

1.50

202688_at

TNFSF10

0.06

210314_x_at

TNFSF13

0.46

209500_x_at

TNFSF13

0.44

221601_s_at

TOSO

5.07

201746_at

TP53

1.62

209863_s_at

TP73L

0.36

209227_at

TUSC3

0.50

201009_s_at

TXNIP

0.31

201010_s_at

TXNIP

0.23

226681_at

UBE2H

1.90

208998_at

UCP2

0.51

225242_s_at

URB

0.33

210513_s_at

VEGF

3.09

212171_x_at

VEGF

2.48

210512_s_at

VEGF

2.15

202664_at

WASPIP

8.87

213425_at

WNT5A

9.30

203585_at

ZNF185

0.37

213196_at

ZNF629

0.44

211796_s_at

30.26

213193_x_at

2.60

243020_at

0.63

244579_at

0.57

210136_at

0.23
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Table 1. S100A2 shRNA sequence.
Mature Product
(22 mer) Sequence
CCAGACCGACCC
TGAAGCA

Hairpin Sequence
TGCTGTTGACAGTGAGCGACCCAGACCGACCCTGAAG
CAGTAGTGAAGCCACAGATGTACTGCTTCAGGGTCGG
TCTGGGCTGCCTACTGCCTCGGA
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21NT
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Figure 1.
Quantification of characteristics of 21T and VANGL1
overexpressing cells after 9 days growth in 3D Matrigel. 21PT+VANGL1 cells
show no lumen formation and fewer polarized cells than 21PT+empty vector
(EV) cells, indicating that the VANGL1 cells are more disorganized. In
addition, VANGL1 transfected cells also formed far fewer spherical colonies,
with the percentage being lower than even 21MT-1 cells. The percentage of
single cells seen in Matrigel plugs for 21PT+VANGL1 cells was at the same
level as 21NT cells. 21PT+EV cells show no differences from 21PT cells. For
‘single cells’, an event is either a single cell or a cell group, whereas for the
‘lumen formation’ , ‘polarized cells’ and ‘spherical colonies’ comparisons, an
‘event’ was defined as a cell group only. Bars labeled with letters that are not
the same indicate significant difference between the bars at a p-value of at
least <0.05. Statistics for each comparison were calculated separately from
the other comparisons.

180

B)

b

20
16
14

c

10
8

a

4

a

2
0

16
14
12
10

a

8

a

a

a

6
4
2

21
PT
+

b
2.4
2.0
1.6

c

1.2
0.8

a

a

0.4

21
NT

21
PT
+E
21
V
PT
+V
AN
GL
1

0.0

21
PT

Ki67/Caspase3 Labeling Index (%)

C)

21
NT

21
PT

21
NT

L1
1
AN
G

21
PT
+V

21
PT
+E
V

21
PT

0

VA
NG
L1

6

18

21
PT
+E
V

Ki67 Labeling Index (%)

18

12

20

Caspase 3 Labeling Index (%)

A)

Figure 2.
Proliferative and apoptotic activity of 21T and VANGL1
overexpressing cell lines after 9 days growth in 3D Matrigel. Proliferation (A)
was quantified by Ki67 immunohistochemical staining of Matrigel plugs, while
apoptosis (B) was quantified by caspase 3 immunohistochemistry.
21PT+VANGL1 cells showed a large increase in proliferation (A) over
21PT+EV cells, while apoptosis levels (B) were unaltered from 21PT+EV
cells. When the ratio of proliferation/apoptosis was calculated (C), VANGL1
overexpressing cells showed a much higher ratio than the 21PT+EV and
even the 21NT cells. 21PT+EV cells showed no differences from the 21PT
cells. Bars labeled with letters that are not the same indicate significant
difference between the bars at a p-value of at least <0.05.
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Figure 3. Quantification of characteristics of 21T and S100A2 knockdown
cells after 9 days growth in 3D Matrigel. 21NT+shS100A2 cells show
complete loss of lumen forming ability and fewer polarized cells than
21NT+EV or 21MT-1 cells, indicating that the S100A2 knockdown cells are
less organized. In addition, S100A2 shRNA cells also formed fewer spherical
colonies than 21NT+EV cells and in line with 21MT-1 cells. The percentage of
single cells seen in Matrigel plugs for 21NT+shS100A2 cells was unaltered
from 21NT+EV (or 21NT) cells. 21NT+EV cells show no differences from
21NT cells. For ‘single cells’, an event is either a single cell or a cell group,
whereas for the ‘lumen formation’ , ‘polarized cells’ and ‘spherical colonies’
comparisons, an ‘event’ was defined as a cell group only. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05. Statistics for each comparison were calculated
separately from the other comparisons.
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Figure 4. Proliferative and apoptotic activity of 21T and S100A2 knockdown cell
lines after 9 days growth in 3D Matrigel. Proliferation (A) was quantified by Ki67
immunohistochemical staining of Matrigel plugs, while apoptosis (B) was
quantified by caspase 3 immunohistochemistry. 21NT+shS100A2 cells showed
an increase in proliferation (A) over 21NT+shEV and 21MT-1 cells, while
apoptosis levels (B) of S100A2 shRNA cells were not different from 21NT cells.
When the ratio of proliferation/apoptosis was calculated (C), S100A2 knockdown
21NT cells showed a higher ratio than 21NT+EV cells. 21NT+shEV cells
showed no differences from the 21NT cells. Bars labeled with letters that are not
the same indicate significant difference between the bars at a p-value of at least
<0.05.
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Figure 5. Quantification of characteristics of 21T and TBX3 transfected cells
after 9 days growth in 3D Matrigel. 21NT +TBX3 Iso1 and Iso2 cells form
fewer lumens and polarized cells than 21NT+EV cells, indicating that the
TBX3 cells are less organized. In addition, TBX3 transfected cells also
formed less spherical colonies than 21NT+EV cells and more single cells,
similarly to 21MT-1 cells. 21NT+EV cells show no differences from 21NT
cells. For ‘single cells’, an event is either a single cell or a cell group, whereas
for the ‘lumen formation’, ‘polarized cells’ and ‘spherical colonies’
comparisons, an ‘event’ was defined as a cell group only. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05. Statistics for each comparison were calculated
separately from the other comparisons.
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Figure 6. Proliferative and apoptotic activity of 21T and TBX3 transfected
cell lines after 9 days growth in 3D Matrigel. Proliferation (A) was quantified
by Ki67 immunohistochemical staining of Matrigel plugs, while proliferation
(B) was quantified by caspase 3 immunohistochemistry. 21NT+TBX3 Iso1
and Iso2 cells showed a large increase in proliferation (A) over 21NT+EV
cells, while apoptosis levels (B) remained similar to the 21T cells. When the
ratio of proliferation/apoptosis was calculated (C), TBX3 transfected cells
showed a much higher ratio than the 21NT+EV and the 21MT-1 cells.
21NT+EV cells showed no differences from the 21NT cells. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05.
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